UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ~~For the quarterly period ended September 30, 2017~~

For the quarterly period ended March 31, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ~~For the transition period from _______________ to _______________~~

For the transition period from _______________ to _______________

Commission File Number: 000-28107

GILLA INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada		88-0335710
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

475 Fentress Blvd., Unit L, Daytona Beach, Florida		32114
(Address of Principal Executive Offices)		(Zip Code)

(416) 843-2881

Registrant’s telephone number, including area code

Not Applicable

(Former name, Former Address and Former Fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, ~~smaller reporting company,~~ or ana ~~emerging~~smaller reporting ~~growth~~ company. See the definitions of “large accelerated filer,” “accelerated filer”, and “smaller reporting company” ~~and "emerging growth company"~~ in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ~~☒ Emerging growth company ☐~~☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☑ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The Registrant had ~~134~~143,~~869~~818,~~261~~368 shares of common stock (“Common Shares” or “Common Stock”), $0.0002 par value per share, issued and outstanding as of ~~November~~June 1328, ~~2017~~2018.

GILLA, INC.

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

		Page
PART I - Financial Information
Item 1.	Interim Financial Statements (Unaudited)	3
	Condensed Consolidated Interim Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016 (Audited)	3
	Condensed Consolidated Interim Balance Sheets as at March 31, 2018 (Unaudited) and December 31, 2017 (Audited)	3
	Unaudited Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2017 and September 30, 2016	4
	Unaudited Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2018 and March 31, 2017	4
	Unaudited Condensed Consolidated Interim Statement of Changes in Shareholders’ Deficiency for the Nine Months Ended September 30, 2017	5
	Unaudited Condensed Consolidated Interim Statement of Changes in Shareholders’ Deficiency for the Three Months Ended March 31, 2018	5
	Unaudited Condensed Consolidated Interim Statements of Cash Flows for the Nine Months Ended September 30, 2017 and September 30, 2016	6
	Unaudited Condensed Consolidated Interim Statements of Cash Flows for the Three Months Ended March 31, 2018 and March 31, 2017	6
	Notes to Unaudited Condensed Consolidated Interim Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3635
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4849
Item 4.	Controls and Procedures	4849
PART II - Other Information		49
Item 1.	Legal Proceedings	4849
Item 1A.	Risk Factors	4950
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4950
Item 3.	Defaults Upon Senior Securities	4950
Item 4.	Mine Safety Disclosures	4950
Item 5.	Other Information	4950
Item 6.	Exhibits	5051
SIGNATURES		5152

Gilla Inc.

Condensed Consolidated Interim Balance Sheets

(Amounts expressed in US Dollars)

	As at September 30, 2017	As at December 31, 2016
	As at March 31, 2018	As at December 31, 2017
	(unaudited)	(audited)
ASSETS
Current assets
Cash and cash equivalents	$753,~~683~~647	$~~184~~62,~~754~~292
Trade receivables (net of allowance for doubtful accounts $161,340 (December 31, 2016 – $nil))	280,551	80,409
Trade receivables (net of allowance for doubtful accounts $283,011 (December 31, 2017 – $190,543)	210,553	232,386
Inventory (note 6)	~~403~~527,~~583~~415	~~545~~451,~~135~~318
Other current assets (note 5)	~~364~~353,~~748~~429	~~462~~323,~~708~~548
Total current assets	1,~~124~~095,~~565~~044	1,~~273~~069,~~006~~544
Long term assets
Property and equipment (note 7)	~~336~~249,~~504~~860	93285,~~068~~817
Website development (note 8)	54,583	75,083
Intangibles (note 9)	~~126~~652,~~850~~416	~~160~~691,~~300~~809
Goodwill (note 10)	32,~~106~~376,~~458~~605	~~889~~2,~~497~~376,605
Total long term assets	3,~~575~~283,~~395~~464	13,~~149~~359,~~948~~314
Total assets	$4,~~699~~378,~~960~~508	$24,~~422~~428,~~954~~858
LIABILITIES
Current liabilities
Accounts payable	$12,~~956~~633,~~323~~269	$12,~~740~~335,~~071~~615
Accrued liabilities (note 11)	422,998	404,633
Accrued liabilities (note 11 and 13)	720,658	419,436
Accrued interest - related parties (note 20)	425,185	263,790
Customer deposits	50,456	97,400
Customer deposits	34,399	56,834
Loans from shareholders (note 11)	284,999	257,303
Loans from shareholders (note 11)	1,210,966	502,288
Due to related parties (note 19)	404,605	252,841
Due to related parties (note 20)	2,166,221	1,478,883
Promissory notes (note 13)	706,837	498,522
Promissory notes (note 14)	179,121	17,750
Amounts owing on acquisition (note 4)	653,627	538,952
Amounts owing on acquisition (note 4)	468,055	838,317
Convertible debentures (note 14)	337,000	277,149
Convertible debentures (note 15)	270,457	-
Term loan (note 12)	1,053,993	1,051,334
Term loan (note 13)	1,126,192	1,144,337
Total current liabilities	6,845,444	5,728,552
Total current liabilities	8,259,917	6,446,903
Long term liabilities
Promissory notes (note 14)	367,710	-
Promissory notes (note 13)	95,042	346,002
Amounts owing on acquisitions (note 4)	1,~~547~~254,~~379~~003	-1,364,274
Loans from shareholders (note 11)	-788,196	~~497~~794,~~351~~635
Due to related parties (note 20)	-	1,085,906
Accrued interest - related parties (note 19)	511,676	468,825
Convertible debentures (note 15)	-	83,704
Due to related parties (note 19)	2,247,104	2,281,773
Total long term liabilities	14,~~915~~896,~~089~~021	15,~~666~~255,~~961~~509
Total liabilities	1011,~~175~~741,~~006~~465	810,~~113~~984,~~864~~061
Going concern (note 2)
Related party transactions (note 20)
Related party transactions (note 19)
Commitments and contingencies (note 22)
Commitments and contingencies (note 21)
Subsequent events (note 25)
Subsequent events (note 24)
STOCKHOLDERS’ DEFICIENCY
STOCKHOLDERS' DEFICIENCY
Common stock: $0.0002 par value, 300,000,000 common shares authorized; 134,869,261 and 100,753,638 common shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively (note 16)	$26,976	$20,151
Common stock: $0.0002 par value, 300,000,000 common shares authorized; 143,218,368 and 134,869,261 common shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively (note 15)	$28,645	$26,976
Additional paid-in capital	1213,~~221~~667,~~912~~570	712,~~047~~758,~~979~~700
Common shares to be issued (note 19)	23,000	146,550
Common shares to be issued (note 18)	23,000	485,184
Accumulated deficit	(1721,~~762~~360,~~750~~143)	(1319,~~250~~898,~~894~~841)
Accumulated other comprehensive income	15277,~~816~~971	~~345~~72,~~304~~778
Total stockholders’ deficiency	(57,~~475~~362,~~046~~957)	(56,~~690~~555,~~910~~203)
Total liabilities and stockholders’ deficiency	$4,~~699~~378,~~960~~508	$24,~~422~~428,~~954~~858

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

Gilla Inc.

Unaudited Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

(Amounts expressed in US Dollars)

	For the Three Months Ended September 30, 2017	For the Three Months Ended September 30, 2016	For the Nine Months Ended September 30, 2017	For the Nine Months Ended September 30, 2016
	For the Three Months Ended March 31, 2018	For the Three Month Ended March 31, 2017
Sales revenue	$1,~~075~~266,~~975~~239	$1,~~048~~243,~~474~~539	~~$3,585,540~~	~~$3,317,002~~
Cost of goods sold	~~451~~528,~~828~~900	~~321~~546,~~729~~733	~~1,492,548~~	~~1,527,711~~
Gross profit	~~624~~737,~~147~~339	~~726~~696,~~745~~806	~~2,092,992~~	~~1,789,291~~
Operating expenses:
Administrative	1,~~046~~453,~~253~~336	1997,~~331,755~~350	~~3,190,313~~	~~4,130,393~~
Consulting fees - related parties (note 20)	130,786	134,046	374,490	353,690
Consulting fees - related parties (note 19)	130,975	119,459
Depreciation (note 7)	2130,~~106~~761	169,~~472~~656	~~40,807~~	~~44,982~~
Amortization (notes 8 and 9)	11,650	19,500	34,950	74,500
Amortization (note 8 and 9)	39,892	11,650
Bad debt expense (recovery)	4,343	-	165,683	(1,198)
Bad debt expense	93,030	161,340
Stock option expense (note 18)	-	-	1,213,605	-
Total operating expenses	1,747,994	1,299,455
Impairment of inventory	191,143	24,453	191,143	24,453
Loss from operations	(1,010,655)	(602,649)
Impairment of fixed assets	12,020	70,142	12,020	70,142
Other income (expenses):
Impairment of goodwill (note 10)	-	-	-	208,376
Foreign exchange gain (loss)	(81,247)	4,947
Loss on settlement	-	-	23,840	-
Amortization of debt discount on debentures	(59,851)	(71,289)
(Gain) on settlements (note 4(a))	-	-	-	(245,625)
Interest expense, net	(309,549)	(229,277)
Total operating expenses	1,417,301	1,596,368	5,246,851	4,659,713
Total other expenses	(450,647)	(295,619)
Loss from operations	(793,154)	(869,623)	(3,153,859)	(2,870,422)
Net loss before income taxes	(1,461,302)	(898,268)
Other expenses:
Income tax recovery	-	-
Gain on settlements (note 4(a))	352,284	-	352,284	-
Net loss	$(1,461,302)	$(898,268)
Foreign exchange	(153,764)	18,893	(213,658)	(70,199)
Loss per share (basic and diluted)	$(0.013)	$(0.008)
Amortization of debt discount (note 15)	(138,761)	(19,894)	(799,753)	(56,180)
Weighted average number of common shares outstanding (basic and diluted)	113,809,179	107,378,584
Interest expense, net	(247,222)	(172,610)	(696,870)	(444,526)
Comprehensive loss:
Total other expenses	(187,463)	(173,611)	(1,357,997)	(570,905)
Net loss	$(1,461,302)	$(898,268)
Net loss before income taxes	(980,617)	(1,043,234)	(4,511,856)	(3,441,327)
Foreign exchange translation adjustment	205,193	(67,282)
Income taxes	-	-	-	-
Comprehensive loss	$(1,256,109)	$(965,550)
Net loss	$(980,617)	$(1,043,234)	$(4,511,856)	$(3,441,327)
Loss per weighted average number of shares outstanding (basic and diluted)	$(0.007)	$(0.010)	$(0.038)	$(0.034)
Weighted average number of shares outstanding (basic and diluted)	133,314,186	100,753,638	119,952,643	100,067,872
Comprehensive loss:
Net loss	$(980,617)	$(1,043,234)	$(4,511,856)	$(3,441,327)
Foreign exchange translation adjustment	(162,221)	25,562	(329,488)	(98,024)
Comprehensive loss	$(1,142,838)	$(1,017,672)	$(4,841,344)	$(3,539,351)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

Gilla Inc.

Unaudited Condensed Consolidated Interim Statement of Changes in Stockholders’ Deficiency

(Amounts expressed in US Dollars)

	Common Stock		Additional Paid-In	Shares To Be	Accumulated	Accumulated Other Comprehensive	Total Stockholders’
	Shares	Amount	Capital	Issued	Deficit	Income	Deficiency
Balance, December 31, 2016	100,753,638	$20,151	$7,047,979	$146,550	$(13,250,894)	$345,304	$(5,690,910)
Balance, December 31, 2017	134,869,261	$26,976	$12,758,700	$485,184	$(19,898,841)	$72,778	$(6,555,203)
Private placement units issued for cash, net of issuance costs	19,083,818	3,817	1,814,855	-	-	-	1,818,672
Private placement units issued for cash (note 15)	3,486,362	697	382,803	-	-	-	383,500
Private placement units issued for settlement of amounts owing to related parties (note 20(c))	1,998,950	400	199,495	-	-	-	199,895
Common shares issued for settlement of consulting fees owing to unrelated parties (note 15)	190,909	38	20,962	-	-	-	21,000
Private placement units issued for settlement of amounts owing to a shareholder (note 11(i))	226,920	45	22,647	-	-	-	22,692
Common shares issued on exercise of warrants (note 15)	50,000	10	9,990	-	-	-	10,000
Common shares issued for settlement of amounts owing to a shareholder	320,022	65	49,935	(50,000)	-	-	-
Common shares issued on conversion of debentures and settlement of accrued interest on debentures (note 15)	4,621,836	924	461,260	(462,184)	-	-	-
Common shares issued for settlement of consulting fees owing to unrelated parties	510,382	103	73,447	(73,550)	-	-	-
Warrants issued as stock based compensation (note 17)	-	-	33,855	-	-	-	33,855
Common shares issued for settlement of amounts owing to a director of the Company (note 20(a))	300,000	60	32,940	-	-	-	33,000
Foreign currency translation gain	-	-	-	-	-	205,193	205,193
Common shares issued for settlement of amounts owing as charitable contributions to an unrelated party (note 22(d))	300,000	60	35,940	-	-	-	36,000
Net loss	-	-	-	-	(1,461,302)	-	(1,461,302)
Common shares issued as employment income to an unrelated party	50,000	10	5,990	-	-	-	6,000
Balance, March 31, 2018	143,218,368	$28,645	$13,667,570	$23,000	$(21,360,143)	$277,971	$(7,362,957)
Common shares issued for settlement of fees owing to former directors of the Company (note 20(a))	871,000	174	121,766	-	-	-	121,940
Common shares issued on conversion of convertible debentures to unrelated parties (note 15)	3,220,000	644	321,356	-	-	-	322,000
Common shares issued on conversion of convertible debentures to related parties (note 15)	2,910,000	582	290,418	-	-	-	291,000
Common shares issued on settlement of interest owing on convertible debentures to unrelated parties (note 15)	285,822	57	28,525	-	-	-	28,582
Common shares issued on settlement of interest owing on convertible debentures to related parties (note 15)	308,429	62	30,781	-	-	-	30,843
Private placement units issued for settlement of financing fees related to an amendment of the term loan (note 13)	500,000	100	49,900	-	-	-	50,000
Common shares issued as part of a private placement to unrelated parties (note 19)	730,280	146	72,882	-	-	-	73,028
Common shares issued as part of acquisition of subsidiary (note 4(c))	2,500,000	500	349,500	-	-	-	350,000
Issuance of stock options (note 21)	-	-	1,213,605	-	-	-	1,213,605
Warrants issued as stock based compensation (note 18)	-	-	132,320	-	-	-	132,320
Warrants issued with convertible debentures (note 17)	-	-	43,737	-	-	-	43,737
Warrants issued as part of acquisition of subsidiary (note 17)	-	-	252,631	-	-	-	252,631
Embedded conversion feature of convertible debentures (note 15)	-	-	31,263	-	-	-	31,263
Foreign currency translation gain	-	-	-	-	-	(329,488)	(329,488)
Net loss	-	-	-	-	(4,511,856)	-	(4,511,856)
Balance, September 30, 2017	134,869,261	$26,976	$12,221,912	$23,000	$(17,762,750)	$15,816	$(5,475,046)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

Gilla Inc.

Unaudited Condensed Consolidated Interim Statements of Cash Flows

(Amounts Expressed in US Dollars)

	For the Nine Months Ended September 30, 2017	For the Nine Months Ended September 30, 2016
	For the Three Months Ended March 31, 2018	For the Three Months Ended March 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(41,~~511~~461,~~856~~302)	$(3898,~~441,327~~268)
Items not requiring an outlay of cash
Depreciation	4030,~~807~~761	449,~~982~~656
Amortization	3439,~~950~~892	7411,~~500~~650
Stock based compensation	138,320	465,130
Stock based compensation (note 17)	54,855	39,077
Amortization of debt discount	799,753	56,180
Amortization of debt discount on amounts owing on acquisition	64,769	-
Stock option expense	1,213,605	-
Bad debt expense	93,030	161,340
Interest accrued on related party fee deferrals	66,940	-
Amortization of debt discount on term loan	25,435	-
Loss on settlement of debt	23,840	-
Amortization of debt discount on shareholder loans	25,667	-
Gain on settlement of debt	(352,284)	(245,625)
Amortization of debt discount on promissory notes	5,483	-
Interest accrued on term loan	129,043	-
Amortization of debt discount on debentures	59,851	71,289
Interest on amounts owing on acquisition	39,734	40,975
Interest on term loan	42,577	42,563
Bad debt expense	165,683	(1,198)
Impairment of inventory	191,143	24,453
Impairment of fixed assets	12,020	70,142
Impairment of goodwill	-	208,376
Changes in operating assets and liabilities
Trade receivable	(~~351~~87,~~035~~157)	(~~303~~422,~~522~~687)
Other current assets	~~198~~(28,~~435~~520)	2343,~~326~~794
Inventory	~~122~~(86,~~541~~787)	(~~273~~2,~~142~~268)
Bank indebtedness	(11,213)	-
Accounts payable	318,068	(77,542)
Accounts payable	55,913	1,033,815
Accrued liabilities	301,225	26,691
Accrued liabilities	68,365	129,077
Customer deposits	(31,623)	23,795
Customer deposits	(25,798)	(318,741)
Due to related parties	148,893	(23,984)
Amounts owing on acquisition	-	(45,000)
Accrued interest-related parties	43,039	77,625
Due to related parties	255,968	565,952
Net cash used in operating activities	(441,844)	(917,269)
Accrued interest-related parties	161,395	86,714
Net cash used in operating activities	(1,533,731)	(1,804,933)
CASH FLOWS FROM INVESTING ACTIVITIES:
(Addition) of capital assets	(73,472)	(89,612)
Additions of capital assets	(590)	(11,673)
Net cash used in investing activities	(~~73,472~~590)	(8911,~~612~~673)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from promissory notes	320,390	-
Repayments to promissory notes	(26,560)	-
Repayments to promissory notes	(45,106)	-
Payments of amounts owing on acquisitions	(20,000)	-
Proceeds from short term loan	-	21,000
Repayments to term loan	(44,651)	(110,809)
Proceeds from term loan of principal interest	-	783,629
Shareholder loans received	24,518	150,380
Repayments to term loan	(239,908)	(27,323)
Repayments to related parties	(9,358)	(241,454)
Shareholder loan repayments	(3,512)	-
Proceeds from sale of convertible debentures	-	33,181
Shareholder loans received	150,380	470,467
Proceeds from issuance of common shares	393,500	1,277,903
Payments of amounts owing on acquisition	(20,000)	-
Net cash provided by financing activities	317,449	1,109,201
Proceeds from related parties	106,488	640,452
Effect of exchange rate changes on cash	66,340	(49,277)
Repayments to related parties	(505,464)	(282,103)
Net (decrease) increase in cash	(58,645)	130,982
Proceeds from sale of convertible debentures	-	351,500
Cash at beginning of year	62,292	184,754
Repayment of convertible debentures	-	(25,000)
Cash at end of year	$3,647	$315,736
Proceeds from issuance of common shares	1,868,672	-
Net cash provided by financing activities	1,631,940	1,932,622
Effect of exchange rate changes on cash	(133,808)	46,967
Net increase (decrease) in cash	(109,071)	85,044
Cash at beginning of period	184,754	81,696
Cash at end of period	$75,683	$166,740
Supplemental Schedule of Cash Flow Information:
Cash paid for interest	$~~192~~48,~~476~~858	$9457,~~816~~514
Cash paid for income taxes	$-	$-
Non cash financing activities:
Convertible debentures issued for settlement of related party fees	$-	$20,000
Common shares issued in settlement of related party and shareholder loans	$-	$222,587
Convertible debentures issued for settlement of accounts payable	$-	$10,000
Common shares issued for settlement of interest payable	$37,124	$-
Convertible debentures issued for settlement of related party and shareholder loans	$75,000	$35,000
Common shares issued/to be issued for settlement of consulting fees payable	$21,000	$-
Common shares issued for settlement of accounts payable	$59,028	$-
Debentures issued for settlement of related party and shareholder loans	$-	$75,000
Common shares issued in settlement of related party fees	$154,940	$-
Common shares issued in settlement of related party and shareholder loans	$222,587	$-
Common shares issued in settlement of deferred related party fees	$-	$48,000

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

Gilla Inc.

Notes to Unaudited Condensed Consolidated Interim Financial Statements

(Amounts expressed in US Dollars)

1. NATURE OF OPERATIONS

Gilla Inc. (“Gilla”, the “Company” or the “Registrant”) was incorporated under the laws of the state of Nevada on March 28, 1995 under the name of Truco, Inc. The Company’s registered address is 475 Fentress Blvd., Unit L, Daytona Beach, Florida 32114.

The current business of the Company consists of the manufacturing, marketing and distribution of E-liquid (“E-liquid”), which is the liquid used in vaporizers and electronic cigarettes (“E-cigarettes”), and developer of turn-key vapor and cannabis concentrate solutions for high-terpene vape oils, pure crystalline, high-performance vape pens and other targeted products. The Company aims to be a global leader in developing the most efficient and effective vaping solutions for nicotine and cannabis related products. The Company’s multi-jurisdictional, broad portfolio approach services both the nicotine and cannabis markets with high-quality products that deliver a consistent and reliable user experience. Gilla’s proprietary product portfolio includes: Coil Glaze™, Craft Vapes™, Siren, The Drip Factory, Shake It, Surf Sauce, Ohana, Moshi, Crisp, Just Fruit, Vinto Vape, Vapor’s Dozen, Enriched Vapor and Crown E-liquid™.

2. GOING CONCERN

~~These~~ These unaudited condensed consolidated interim financial statements ~~have~~ have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in these unaudited condensed consolidated interim financial statements, at ~~September~~March 3031, ~~2017~~2018, ~~the~~ the Company has an accumulated deficit of $1721,~~762~~360,~~750~~143 (December 31, 2017 – $19,898,841) and a working capital deficiency of $5,750,400 (December 31, 2017 – $74,~~135~~659,~~352~~008) as well as negative cash flows from operating activities of $1441,~~533~~844 (March 31,~~731~~ 2017 – $917,269) for the ~~nine~~three ~~month~~months ~~period~~ ended ~~September~~March 3031, ~~2017~~ 2018. These conditions represent material uncertainty that cast significant ~~doubt~~doubts about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon achieving a profitable level of operations or on the ability of the Company to obtain necessary financing to fund ongoing operations. Management believes that the Company will not be able to continue as a going concern for the next twelve months without additional financing or ~~increased~~ increased revenues.

To meet these objectives, the Company continues to seek other sources of financing in order to support existing operations and to expand the range and scope of its business. However, there are no assurances that any such financing can be obtained on acceptable terms and in a timely manner, if at all. Failure to obtain the necessary working capital would have a material adverse effect on the business prospects and, depending upon the shortfall, the Company may have to curtail or cease its operations.

~~These~~ These unaudited condensed consolidated interim financial statements do do not include any adjustments to the recorded assets or ~~liabilities~~ liabilities, that might be ~~necessary~~material, should the Company have to ~~curtail~~ curtail operations or be unable to continue in existence.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may bebeexpected ~~expected~~ for a full year. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016~~2017, as filed with the U.S. Securities and Exchange Commission. Certain comparative figures have been reclassified to conform with the current year’s presentation.

The accounting policies of the Company are in accordance with accounting principles generally accepted in the United States of America. Outlined below are those policies considered particularly significant:

(a)

Basis of Consolidation

These unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly owned subsidiaries: Gilla Operations, LLC; E Vapor Labs Inc. (“E Vapor Labs”); Gilla Enterprises Inc. (“Gilla Enterprises”) and its wholly owned subsidiaries Gilla Europe Kft., Gilla Operations Europe s.r.o. and Vape Brands International Inc. (“VBI”); HyStyle Brands Inc.; E-Liq World, LLC; Charlie’s Club, Inc.; Gilla Operations Worldwide Limited (“Gilla Worldwide”); Gilla Franchises, LLC and its wholly owned subsidiary Legion of Vape, LLC; and Snoke Distribution Canada Ltd. and its wholly owned subsidiary Snoke Distribution USA, LLC. All inter-company accounts and transactions have been eliminated in preparing these unaudited condensed consolidated interim financial statements.

(b)

Advertising Costs

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 720, Other Expenses (“ASC 720”), ~~the~~ Company expenses ~~the~~all ~~production costs of~~ advertising ~~the first time the advertising takes place. The Company expenses all advertising~~ costs as incurred. During the three ~~and nine~~ month ~~periods~~period ended ~~September~~ 30March 31, ~~2017~~2018, the Company expensed $3615,~~393~~702 ~~and $128,240, respectively, as corporate promotions~~ (~~September~~March 3031, ~~2016~~ 2017 – $6552,~~045 and $223,597~~534). ~~These~~as ~~amounts~~corporate promotions which have been recorded as an administrative expense.

(c)

Recently Adopted Accounting Pronouncements

In ~~November~~ ~~2015~~May 2014, the FASB issued ~~Accounting Standards Update (“~~ASU”) No. ~~2015~~ 2014-1709, ~~Income~~Revenue ~~Taxes~~from ~~(Topic~~Contracts ~~740):~~with ~~Balance~~Customers ~~Sheet~~(Topic ~~Classification~~606) ~~of Deferred Taxes~~ (“ASU ~~2015~~ 2014-1709”)., ~~ASU~~requiring ~~2015-17~~an ~~simplifies~~entity ~~the presentation of~~to ~~deferred~~recognize ~~income~~revenue ~~taxes~~when byit ~~eliminating~~transfers ~~the~~promised ~~separate~~goods ~~classification~~or ofservices to ~~deferred~~customers ~~income~~in ~~tax~~an ~~liabilities~~amount ~~and~~that ~~assets~~reflects ~~into~~the ~~current~~consideration ~~and~~to which the ~~noncurrent~~entity ~~amounts~~expects into ~~the~~be ~~consolidated~~entitled ~~balance~~to ~~sheet~~in ~~statement~~exchange ~~of financial~~for ~~position.~~those ~~The~~goods ~~amendments~~or services. inASU ~~the~~2014-09 ~~update~~will ~~require~~supersede ~~that~~nearly all existing revenue ~~deferred~~recognition ~~tax~~guidance ~~liabilities~~under ~~and~~U.S. ~~assets~~GAAP bewhen ~~classified~~it becomes effective. ASU 2014-09 as ~~noncurrent~~amended inby ASU No. 2015-14, ASU No. ~~the~~2016-08, ~~consolidated~~ASU ~~balance~~No. ~~sheet~~2016-10, ASU No. ~~The~~2016-12 ~~amendments~~and inASU ~~this~~No. ~~update~~2016-20, ~~are~~is effective for interim and annual periods beginning after December 15, ~~2016,~~2017 and ~~interim~~ ~~periods~~is ~~therein and may be~~ applied on either ~~prospectively~~a ormodified ~~retrospectively~~retrospective toor ~~all~~full ~~periods~~retrospective ~~presented~~basis. Adoption of ASU ~~2015~~No. 2014-1709 did not have an impact on the Company’s ~~condensed~~ consolidated ~~interim financial~~ financial statements.

In ~~March~~April 2016, the FASB issued ASU No. 2016-0910, ~~Compensation~~Revenue –from ~~Stock~~Contracts ~~Compensation~~with Customers (Topic ~~718~~606): ~~Improvements~~Identifying ~~to Employee~~Performance ~~Share-Based~~Obligations ~~Payment~~and Licensing ~~Accounting~~ (“ASU 2016-0910”). ~~This update~~ASU ~~requires that all excess tax benefits and tax deficiencies arising from share~~2016-~~based~~10 ~~payment awards should be recognized as~~clarifies ~~income tax expense or benefit on~~ the ~~income~~following ~~statement.~~two ~~The amendment~~aspects ~~also~~of ~~states~~Topic ~~that~~606: ~~excess~~identifying ~~tax benefits should be classified~~performance ~~along~~obligations ~~with~~and ~~other~~the ~~income~~licensing ~~tax~~implementation ~~cash flows as an operating activity. In addition~~guidance, ~~an entity can make an entity-wide accounting policy~~while ~~election~~retaining ~~to either estimate~~ the ~~number~~related ofprinciples ~~awards expected to vest or account~~ for ~~forfeitures~~those ~~as they occur~~areas. The provisions of ~~this~~ this update are effective for annual and interim periods beginning after December 15, ~~2016.~~2017, ~~Adoption~~with early application permitted. Adoption of ASU No. 2016-0910 did not have an impact on the Company’s ~~condensed~~ consolidated ~~interim~~ financial statements.

In ~~October~~ May 2016, the FASB issued ASU No. 2016-1712, ~~Consolidation~~Revenue from Contracts with Customers (Topic ~~810~~ 606): Narrow-Scope ~~Interests~~Improvements ~~Held~~and ~~through~~Practical ~~Related~~Expedients ~~Parties That Are under Common Control~~ (“ASU 2016-1712”). The ~~new~~core ~~guidance~~principal ~~changed~~of ~~how~~ASU a2016-12 ~~reporting~~is ~~entity~~the ~~that~~recognition isof arevenue ~~single~~to ~~decision~~depict ~~maker~~the ~~for~~transfer aof ~~variable~~promised ~~interest~~goods ~~entity~~or ~~(“VIE”)~~services ~~will~~to ~~consider~~customers ~~its~~in ~~indirect~~an ~~interests~~amount in that ~~VIE~~ ~~when~~reflects ~~determining whether~~ the ~~reporting entity is the primary~~consideration ~~beneficiary~~to ~~and~~which ~~should consolidate~~ the ~~VIE.~~entity ~~Under~~expects ~~previous U.S.~~to ~~GAAP,~~be aentitled ~~single~~in ~~decision~~exchange ~~maker~~for inthose agoods ~~VIE~~or isservices. The ~~required~~provisions toof ~~consider~~this anupdate ~~indirect~~are ~~interest held by a~~effective ~~related~~for ~~party~~annual ~~under~~and ~~common~~interim ~~control~~periods inbeginning ~~its~~after December ~~entirety. Under ASU~~15, ~~2016-17~~2017, ~~the~~with ~~single~~early ~~decision~~application ~~maker will consider the indirect interest on a proportionate basis~~permitted. Adoption of ASU No. 2016-17 12 did not have an impact on the Company’s ~~condensed~~ consolidated ~~interim~~ financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (“ASU 2016-15”), which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. Among other clarifications, the guidance requires that cash proceeds received from the settlement of corporate-owned life insurance (COLI) policies be classified as cash inflows from investing activities and that cash payments for premiums on COLI policies may be classified as cash outflows for investing activities, operating activities or a combination of both. The guidance is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. Retrospective application is required. Adoption of ASU No. 2016-15 did not have an impact on the Company’s consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). ASU 2016-16 prohibits the recognition of current and deferred income taxes for an intra-entity transfer until the asset has been sold to an outside party. The amendment in ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Adoption of ASU No. 2016-16 did not have an impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. Adoption of ASU No. 2017-09 did not have an impact on the Company’s consolidated financial statements.

Effective January 1, 2018, the Company adopted ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) which revises the classification and measurement of investments in equity securities. ASU 2016-01 requires that equity investments, except those accounted for under the equity method of accounting, be measured at fair value and changes in fair value are recognized in net income. ASU 2016-01 also provides a new measurement alternative for equity investments that do not have a readily determinable fair value (cost method investments). These investments are measured at cost, less any impairment, adjusted for observable price changes. Adoption of ASU 2016-01 did not have an impact on the Company’s consolidated financial statements.

(d)

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and other than the below, does not expect the future adoption of any such pronouncements to have a significant impact on its results of operations, financial condition or cash flow.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), requiring an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 will supersede nearly all existing revenue recognition guidance under U.S. GAAP when it becomes effective. ASU 2014-09 as amended by ASU No. 2015-14, ASU No. 2016-08, ASU No. 2016-10, ASU No. 2016-12 and ASU No. 2016-20, is effective for interim and annual periods beginning after December 15, 2017 and is applied on either a modified retrospective or full retrospective basis. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize all leases with terms in excess of one year on their balance sheet as a right-of-use asset and a lease liability at the commencement date. The new standard also simplifies the accounting for sale and leaseback transactions. The amendments in this update are effective for annual periods beginning after December 15, 2018, and interim periods therein and must be adopted using a modified retrospective method for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”). ASU 2016-10 clarifies the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. The provisions of this update are effective for annual and interim periods beginning after December 15, 2017, with early application permitted. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). The core principal of ASU 2016-12 is the recognition of revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The provisions of this update are effective for annual and interim periods beginning after December 15, 2017, with early application permitted. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The measurement of expected losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (“ASU 2016-15”), which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. Among other clarifications, the guidance requires that cash proceeds received from the settlement of corporate-owned life insurance (COLI) policies be classified as cash inflows from investing activities and that cash payments for premiums on COLI policies may be classified as cash outflows for investing activities, operating activities or a combination of both. The guidance is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. Retrospective application is required. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). ASU 2016-16 prohibits the recognition of current and deferred income taxes for an intra-entity transfer until the asset has been sold to an outside party. The amendment in ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). The new guidance eliminates the requirement to calculate the implied fair value of goodwill (Step 2 of the current two-step goodwill impairment test under ASC 350). Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (Step 1 of the current two-step goodwill impairment test). ASU 2017-04 is effective prospectively for reporting periods beginning after December 15, 2019, with early adoption permitted for annual and interim goodwill impairment testing dates after January 1, 2017. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In ~~May~~July 2017, the FASB issued ASU No. 2017-0911, ~~Compensation-Stock~~Earnings ~~Compensation~~Per Share (Topic ~~718~~260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down ~~Scope~~Round Features; II. Replacement of ~~Modification~~the ~~Accounting~~Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-0911”). ASU 2017-0911 ~~clarifies~~allows ~~which~~a ~~changes~~financial instrument with a down-round feature to ~~the~~no ~~terms~~longer automatically be classified as a orliability ~~conditions~~solely based on the existence of athe ~~share~~down-~~based~~round provision. ~~payment~~The ~~award~~update ~~require~~also anmeans ~~entity~~the instrument would not have to ~~apply~~be ~~modification~~accounted ~~accounting~~for inas ~~Topic~~a ~~718~~derivative and be subject to an updated fair value measurement at each reporting period. The standard is effective for interim and annual reporting periods beginning after December 15, ~~2017~~2018, with early adoption permitted. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In ~~July 2017~~February 2018, the FASB issued ASU No. ~~2017~~ 2018-1102, ~~Earnings~~Income ~~Per~~Statement ~~Share~~- ~~(Topic 260) Distinguishing~~Reporting ~~Liabilities~~Comprehensive ~~from Equity (Topic 480) Derivatives and Hedging (Topic 815)~~Income: I.Reclassification ~~Accounting for Certain Financial Instruments with Down Round Features; II. Replacement~~ of ~~the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of~~ Certain ~~Nonpublic Entities~~Tax ~~and~~effects ~~Certain Mandatorily Redeemable Noncontrolling~~from ~~Interests~~Accumulated ~~with~~Other aComprehensive ~~Scope~~Income ~~Exception~~ (“ASU ~~2017~~2018-1102”). ~~ASU~~which ~~2017-11~~ allows afor ~~financial~~the ~~instrument~~reclassification ~~with a~~from ~~down-round~~accumulated ~~feature~~other tocomprehensive noincome ~~longer~~to ~~automatically~~retained beearnings ~~classified~~for ~~as a~~the ~~liability~~stranded ~~solely~~tax ~~based~~effects onarising from the ~~existence~~change ofin the ~~down-round~~reduction of ~~provision~~the U.S. ~~The~~federal ~~update~~statutory ~~also~~income ~~means~~tax ~~the~~rate ~~instrument~~to ~~would~~21% ~~not~~from ~~have~~35%. toThe tax beeffects ~~accounted~~of ~~for~~items asincluded ain ~~derivative~~accumulated ~~and~~comprehensive beincome ~~subject~~at December to31, an2017 ~~updated~~do ~~fair value~~not ~~measurement~~reflect ~~each~~the ~~reporting~~appropriate ~~period~~tax rate. ~~The~~ASU 2018-02 ~~standard~~ is effective for interim and annual ~~reporting~~ periods beginning after ~~December~~ December 15, 2018~~, with early adoption permitted~~. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

4. AMOUNTS OWING ON ACQUISITIONS

The Company has outstanding current amounts owing on acquisitions as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Unsecured Promissory Notes(a)	$-	$783,317
Promissory Note Settlement(a)	$120,000	$120,000
Promissory Note Settlement(a)	130,000	-
Due to TMA Vendors(b)	55,000	55,000
Earn out on VBI acquisition(c)	178,597	-
Earn-Out on VBI acquisition(c)	296,374	209,487
VBI Vendor take back(c)	104,458	-
VTB on VBI acquisition (c)	182,253	154,465
	$468,055	$838,317
	$653,627	$538,952

The Company has outstanding long term amounts owing on acquisitions as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Promissory Note Settlement(a)	$~~286~~265,~~114~~436	$-270,967
Due to TMA Vendors(b)	-	-
Earn-Out on VBI acquisition(c)	792,713	871,825
Earn out on VBI acquisition(c)	1,000,773	-
VTB on VBI acquisition(c)	195,854	221,482
VBI Vendor take back(c)	260,492	-
	$1,254,003	$1,364,274
	$1,547,379	$-

(a) On July 1, 2015, the Company acquired all of the issued and outstanding shares of E Vapor Labs, a Florida based E-liquid manufacturer. The Company acquired E Vapor Labs in order to procure an E-liquid manufacturing platform allowing the Company to secure large private label contracts as well as manufacture its own brands going forward.

~~In consideration~~On ~~for~~July ~~the acquisition~~1, 2015, the Company ~~paid~~acquired toall ~~the~~of ~~vendors, $225,000 in cash and issued $900,000 in unsecured promissory notes on closing (collectively,~~ the ~~“Unsecured Promissory Notes”). The Unsecured Promissory Notes were~~ issued inand ~~three equal~~outstanding ~~tranches~~shares of ~~$300,000 due four (4), nine (9) and eighteen (18)~~E ~~months~~Vapor ~~respectfully from closing (individually~~Labs, ~~“Promissory Notes~~a ~~A”,~~Florida ~~“Promissory~~based ~~Notes~~E-liquid ~~B”,~~manufacturer. The ~~and~~Company ~~“Promissory~~acquired ~~Notes~~E ~~C”,~~Vapor ~~respectively).~~Labs ~~The~~in ~~Unsecured Promissory~~order ~~Notes~~to ~~were~~procure ~~all~~an ~~unsecured and non~~E-~~interest~~liquid ~~bearing. The~~manufacturing ~~Unsecured~~platform ~~Promissory~~allowing ~~Notes~~the ~~were~~Company ~~all~~to ~~and~~secure ~~each~~large ~~subject~~private ~~to adjustments~~label contracts as ~~outlined~~well inas ~~the~~manufacture ~~share~~its ~~purchase~~own ~~agreement~~brands ~~(the~~going ~~“SPA”), dated June 25, 2015~~forward.

AtIn ~~December~~consideration ~~31,~~for ~~2015~~the acquisition, the Company ~~adjusted~~paid to the ~~Promissory Notes A for~~vendors, $~~116~~225,~~683~~000 ~~which~~in ~~was~~cash ~~the~~and ~~known~~issued ~~difference~~$900,000 in ~~the~~unsecured ~~working~~promissory ~~capital~~notes ~~balance~~on at closing of(collectively, the ~~acquisition~~“Unsecured ~~from~~Promissory Notes”). ~~the~~The ~~amount~~Unsecured ~~specified~~Promissory Notes were issued in three ~~the~~equal ~~SPA.~~tranches ~~Furthermore~~of $300,000 adue ~~12%~~four ~~discount~~(4), ~~rate~~nine ~~was~~(9) ~~used~~and toeighteen ~~calculate the~~(18) ~~present~~months ~~value~~respectfully offrom ~~the~~closing ~~Unsecured~~(individually, “Promissory Notes ~~based~~A”, on“Promissory ~~the Company’s~~Notes ~~estimate~~B”, ofand “Promissory ~~cost~~Notes ofC”, ~~financing~~respectively). ~~for~~The ~~comparable notes~~Unsecured ~~with~~Promissory ~~similar~~Notes ~~term~~were all unsecured and ~~risk~~non-interest ~~profiles~~bearing. ~~Over the term of the~~The ~~respective~~ Unsecured Promissory Notes, ~~interest~~were ~~was~~all ~~accrued~~and ateach ~~12% per~~subject ~~annum~~ to ~~accrete~~adjustments as ~~the~~outlined ~~Unsecured~~in ~~Promissory~~the ~~Notes~~share topurchase ~~their~~agreement (the ~~respective~~“SPA”), ~~principal~~dated ~~amounts~~June 25, 2015. ~~During~~At December 31, 2015, the Company ~~three~~adjusted ~~and~~the ~~nine~~Promissory ~~month periods~~Notes ~~ended~~A ~~September~~for 30$116,683 ~~2017,~~which was the known ~~Company~~difference ~~recorded $nil~~ in ~~interest~~ ~~expense~~the ~~related~~working tocapital ~~the~~balance ~~accretion~~at closing of the ~~Unsecured~~ ~~Promissory~~acquisition ~~Notes~~from ~~(September~~the ~~30,~~amount ~~2016~~specified -in ~~$8,146~~the ~~and $31,392, respectively)~~SPA.

	Promissory Notes A	Promissory Notes B	Promissory Notes C	Total
Present value at December 31, 2015	$203,573	$291,620	$267,857	$763,050
Measurement period adjustment	(19,505)	-	-	(19,505)
Interest expense related to accretion	(751)	8,380	32,143	39,772
Present value at December 31, 2016	$183,317	$300,000	$300,000	$783,317

On August 30, 2017, the Company entered into a settlement agreement (the “Promissory Note Settlement”) with the holders of the Unsecured Promissory Notes to settle all claims between them. As a result of the Promissory Note Settlement, the Company agreed to settle the Unsecured Promissory Notes with a total payment of $600,000 payable as two (2) payments of $20,000 due September 21, 2017 and October 21, 2017 and $10,000 per month for the following fifty-six (56) months beginning November 21, 2017. The Company may prepay the balance of the Promissory Note Settlement at any time and would receive a 10% discount on the outstanding balance upon doing so. A 15% discount rate has been used to calculate the present value of the Promissory Note Settlement based on the Company’s estimate of cost of financing for comparable instruments with similar term and risk profiles. Over the term of the Promissory Note Settlement, interest will be accrued at 15% per annum to accrete the Promissory Note Settlement to its respective principal amount. During the three month period ended March 31, 2018, the Company recorded $14,469 in interest expense related to the accretion of the Promissory Note Settlement (March 31, 2017 – $nil).

	Total
Present value of Promissory Note Settlement at the settlement date	$431,033
Payments made	(60,000)
Interest expense related to accretion	19,934
Present value at December 31, 2017	$390,967
Payments made	(20,000)
Interest expense related to accretion	14,469
Less: Current amount owing	(120,000)
Long term portion at March 31, 2018	$265,436

(b)

On December 2, 2015, the Company acquired all of the assets of The Mad Alchemist, LLC (“TMA”), an E-liquid manufacturer, including the assets, rights and title to own and operate The Mad Alchemist™ and Replicant E-liquid brands (the “TMA Brands”).

In consideration for the acquisition, the Company issued 819,672 Common Shares valued at $0.122 per share for a total value of $100,000; agreed to pay a total of $400,000 in deferred payments (the “Amounts Owing on Acquisition”), payable in ten (10) equal payments of $20,000 in cash and $20,000 in Common Shares every three (3) months following the closing date; and agreed to a quarterly earn-out based on the gross profit stream derived from product sales of the TMA Brands. No earn-out had ever been achieved and the Company has since retired the TMA Brands.

On ~~August~~April 3015, ~~2017~~2016, the Company entered into a settlement agreement (the “~~Promissory~~TMA ~~Note~~ Settlement Agreement”) with ~~the~~TMA ~~holders~~and of the ~~Unsecured Promissory Notes to settle all claims between them.~~ Asvendors ~~a result~~ of ~~the~~TMA ~~Promissory Note Settlement~~(collectively, the ~~Company~~“TMA ~~agreed~~Vendors”). Subject to ~~settle~~ the ~~Unsecured~~terms ~~Promissory~~and ~~Notes~~conditions ~~with~~of athe ~~total~~TMA ~~payment of~~Settlement ~~$600~~Agreement,~~000~~ ~~payable~~the asparties ~~two~~settled: (2i) ~~payments~~any ~~of $20,000 due September 21, 2017~~ and ~~October~~all ~~21,~~compensation ~~2017~~ and expenses ~~$10,000~~owing ~~per~~by ~~month for~~ the ~~following fifty-six (56) months beginning November 21, 2017. The~~ Company ~~may prepay~~to the ~~balance~~TMA ofVendors ~~the Promissory Note Settlement at any time~~ and ~~would~~(ii) ~~receive a 10% discount on~~ the ~~outstanding balance upon~~ ~~doing~~$400,000 ~~so. A 15% discount rate has been used to calculate the present value~~ of ~~the~~Amounts ~~Promissory~~Owing ~~Note Settlement based~~ on ~~the Company’s~~Acquisition ~~estimate~~in ofexchange ~~cost of financing~~ for ~~comparable notes with similar term and risk profiles. The present value of~~ the ~~Promissory~~Company ~~Note~~paying ~~Settlement was calculated~~ to ~~be $431,033, and as a result,~~ the ~~Company~~TMA ~~has~~Vendors ~~recorded~~ a ~~gain~~total on settlement ~~in the amount~~consideration of $~~352~~133,~~284.~~163 ~~Over~~payable ~~the~~as ~~term~~$100,000 ofin ~~the~~cash ~~Promissory~~and ~~Note Settlement~~$33, ~~interest~~163 ~~will~~in ~~be accrued at 15% per annum to accrete~~ the ~~Promissory~~ ~~Note~~Company’s ~~Settlement~~assets toas ~~its~~a ~~respective principal amount~~payment-in-kind. ~~During~~As ~~the three~~at ~~and~~March ~~nine~~31, ~~month~~2018, $55,000 ~~periods~~(December ~~ended September 30~~31, 2017, ~~the~~– ~~Company recorded~~ $555,~~081~~000) inremains ~~interest~~payable ~~expense related~~ to the ~~accretion of the~~ ~~Promissory~~TMA ~~Note Settlement (September 30, 2016 - $nil)~~Vendors.

	Total
Present value of Promissory Note Settlement at the settlement date	$431,033
Payments made	(20,000)
Interest expense related to accretion	5,081
Less: Current amount owing	(130,000)
Present value at September 30, 2017	$286,114

(c)

~~(b)~~ On ~~December 2,~~July ~~2015~~31, 2017, the Company’s ~~acquired~~wholly ~~all~~owned ~~of the assets of The Mad Alchemist~~subsidiary, ~~LLC~~Gilla ~~(“TMA”)~~Enterprises, an ~~E-liquid~~acquired ~~manufacturer,~~all ~~including~~of the ~~assets,~~issued ~~rights~~ and ~~title~~outstanding ~~to own~~shares ~~and~~of ~~operate~~VBI, ~~The~~a Canada-based ~~Mad Alchemist™ and Replicant~~ E-liquid ~~brands~~ ~~(the~~manufacturer ~~“TMA~~and ~~Brands”)~~distributor.

InThe ~~consideration~~following ~~for~~summarizes the ~~acquisition,~~fair ~~the Company issued 819,672 Common Shares valued at $0.122 per share for a total~~ value of ~~$100,000;~~ ~~agreed to pay a total of $400,000 in deferred payments (~~the ~~“Amounts~~assets ~~Owing on Acquisition”)~~acquired, ~~payable in ten~~ ~~(10)~~liabilities ~~equal~~assumed ~~payments of $20,000 in cash~~ and ~~$20,000 in Common Shares every three (3) months following~~ the ~~closing~~consideration ~~date;~~transferred and agreed to a quarterly earn-out based on the gross profit stream derived from product sales of the TMA Brands. The earn-out commenced on the closing date and payed up to a maximum of 25% of the gross profit stream. Furthermore, a 12% discount rate had been used to calculate the present value of the Amounts Owing on Acquisition. Over the term of the respective deferred payments, interest was accrued at ~~12%~~ ~~per annum to accrete~~ the ~~payments to their respective principal~~ ~~amounts.~~acquisition No earn-out had ever been achieved and the Company has since retired the TMA Brands. During the three and nine month periods ended September 30, 2017, the Company recorded $nil in interest expense related to the accretion of the Amounts Owing on Acquisition (September 30, 2016 – $nil and $9,582, respectively).date:

On April 15, 2016, the Company entered into a settlement agreement (the “TMA Settlement Agreement”) with TMA and the vendors of TMA (collectively, the “TMA Vendors”). Subject to the terms and conditions of the TMA Settlement Agreement, the parties settled: (i) any and all compensation and expenses owing by the Company to the TMA Vendors and (ii) the $400,000 of Amounts Owing on Acquisition in exchange for the Company paying to the TMA Vendors a total settlement consideration of $133,163 payable as $100,000 in cash and $33,163 in the Company’s assets as a payment-in-kind. Of the $100,000 payable in cash under the TMA Settlement Agreement, $45,000 was paid upon execution of the settlement, $27,500 was payable thirty (30) days following execution of the settlement and the remaining $27,500 was payable at the later of: (i) sixty (60) days following execution of the settlement or (ii) the completion of the historical audit of TMA. As a result of the TMA Settlement Agreement, the Company has recorded a gain on settlement in the amount of $274,051. As at September 30, 2017, $55,000 (December 31, 2016 – $55,000) remains payable to the TMA Vendors. In addition, the Company and the TMA Vendors mutually terminated all employment agreements between the Company and the TMA Vendors, entered into on the date of closing of the acquisition by the Company, and all amounts were fully settled pursuant to the TMA Settlement Agreement. Due to the change in circumstances, during the year ended December 31, 2016, the Company tested goodwill and intangibles for impairment and as a result, the Company has fully impaired goodwill and intangible assets related to the acquired assets of TMA in the amount of $208,376 and $122,983, respectively, which formerly represented the value of brands, customer relationships, workforce and business acumen acquired.

	Allocation
Assets acquired:
Cash	$1,377
Receivables	5,576
Other current assets	74,598
Inventory	83,820
Fixed assets	214,765
Intangible assets	704,846
Goodwill	1,596,553
Total assets acquired	$2,681,535

Liabilities assumed:
Bank indebtedness	$5,597
Accounts payable	218,028
Customer deposits	33,008
Loans payable	112,218
Capital lease	125,893
Due to related parties	15,707
Deferred tax liability	186,793
Total liabilities assumed	$697,244

Consideration:
Issuance of Common Shares	$350,000
Issuance of warrants	252,631
Vendor Take Back	356,443
Earn out	1,025,217
Total consideration	$1,984,291

In consideration for the acquisition, the Company paid to the vendors of VBI the following consideration: (ci) On2,500,000 ~~July~~Common ~~31,~~Shares of ~~2017~~the Company valued at $0.14 per share for a total value of $350,000; (ii) warrants for the purchase of 2,000,000 Common Shares of the Company ~~acquired~~exercisable ~~all~~over twenty-four (24) months at an exercise price of $0.20 per share from the ~~issued~~closing ~~and~~date, ~~outstanding~~such warrants ~~shares~~vesting in five (5) equal tranches every four (4) months following the closing date; (iii) a total of ~~VBI~~CAD $550,000 in non-interest bearing, unsecured vendor-take-back loans (the “VTB”) due over twenty-four (24) months, with principal repayments beginning five (5) months from the closing date until maturity of up to CAD $25,000 per month; and (iv) an earn-out (the “Earn-Out”) capped at: (a) the total cumulative amount of CAD $2,000,000; or (b) five (5) years from the closing date. The Earn-Out shall be calculated as: 15% of the gross profit generated in Canada by VBI’s co-~~based~~pack and distribution business; 10% of the revenue generated in Canada by Gilla’s existing E-liquid brands; ~~manufacturer~~and 15% of the revenue generated globally on VBI’s existing E-liquid brands. Furthermore, the Earn-Out shall be calculated and ~~distributor~~paid to the vendors of VBI quarterly in arrears and only as 50% of the aforementioned amounts on incremental revenue between CAD $300,000 and CAD $600,000 per quarter and 100% of the ~~through~~aforementioned ~~its~~amounts ~~wholly~~on ~~owned~~incremental ~~subsidiary~~revenue ~~Gilla~~above ~~Enterprises~~CAD $600,000 per quarter with the Earn-Out payable to the vendors in the fifth year repeated and paid to the vendors in four (4) quarterly payments after the end of the Earn-Out period, subject to the cumulative limit of the Earn-Out. No Earn-Out shall be payable to the vendors of VBI if total revenue for the Earn-Out calculation period is less than CAD $300,000 per quarter. A 15% discount rate has been used to calculate the present value of the Earn-Out on the Company’s estimate of cost of financing for comparable instruments with similar term and risk profiles. Over the term of the respective Earn-Out, interest will be accrued at 15% per annum to accrete the Earn-Out to maximum payable amount.

The following summarizes the preliminary fair value of the assets acquired, liabilities assumed and the consideration transferred at the acquisition date:

	Total
Present value of Earn-Out at the acquisition date	$1,025,217
Interest expense related to accretion	59,110
Exchange rate differences	(3,015)
Present value at December 31, 2017	$1,081,312
Interest expense related to accretion	37,733
Exchange rate differences	(29,958)
Less: Current amount owing	(296,374)
Long term portion at March 31, 2018	$792,713

Assets acquired:	Preliminary Allocation
Receivables	$9,619
Other current assets	36,435
Inventory	79,971
Fixed assets	218,687
Goodwill	2,216,961
Total assets acquired	$2,561,673
Liabilities assumed:
Bank indebtedness	$11,722
Accounts payable	185,645
Loans payable	254,131
Total liabilities assumed	$451,498
Consideration:
Issuance of Common Shares	$350,000
Issuance of warrants	252,631
Vendor Take Back	356,443
Earn out	1,151,101
Total consideration	$2,110,175

A 15% discount rate has been used to calculate the present value of the VTB based on the Company’s estimate of cost of financing for comparable instruments with similar term and risk profiles. Over the term of the VTB, interest will be accrued at 15% per annum to accrete the VTB to its respective principal amount.

In consideration for the acquisition, the Company paid to the vendors of VBI the following consideration: (i) 2,500,000 Common Shares of the Company valued at $0.14 per share for a total value of $350,000; (ii) warrants for the purchase of 2,000,000 Common Shares of the Company exercisable over twenty-four (24) months at an exercise price of $0.20 per share from the closing date, such warrants vesting in five (5) equal tranches every four (4) months following the closing date; (iii) a total of CAD $550,000 in non-interest bearing, unsecured vendor-take-back loans (the “VTB”) due over twenty-four (24) months, with principal repayments beginning five (5) months from the closing date until maturity of up to CAD $25,000 per month; and (iv) an earn-out (the “Earn-out”) capped at: (a) the total cumulative amount of CAD $2,000,000; or (b) five (5) years from the closing date. The Earn-Out shall be calculated as: (x) 15% of the gross profit generated in Canada by VBI’s co-pack and distribution business; (y) 10% of the revenue generated in Canada by Gilla’s existing E-liquid brands; and (z) 15% of the revenue generated globally on VBI’s existing E-liquid brands. Furthermore, the Earn-Out shall be calculated and paid to the vendors of VBI quarterly in arrears and only as 50% of the aforementioned amounts on incremental revenue between CAD $300,000 and CAD $600,000 per quarter and 100% of the aforementioned amounts on incremental revenue above CAD $600,000 per quarter with the Earn-Out payable to the vendors in the fifth year repeated and paid to the vendors in four (4) quarterly payments after the end of the Earn-Out period, subject to the cumulative limit of the Earn-Out. No Earn-Out shall be payable to the vendors of VBI if total revenue for the Earn-Out calculation period is less than CAD $300,000 per quarter. A 15% discount rate has been used to calculate the present value of the Earn Out on the Company’s estimate of cost of financing for comparable notes with similar term and risk profiles. Over the term of the respective Earn Out, interest will be accrued at 15% per annum to accrete the Earn-Out to maximum payable amount.

	Total
Present value of the VTB at the acquisition date	$356,443
Interest expense related to accretion	26,681
Exchange rate differences	(7,177)
Present value at December 31, 2017	$375,947
Interest expense related to accretion	12,566
Exchange rate differences	(10,406)
Less: Current amount owing	(182,253)
Long term portion at March 31, 2018	$195,854

	Total
Present value of Earn Out at the acquisition date	$1,151,101
Interest expense related to accretion	26,619
Exchange rate differences	1,650
Less: Current amount owing	(178,597)
Present value at September 30, 2017	$1,000,773

A 15% discount rate has been used to calculate the present value of the VTB based on the Company’s estimate of cost of financing for comparable notes with similar term and risk profiles. Over the term of the respective Vendor take Back, interest will be accrued at 15% per annum to accrete the VTB to its respective principal amount.

	Total
Present value of the VTB at the acquisition date	$356,443
Interest expense related to accretion	8,034
Exchange rate differences	473
Less: Current amount owing	(104,458)
Present value at September 30, 2017	$260,492

The results of operations of VBI have been included in the consolidated statements of operations from the acquisition date. The following table presents pro forma results of operations of the Company and VBI as if the companies had been combined as of January 1, 2016. The unaudited condensed combined pro forma information is presented for informational purposes only. The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.

	September 30, 2017	December 31, 2016
	March 31, 2018	March 31, 2017
Pro forma revenue	$41,~~833~~266,~~097~~239	$51,~~984~~691,~~345~~581
Pro forma loss from operations	$(21,~~956~~010,~~012)~~655	$(3649,~~846,459)~~633
Pro forma net loss	$(41,~~650~~461,~~457)~~302	$(4943,~~618,919)~~349

5. OTHER CURRENT ASSETS

Other current assets consist of the following:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Vendor deposits	$2238,~~820~~490	$1322,~~256~~760
Prepaid expenses	~~147~~25,~~260~~195	~~301~~17,~~348~~240
Trade currency	4522,~~000~~906	4523,~~000~~550
Other receivables	~~149~~266,~~668~~838	~~103~~259,~~104~~998
	$364,748	$462,708
	$353,429	$323,548

Other receivables include VAT receivable, HST receivable and holdback amounts related to the Company’s merchant services accounts.

6. INVENTORY

Inventory consists of the following:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Vaping hardware and accessories	$5,954	$105,496
E-liquid bottles - finished goods	$153,954	$104,092
E-liquid bottles - finished goods	73,931	181,392
E-liquid components	118,279	113,620
E-liquid components	65,803	158,050
Bottles and packaging	255,182	233,606
Bottles and packaging	257,895	100,197
	$527,415	$451,318
	$403,583	$545,135

During the three and nine months ended September 30, 2017, the Company wrote off $191,143 in obsolete inventory consisting of $93,847 in obsolete inventory held in the Company’s warehouse in Slovakia and $97,296 of consignment inventory. During the three and nine month period ended September 30, 2016, the Company wrote off $24,453 in obsolete inventory that it was unable to sell.12

~~During~~ During the three ~~and~~month ~~nine~~periods ~~months~~ ended ~~September~~March 3031, 2018 and 2017, the ~~Company~~ Company expensed $~~451~~528,~~828~~900 and 1$546,~~492~~733,~~548~~ respectively, of inventory as cost of goods sold ~~(September 30, 2016 - $321,729 and $1,527,711)~~. At ~~September~~ 30March 31, ~~2017~~2018, the full amount of the Company’s inventory serves as collateral for the Company’s secured borrowings. No provision has been recorded against inventory.

7. PROPERTY AND EQUIPMENT

Property and equipment ~~consists~~consist of the following:

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	Cost	Accumulated Depreciation	Net	Net
Furniture and equipment	$6879,~~026~~347	$3143,~~364~~473	$3635,~~662~~874	$4541,~~917~~756
Leasehold improvements	6173,~~262~~035	422,~~362~~431	5650,~~900~~604	-61,904
Computer hardware	7538,~~703~~826	1023,~~099~~475	6515,~~604~~351	1518,~~985~~906
Manufacturing equipment	~~212~~209,~~046~~952	3461,~~708~~921	~~177~~148,~~338~~031	31163,~~166~~251
	$417,037	$80,533	$336,504	$93,068
	$401,160	$151,300	$249,860	$285,817

During the three ~~and~~month ~~nine~~periods ~~months~~ ended ~~September~~March 3031, 2018 and 2017, the Company ~~closed~~expensed ~~its~~$30,761 ~~office in Budapest~~ and as$9,656, arespectively, ~~result~~in ~~wrote~~depreciation. ~~off the value~~At ofMarch ~~the~~31, ~~fixed~~2018, ~~assets located in~~ the ~~premises~~full ~~in the~~ amount of ~~$12,020.~~ ~~During~~ the ~~three and nine months ended September 30, 2016, the~~ Company’s ~~wrote~~property ~~off $70,142 of~~and ~~manufacturing~~ equipment ~~that~~serves ~~was~~as ~~not~~collateral infor ~~working order and that~~ the Company’s ~~was unable to sell~~secured borrowings.

During the three and nine months ended September 30, 2017, the Company expensed $21,106 and $40,807, respectively, in depreciation (September 30, 2016 - $16,472 and $44,982). At September 30, 2017, the full amount of the Company’s property and equipment serves as collateral for the Company’s secured borrowings.

8. WEBSITE DEVELOPMENT

Website development consists of the following:

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	Cost	Accumulated Amortization	Net	Net
VaporLiq website	$10,000	$45,417	$54,583	$75,083

Amortization expense on website development for the three ~~month~~months ~~periods~~ ended ~~September~~ 30March 31, 2018 ~~2017~~ and ~~2016~~2017 amounted to $500 for each period. ~~Amortization~~ ~~expense on website development for the nine month periods ended September 30, 2017 and 2016 amounted to $1,500 for each period.~~ The estimated amortization expense for the ~~next 3~~ years ~~ending~~ended December 31, ~~2017,~~ 2018 and 2019 approximates $2,000 per year. For the year ~~ending~~ended December 31, 2020, ~~estimated~~ estimated amortization expense approximates $1,083.

9. INTANGIBLE ASSETS

Intangible assets consist of the following:

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	Cost	Accumulated Amortization	Net	Net
Brands	$50394,~~000~~413	$2071,~~500~~422	$29322,~~500~~991	$37342,~~000~~712
Customer relationships	~~173~~393,~~000~~433	7564,~~650~~008	97329,~~350~~425	~~123~~349,~~300~~097
	$223,000	$96,150	$126,850	$160,300
	$787,846	$135,430	$652,416	$691,809

Amortization expense on intangible assets for the three month periods ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017, amounted to $1139,~~150~~392 and $1911,~~000~~150, respectively. ~~Amortization expense on intangible assets for the nine month periods ended September 30, 2017 and 2016 amounted to $33,450 and $73,000, respectively.~~ The estimated amortization expense for the ~~next 3~~ years ending December 31, ~~2017,~~ 2018 and 2019 approximates $44157,~~600~~564 per year. For the ~~year~~years ending December 31, 2020, December 31, 2021 and December 31, 2022 estimated amortization expense approximates $26153,~~500~~464, $140,964 and $82,253, respectively.

1413

10. GOODWILL

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Opening balance	$~~889~~2,~~497~~376,605	$1889,~~252,084~~496
Measurement period adjustment	-	~~(154,211)~~-
Acquisition of VBI (Note 4)	~~2,216,961~~-	-1,596,553
Impairment	-	(~~208~~109,~~376~~444)
End of period	$32,~~106~~376,~~458~~605	$~~889~~2,~~497~~376,605

During the year ended December 31, ~~2016~~2017, the Company tested ~~the~~ goodwill ~~for~~ for impairment., Asand as a result, the Company fully impaired ~~the~~ goodwill related to the acquisition of the assets of ~~TMA~~Vapor Liq in the ~~amount~~ amount of $~~208~~109,~~376~~444 which formerly represented the value of business acumen ~~workforce~~and access to key E-liquid brands acquired. The goodwill has been impaired as it is difficult to allocate value to VaporLiq business acumen and new purchases of brands are not due to business acumen acquired from the acquisition.

11. LOANS FROM SHAREHOLDERS

The Company has outstanding current loans from shareholders as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Non-interest bearing, unsecured, no specific terms of repayment(i)	$-	$5,000
Bears interest of 1.5% per month on a cumulative basis, unsecured, no specific terms of repayment(i)	$12,763	$13,116
Bears interest of 1.5% per month on a cumulative basis, unsecured, no specific terms of repayment(ii)	13,185	23,223
Bears interest of 6% per annum on a cumulative basis, secured by the assets of the Company, matured on March 2, 2018(iv)	248,192	244,187
Bears interest of 6% per annum on a cumulative basis, secured by the assets of the Company, matures on March 2, 2018(v)	536,871	474,065
Bears interest of 1.5% per month on a cumulative basis, unsecured, no specific terms of repayment(vii)	24,044	-
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on July 1, 2018(iii)	400,650	-
	$284,999	$257,303
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on July 1, 2018(iv)	100,000	-
Non-interest bearing, secured by the assets of the Company, matures on March 12, 2017 and currently in default(vi)	160,260	-
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on July 1, 2018(iv)	$1,210,966	$502,288

The Company has outstanding long term loans from shareholders as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on July 1, 2018(iii)	$-	$372,400
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(ii)	$348,424	$351,679
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on July 1, 2018(iv)	-	100,000
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(iii)	92,296	90,828
Bears interest of 6% per annum on a cumulative basis, secured by the assets of the Company, matures on March 2, 2018(v)	-	24,951
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(v)	142,701	144,611
	$-	$497,351
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(vi)	204,775	207,517
	$788,196	$794,635

(i) During the ~~nine~~ three month period ended ~~September~~March 3031, ~~2017~~2018, the ~~amount owing to the~~Company ~~shareholder~~accrued ~~increased~~interest ~~from~~of $51,~~000~~471 toon ~~$22,692~~this ~~and~~shareholder ~~was~~loan ~~then~~(March ~~fully settled through the issuance of 226~~31,~~920~~ ~~private placement units at~~2017 a– ~~price of~~ $01,399).10 ~~per~~Total ~~unit.~~accrued ~~Each~~interest ~~unit~~owing ~~consisted~~on ofsuch ~~one Common Share~~shareholder ~~and~~loan aat ~~half~~March ~~Common~~31, ~~Share~~2018 ~~purchase~~was ~~warrant~~$20,262 ~~exercisable~~(December ~~over~~31, ~~twelve~~2017 – ~~months~~$19,341) atwhich anis ~~exercise~~included ~~price~~in ofaccrued $0liabilities.~~20 per share.~~

(ii) ~~During~~On February 13, 2014, the ~~three~~Company entered into a secured promissory note (the “Secured Note”) with a shareholder, whereby the Company agreed to pay the party the aggregate unpaid principal amount of CAD $500,000 on or before August 13, 2014, bearing interest at a rate of 10% per annum, such interest to accrue monthly and ~~nine~~added ~~month~~to ~~period~~the principal. The Secured Note is secured by a general security agreement granting a general security interest over all the assets of the Company. During the years ended ~~September~~December 3031, ~~2017~~2014 and 2015, the Company and the ~~Company~~shareholder ~~accrued~~extended ~~interest~~the maturity date of $the Secured Note to January 1,~~358~~ 2016 and $4July 1,~~249~~ 2017, respectively. During the years ended December 31, on2016 and 2017, the Company and ~~this~~the shareholder ~~loan~~extended ~~(September~~the ~~30,~~maturity ~~2016~~date –of $the Secured Note to July 1,~~527~~ 2018 and $4 April 30,~~324~~ 2019, respectively. In connection to the maturity date extensions, the Company issued warrants for the purchase of Common Shares (note 16(l and hh)). ~~Total~~The ~~accrued~~relative ~~interest~~fair ~~owing~~value onof the ~~shareholder~~warrants ~~loan~~issued atwere ~~September~~recorded 30as debt discount to be amortized over the life of the loan. At March 31, ~~2017~~2018, the value of the Secured Note was $18348,~~018~~ 424 (December 31, ~~2016~~2017 – $12351,~~784~~679) including a debt discount of ~~which~~$39,376 is(December ~~included~~31, in2017 ~~accrued~~- ~~liabilities~~$46,871). During the ~~nine~~three month ~~period~~periods ended ~~September~~March 3031, 2018 and 2017, the Company expensed $107,~~000~~495 and ~~owing~~$2,386, onrespectively, ~~this~~in ~~shareholder loan~~interest ~~was~~expense ~~settled~~related ~~with~~to the amortization ~~issuance~~ of ~~face~~the ~~value~~debt ~~$10,000~~discount. ofThe amendments to the Secured ~~Convertible~~Note ~~Debentures~~were ~~Series~~accounted ~~C-3~~for ~~(note~~as ~~15)~~a modification of debt and ~~$3,512~~no ~~was~~gain ~~settled~~or ~~with~~loss ~~cash~~was recognized on the amendments.

During the three month period ended March 31, 2018, the Company accrued interest of $13,769 on the Secured Note (March 31, 2017 – $11,914). Total accrued interest owing on the Secured Note at March 31, 2018 was $161,352 (December 31, 2017 – $151,948) which is included in accrued liabilities.

(iii) On July 15, 2014, the Company entered into a secured promissory note (the “Secured Note No.2”) with a shareholder, whereby the Company agreed to pay the party the aggregate unpaid principal amount of $100,000 on or before July 18, 2014, bearing interest at a rate of 10% per annum, such interest to accrue monthly and added to the principal. The Secured Note No.2 is secured by the general security agreement issued with the Secured Note. During the years ended December 31, 2014 and 2015, the Company and the shareholder extended the maturity date of the Secured Note No.2 to January 1, 2016 and July 1, 2017, respectively. During the years ended December 31, 2016 and 2017, the Company and the shareholder extended the maturity date of the Secured Note No.2 to July 1, 2018 and April 30, 2019, respectively. In connection to the maturity date extensions, the Company issued warrants for the purchase of Common Shares (note 15(l and hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Secured Note No.2 was $92,296 (December 31, 2017 - $90,828) including a debt discount of $7,704 (December 31, 2017 – $9,172). During the three month periods ended March 31, 2018 and 2017, the Company expensed $1,468 and $629, respectively, in interest expense related to the amortization of the debt discount. The amendments to the Secured Note were accounted for as a modification of debt and no gain or loss was recognized on the amendments.

During the three month period ended March 31, 2018, the Company accrued interest of $3,485 on the Secured Note No.2 (March 31, 2017 – $3,155). Total accrued interest owing on the Secured Note No.2 at March 31, 2018 was $41,742 (December 31, 2017 – $38,257) which is included in accrued liabilities.

(iv) On March 2, 2016, the Company entered into a loan agreement (the “Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $670,000 (the “Shareholder Loan”) for capital expenditures, marketing expenditures and working capital. Under the terms of the Loan Agreement, the Shareholder Loan was made available to the Company in two equal tranches of CAD $335,000, for a total loan amount of CAD $670,000, with the first tranche (“Loan Tranche A”) received on March 3, 2016 and the second tranche (“Loan Tranche B”) received on April 14, 2016. The Shareholder Loan bears interest at a rate of 6% per annum, on the outstanding principal, and matured on March 2, 2018, whereby the outstanding principal together with all accrued and unpaid interest thereon became due and payable. The Company was also to repay 5% of the initial principal amount of Loan Tranche A and 5% of Loan Tranche B, monthly in arrears, with the first principal repayment beginning on June 30, 2016. The Company could elect to repay the outstanding principal of the Shareholder Loan together with all accrued and unpaid interest thereon prior to maturity without premium or penalty. The Company also agreed to service the Shareholder Loan during the term prior to making any payments to the Company’s Chief Executive Officer, Chief Financial Officer and Board of Directors. The Shareholder Loan is secured by a general security agreement granting a general security interest over all the assets of the Company. On March 2, 2016 and in connection to the Loan Agreement, the Company issued warrants for the purchase of 1,000,000 Common Shares exercisable until March 2, 2018 at an exercise price of $0.20 per share. The warrants shall vest in two equal tranches, with 500,000 warrants to vest upon the close of Loan Tranche A and the remaining 500,000 warrants to vest upon the close of Loan Tranche B. On March 3, 2016 and April 14, 2016, the Company closed Loan Tranche A and Loan Tranche B, respectively, at which dates the warrants became fully vested and exercisable (note 16(g)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Shareholder Loan was $248,192 (December 31, 2017 – $244,187), at March 31, 2018 the debt discount on this loan had fully accreted. During the three month periods ended March 31, 2018 and 2017, the Company expensed $10,885 and $11,234, respectively, in interest expense related to the amortization of the debt discount. During the year ended December 31, 2017, CAD $350,000 of the Shareholder Loan was assumed by a separate shareholder (see (vii) below).

During the three month period ended March 31, 2018, the Company accrued interest of $4,622 on the Shareholder Loan (March 31, 2017 – $7,994). Total accrued interest owing on the Shareholder Loan at March 31, 2018 was $64,401 (December 31, 2017 – $61,523) which is included in accrued liabilities. At March 31, 2018, the Shareholder Loan was in default.

(~~iii~~v) On ~~February~~On 13January 12, ~~2014~~2017, the Company entered into a ~~secured~~bridge ~~promissory~~loan ~~note~~agreement (the “~~Secured~~Bridge ~~Note~~Loan Agreement”) with a shareholder, whereby the ~~Company~~shareholder ~~agreed~~would tomake ~~pay~~available to the Company ~~party~~ the aggregate ~~unpaid~~ principal amount of CAD $~~500~~200,000 (~~USD~~the “Bridge ~~$400,650~~Loan”) ~~(December~~in ~~31,~~two ~~2016~~equal – tranches of CAD $~~500~~100,000;. The ~~USD~~Company ~~$372~~received the first tranche on January 12,~~400~~ 2017 (“Bridge Loan Note A”) onand orthe ~~before~~second ~~August~~tranche ~~13,~~on January ~~2014~~18, ~~bearing~~2017 (“Bridge Loan Note B”). The Bridge Loan is non-interest atbearing aand ~~rate~~was ofto ~~10%~~mature ~~per~~on ~~annum~~March 12, ~~such~~2017. Pursuant ~~interest~~ to ~~accrue~~the terms of the Bridge Loan Agreement, the shareholder ~~monthly~~received a 5% upfront fee upon the closing of Bridge Loan Note A and ~~added~~a to5% upfront fee upon the ~~principal.~~closing ~~The~~of ~~Secured~~Bridge Loan Note B. The Bridge Loan is secured by a the general security agreement ~~granting~~issued ain connection ~~general~~to ~~security~~the ~~interest~~Secured Note. On January 12, 2017 and in ~~over~~connection ~~all~~to the ~~assets~~Bridge ofLoan Agreement, the Company. ~~During~~issued warrants for the ~~years~~purchase ~~ended~~of ~~December~~50,000 Common Shares exercisable until 31January 11, ~~2014~~2018 ~~and~~at ~~2015~~an exercise price of $0.20 per share, ~~the~~with 25,000 ~~Company~~warrants ~~and~~to vest upon the ~~shareholder~~closing ~~extended~~of ~~the~~Bridge Loan Note A and ~~maturity~~the ~~date~~remaining of25,000 warrants vest upon the ~~Secured~~closing of Bridge Loan Note toB. On January 112, ~~2016~~2017 and ~~July~~January 118, 2017, the Company closed Bridge Loan Note A and Bridge Loan Note B, respectively, at which dates the warrants became fully vested and exercisable (note 16(n)). During the year ended December 31, ~~2016~~2017, the Company and the shareholder extended the maturity date of Bridge Loan to April 30, 2019 and, commencing on November 15, 2017, the Company began ~~Secured~~accruing ~~Note~~interest at a rate of 10% per annum. In connection to ~~July~~the amendment, 1the Company issued warrants for the purchase of Common Shares (note 16(hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Bridge Loan was $142,701 (December 31, 2017 - $144,611) including a debt discount of $12,419 (December 31, 2017 – $14,809). During the three month periods ended March 31, 2018 and 2017, the Company expensed $2,390 and $nil, respectively, in interest expense related to the amortization of the debt discount. The amendment to the ~~Secured~~Bridge ~~Note was~~Loan was accounted for as a modification of debt and no gain or loss was recognized on the ~~amendment~~amendments.

During the three ~~and nine~~ month ~~periods~~period ended ~~September~~March 3031, ~~2017~~2018, the Company accrued interest of $134,~~224~~037 ~~and $38,707, respectively,~~ on the ~~Secured~~Bridge ~~Note~~Loan (~~September~~March 3031, ~~2016~~2017 – $~~11,336 and $32,721~~nil). ~~Accrued~~ Total accrued interest owing on the ~~Secured~~Bridge ~~Note~~Loan at ~~September~~March 3031, ~~2017~~ 2018 was $~~139~~5,~~141~~904 (December 31, ~~2016~~2017 – $931,~~221~~998) which is ~~included~~ included in accrued liabilities.

(ivvi) On ~~July~~November 15, ~~2014~~2017, CAD $350,000 of the ~~Company~~Shareholder ~~entered~~Loan ~~into~~was assumed by a ~~secured~~separate ~~promissory~~shareholder ~~note~~ (the “~~Secured~~Shareholder ~~Note~~ Loan No.2”). ~~with~~Upon aassumption ~~shareholder~~of the Shareholder Loan No.2, ~~whereby~~CAD $52,000 (USD $41,449) was offset by the ~~Company~~amount ~~agreed~~held toin ~~pay~~trust by the shareholder ~~party~~under the ~~aggregate~~Shareholder ~~unpaid~~Loan ~~principal amount~~(see of(v) above) and CAD $~~100~~11,000 on(USD or$8,769) ~~before~~was ~~July~~forgiven ~~18,~~by ~~2014,~~the ~~bearing~~shareholder. ~~interest~~During atthe ayear ~~rate~~ended ofDecember ~~10% per annum~~31, ~~such~~2017 ~~interest~~and toas ~~accrue~~a ~~monthly~~result ~~and~~of ~~added~~the loan toforgiveness, the ~~principal.~~Company ~~The~~recorded ~~Secured~~a ~~Note~~gain ~~No.2~~on isloan ~~secured~~settlement byin the ~~general~~ ~~security~~amount ~~agreement~~of ~~issued~~$8,221 ~~with~~and the ~~Secured~~principal ~~Note.~~amount ~~During~~due under the ~~years~~Shareholder ~~ended~~Loan ~~December~~No.2 ~~31,~~was ~~2014~~CAD ~~and 2015~~$287,000. ~~the~~The Company ~~and~~agreed ~~the~~to ~~shareholder extended~~repay the ~~maturity~~unpaid principal ~~date~~amount of the ~~Secured~~Shareholder ~~Note~~Loan No.2 toon ~~January~~or 1,before April ~~2016~~30, ~~and~~2019, ~~July~~bearing 1,interest ~~2017~~at a rate of 10% per annum, ~~respectively.~~such interest ~~During~~to ~~the~~accrue ~~year~~monthly ~~ended~~and ~~December~~due at maturity. In connection to ~~31,~~the ~~2016~~amendment, the Company ~~and~~issued ~~the~~warrants ~~shareholder~~for ~~extended~~ the ~~maturity~~purchase of ~~date~~Common Shares (note 16(hh)). The relative fair value of the warrants ~~Secured~~issued ~~Note~~were ~~No.2~~recorded as debt discount to ~~July~~be 1amortized over the life of the loan. At March 31, 2018., ~~The~~the ~~amendment~~value toof the ~~Secured~~Shareholder ~~Note~~Loan No.2 was ~~accounted~~$204,775 ~~for~~(December as31, 2017 - $207,517) including a ~~modification~~debt discount of ~~debt~~$17,822 (December 31, 2017 – $16,939). During the three month periods ended March 31, 2018 and no2017, ~~gain~~the orCompany ~~loss~~expensed ~~was~~$3,429 ~~recognized~~and on$nil, respectively, in interest expense related to the ~~amendment~~amortization of the debt discount.

During the three ~~and nine~~ month ~~periods~~period ended ~~September~~March 3031, ~~2017~~2018, the Company accrued interest of $35,~~316~~865 ~~and $9,705, respectively,~~ on the ~~Secured~~ ~~Note~~Shareholder Loan No.2 (~~September~~March 3031, ~~2016~~ 2017 – $~~3,002 and $8,786~~nil). ~~Accrued~~ Total accrued interest owing on the ~~Secured~~Shareholder ~~Note~~ Loan No.2 at ~~September~~March 3031, ~~2017~~ 2018 was $3411,~~857~~299 (December 31, ~~2016~~2017 – $255,~~152~~701) which is included in accrued liabilities.

In(vii) On ~~connection~~March to21, 2018, the ~~maturity~~Company ~~date~~received ~~extension~~CAD $31,000 (USD $24,044) from a Shareholder of ~~Secured~~the ~~Note~~Company. ~~and~~The loan bears interest of 1.5% per ~~Secured~~month ~~Note~~on Noa cumulative basis is unsecured and has no specific terms of repayment.2 ~~(together,~~During the ~~“Secured~~three ~~Notes”)~~month period ended March 31, ~~the~~2018, the Company ~~issued~~accrued ~~warrants~~interest ~~for~~of ~~the~~$105 ~~purchase~~on ofthis ~~250~~shareholder loan (March 31,~~000~~ ~~Common~~2017 ~~Shares~~– $nil). Total accrued interest owing on such ~~exercisable~~shareholder ~~until~~loan ~~July~~at 1March 31, 2018 atwas an$105 ~~exercise~~(December ~~price~~31, of2017 – $~~0.20~~nil) ~~per share~~which ~~(note~~is ~~17(b))~~included in accrued liabilities.

(v) On March 2, 2016, the Company entered into a loan agreement (the “Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $670,000 (USD $536,871) (the “Shareholder Loan”) for capital expenditures, marketing expenditures and working capital. Under the terms of the Loan Agreement, the Shareholder Loan was made available to the Company in two equal tranches of CAD $335,000, for a total loan amount of CAD $670,000 (USD $536,871), with the first tranche (“Loan Tranche A”) received on the closing date and the second tranche (“Loan Tranche B”) received on April 14, 2016. At September 30, 2017, CAD $52,000 (USD $41,668) of the Loan Tranche B was being held in trust by the shareholder to be released on the incurrence of specific expenses. The Shareholder Loan bears interest at a rate of 6% per annum, on the outstanding principal, and shall mature on March 2, 2018, whereby any outstanding principal together with all accrued and unpaid interest thereon shall be due and payable. The Company shall also repay 5% of the initial principal amount of Loan Tranche A and 5% of Loan Tranche B, monthly in arrears, with the first principal repayment beginning on June 30, 2016. The Company may elect to repay the outstanding principal of the Shareholder Loan together with all accrued and unpaid interest thereon prior to maturity without premium or penalty. The Company also agreed to service the Shareholder Loan during the term prior to making any payments to the Company’s Chief Executive Officer, Chief Financial Officer and Board of Directors. The Shareholder Loan is secured by a general security agreement granting a general security interest over all the assets of the Company. On March 2, 2016 and in connection to the Loan Agreement, the Company issued warrants for the purchase of 1,000,000 Common Shares exercisable until March 2, 2018 at an exercise price of $0.20 per share. The warrants shall vest in two equal tranches, with 500,000 warrants to vest upon the close of Loan Tranche A and the remaining 500,000 warrants to vest upon the close of Loan Tranche B. On March 3, 2016 and April 14, 2016, the Company closed Loan Tranche A and Loan Tranche B, respectively, at which dates the warrants became fully vested and exercisable (note 17(g)).

During the three and nine month periods ended September 30, 2017, the Company accrued interest of $9,670 and $25,712, respectively, on the Shareholder Loan (September 30, 2016 – $7,759 and $15,894). Accrued interest owing on the Shareholder Loan at September 30, 2017 was $51,016 (December 31, 2016 – $23,433) which is included in accrued liabilities. At September 30, 2017, the Company owes the shareholder $402,653 in principal payments.

~~(vi) On~~ ~~January~~ 12, 2017, the Company entered into a bridge loan agreement (the “Bridge Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $200,000 (USD $160,260) (the “Bridge Loan”) in two equal tranches of CAD $100,000. ~~The~~ ~~Company~~TERM received the first tranche on January 12, 2017 (“Bridge Loan Note A”) and the second tranche on January 18, 2017 (“Bridge Loan Note B”). The Bridge Loan is non-interest bearing and matured on March 12, 2017. Pursuant to the terms of the Bridge Loan Agreement, the shareholder received a 5% upfront fee upon the closing of Bridge Loan Note A and a 5% upfront fee upon the closing of Bridge Loan Note B. The Bridge Loan is secured by the general security agreement issued in connection to the Secured Note. On January 12, 2017 and in connection to the Bridge Loan Agreement, the Company issued warrants for the purchase of 50,000 Common Shares exercisable until January 11, 2018 at an exercise price of $0.20 per share, with 25,000 warrants to vest upon the closing of Bridge Loan Note A and the remaining 25,000 warrants vest upon the closing of Bridge Loan Note B. On January 12, 2017 and January 18, 2017, the Company closed Bridge Loan Note A and Bridge Loan Note B, respectively, at which dates the warrants became fully vested and exercisable (note 17(n)). The Bridge Loan matured on March 12, 2017 and is currently in default.LOAN

On 12January 18, 2016, the Company entered into a term loan (the “Term Loan”) with an unrelated party acting as an agent to a consortium of participants (the “Lenders”), whereby the Lenders would loan the Company the aggregate principal amount of CAD $1,000,000 for capital expenditures, marketing expenditures and working capital. ~~CREDIT~~The ~~FACILITY~~agent who arranged the Term Loan was not a related party of the Company. The Term Loan bears interest at a rate of 16% per annum, on the outstanding principal, and was to mature on July 3, 2017, whereby any outstanding principal together with all accrued and unpaid interest thereon shall be due and payable. The Term Loan is secured by a intercreditor and subordination agreement as well as a security agreement. The Term Loan is subject to a monthly cash sweep, calculated as the total of (i) CAD $0.50 for every E-liquid bottle, smaller than 15 ml, sold by the Company within a monthly period; and (ii) CAD $1.00 for every E-liquid bottle, greater than 15 ml, sold by the Company within a monthly period (the “Cash Sweep”). The Cash Sweep will be disbursed to the Lenders in the following priority: first, to pay the monthly interest due on the Term Loan; and second, to repay any remaining principal outstanding on the Term Loan. The Company may elect to repay the outstanding principal of the Term Loan together with all accrued and unpaid interest thereon prior to the maturity, subject to an early repayment penalty of the maximum of (i) 3 months interest on the outstanding principal; or (ii) 50% of the interest payable on the outstanding principal until maturity (the “Early Repayment Penalty”). The Term Loan shall be immediately due and payable at the option of the Lenders if there is a change in key personnel meaning the Company’s current Chief Executive Officer and Chief Financial Officer. On January 18, 2016 and in connection to the Term Loan, the Company issued warrants for the purchase of 250,000 Common Shares (note 16(d)) exercisable until December 31, 2017 at an exercise price of $0.20 per share. In addition, the Company also extended the expiration date of the 250,000 warrants (note 16(d)) issued on August 1, 2014 in connection with the Credit Facility until December 31, 2017, with all other terms of the warrants remaining the same. The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan.

On August 1, 2014, the Company entered into a revolving credit facility (the “Credit Facility”) with an unrelated party acting as an agent to a consortium of participants (the “Lenders”), whereby the Lenders would make a revolving credit facility in the aggregate principal amount of CAD $500,000 for the exclusive purpose of purchasing inventory for sale in the Company’s ordinary course of business to approved customers. The ~~Credit Facility charged interest at a rate of 15% per annum on~~ all drawn advances and a standby fee of 3.5% per annum on the undrawn portion of the Credit Facility. The Credit Facility matured on August 1, 2015 whereby the outstanding advances together with all accrued and unpaid interest thereon would be due and payable. On August 1, 2014, and in connection to the Credit Facility, the Company ~~issued warrants for the purchase of 250,000 Common Shares exercisable over two years at an exercise price of $0.30 per share. The Company~~’s Chief Executive Officer and Chief Financial Officer are ~~were~~ both participants of the consortium of ~~participants~~Lenders of the ~~Credit Facility~~Term Loan, each having committed to provide ten percent of the principal amount of the ~~Credit~~Term ~~Facility~~Loan. ~~The~~Neither ~~Credit Facility was secured by all of~~ the ~~Company’s~~Chief ~~inventory~~Executive ~~and~~Officer ~~accounts~~nor ~~due~~the ~~relating~~Chief toFinancial ~~any~~Officer ~~inventory~~participated ~~as granted~~ in ~~an intercreditor and subordination agreement by and among~~ the ~~Company,~~warrants ~~the~~issued ~~Secured Note~~or ~~holder~~warrants ~~and~~extended ~~the~~in ~~Lenders~~connection towith ~~establish~~ the ~~relative~~Term ~~rights~~Loan and both parties ~~priorities~~have ofappropriately ~~the~~abstained ~~secured~~from ~~parties~~voting ~~against~~on the ~~Company~~Board ~~and~~of aDirectors ~~security~~to ~~agreement~~approve ~~by and between~~ the ~~Company~~Term ~~and~~Loan, ~~the Lenders~~where applicable.

During the year ended December 31, 2014, the Company was advanced $387,110 (CAD $449,083) from the Credit Facility for the purchase of inventory including $77,453 (CAD $89,852) of advances from the Company’s Chief Executive Officer and Chief Financial Officer as their participation in the Credit Facility.

On April 24, 2015, the Company was advanced $89,590 (CAD $124,000) from the Credit Facility including $17,918 (CAD $24,800) of advances from the Company’s Chief Executive Officer and Chief Financial Officer as their participation in the Credit Facility.

On September 1, 2015, the Company was advanced $122,825 (CAD $170,000) from the Credit Facility including $24,565 (CAD $34,000) of advances from the Company’s Chief Executive Officer and Chief Financial Officer as their participation in the Credit Facility.

On January 18, 2016, and in connection to the Term Loan (note 13), the Company and the Lenders entered into a loan termination agreement whereby the Company and the Lenders terminated and retired the Credit Facility. As a result, the CAD $294,000 in amounts advanced from the Credit Facility and the CAD $3,093 in accrued interest owing on the Credit Facility were rolled into the Term Loan.

During the three and nine month period ended September 30, 2017, the Company paid $nil of interest and standby fees as a result of the Credit Facility (September 30, 2016 – $2,189 and $2,189, respectively).

13. TERM LOAN

On January 18, 2016, the Company entered into a term loan (the “Term Loan”) with the Lenders, whereby the Lenders would loan the Company the aggregate principal amount of CAD $1,000,000 for capital expenditures, marketing expenditures and working capital. The agent who arranged the Term Loan was not a related party of the Company. The Term Loan bears interest at a rate of 16% per annum, on the outstanding principal, and was to mature on July 3, 2017, whereby any outstanding principal together with all accrued and unpaid interest thereon shall be due and payable. The Term Loan is secured the intercreditor and subordination agreement as well as the security agreement issued in connection to the Credit Facility. The Term Loan is subject to a monthly cash sweep, calculated as the total of (i) CAD $0.50 for every E-liquid bottle, smaller than 15 ml, sold by the Company within a monthly period; and (ii) CAD $1.00 for every E-liquid bottle, greater than 15 ml, sold by the Company within a monthly period (the “Cash Sweep”). The Cash Sweep will be disbursed to the Lenders in the following priority: first, to pay the monthly interest due on the Term Loan; and second, to repay any remaining principal outstanding on the Term Loan. The Company may elect to repay the outstanding principal of the Term Loan together with all accrued and unpaid interest thereon prior to the maturity, subject to an early repayment penalty of the maximum of (i) 3 months interest on the outstanding principal; or (ii) 50% of the interest payable on the outstanding principal until maturity (the “Early Repayment Penalty”). The Term Loan shall be immediately due and payable at the option of the Lenders if there is a change in key personnel meaning the Company’s current Chief Executive Officer and Chief Financial Officer. On January 18, 2016 and in connection to the Term Loan, the Company issued warrants for the purchase of 250,000 Common Shares (note 17(d)) exercisable until December 31, 2017 at an exercise price of $0.20 per share. In addition, the Company also extended the expiration date of the 250,000 warrants (note 17(d)) issued on August 1, 2014 in connection with the Credit Facility until December 31, 2017, with all other terms of the warrants remaining the same.

The Company’s Chief Executive Officer and Chief Financial Officer are both participants of the consortium of Lenders of the Term Loan, each having committed to provide ten percent of the principal amount of the Term Loan. Neither the Chief Executive Officer nor the Chief Financial Officer participated in the warrants issued or warrants extended in connection with the Term Loan and both parties have been appropriately abstained from voting on the Board of Directors to approve the Term Loan, where applicable.

On July 15, 2016, the Company and the Lenders of the Term Loan entered into a term loan amendment (the “Term Loan Amendment”) in which the Lenders agreed to extend to the Company an additional CAD $600,000 in principal to increase the Term Loan facility up to the aggregate principal amount of CAD $1,600,000. The parties also extended the maturity date of the Term Loan to July 2, 2018 with all other terms of the Term Loan remaining the same. The Company’s Chief Executive Officer and its Chief Financial Officer are both participants in the consortium of Lenders having each committed to provide a total of CAD $150,000 of the initial principal of the Term Loan and the additional principal of the Term Loan pursuant to the Term Loan Amendment.

On July 15, 2016 and in connection to the Term Loan Amendment, the Company issued warrants for the purchase of 300,000 Common Shares (note 1716(k)) exercisable until December 31, 2018 at an exercise price of $0.20 per share. The Company also extended the expiration dates of: (i) the warrants for the purchase of 250,000 Common Shares (note 1716(d)) issued on January 18, 2016 in connection to the Term Loan; and (ii) the warrants for the purchase of 250,000 Common Shares (note 1716(d)) issued on August 1, 2014 and extended on January 18, 2016 in connection to the Term Loan, both until December 31, 2018, with all other terms of the warrants remaining the same. ~~Neither~~The ~~the~~relative ~~Chief~~fair ~~Executive~~value ~~Officer~~of ~~nor~~ the ~~Chief Financial Officer participated in the~~ warrants issued orwere ~~warrants~~recorded ~~extended~~as indebt ~~connection~~discount ~~with~~to be amortized over the ~~Term~~life ~~Loan~~of ~~Amendment~~the loan.

During the year ended December 31, 2016, the Company was advanced ~~$1,219,840~~ (CAD $1,600,000) from the Term Loan including the CAD $294,000 and CAD $3,093 rolled in from ~~the~~a ~~Credit~~revolving ~~Facility~~credit ~~(note~~facility the Company ~~12)~~previously entered into with the Lenders as well as CAD $240,581 of advances from the Company’s Chief Executive Officer and Chief Financial Officer.

On February 27, 2017, the Company and the Lenders of the Term Loan entered into a term loan amendment (the “Term Loan Amendment No.2”) to amend certain terms and conditions of the Term Loan. Pursuant to the Term Loan Amendment No.2, the parties agreed to modify the Cash Sweep to be calculated as the total of CAD $0.01667 per ml of E-liquid sold by the Company within a monthly period, such modification to be retroactively applied as of January 1, 2017. The Lenders also agreed to cancel the Early Repayment Penalty and waive any interest payment penalties due under the Term Loan. On February 27, 2017 and in connection to the Term Loan Amendment No.2, the Company agreed to issue 500,000 private placement units at a price of $0.10 per unit as a settlement of ~~$50,000 in~~ financing fees with a relative fair value of $48,485. Each unit consisted of one Common Share and a half Common Share purchase warrant exercisable over twelve months at an exercise price of $0.20 per share. On April 4, 2017, the Company issued the 500,000 units. The Company’s Chief Executive Officer and its Chief Financial Officer received a total of 93,622 units which included 93,622 Common Shares and warrants for the purchase of 46,811 Common Shares. The Term Loan Amendment No.2 was accounted for as a modification of debt and no gain or loss was recognized on the amendment.

During the three and nine month periods ended September 30, 2017, the Company expensed $42,370 and $129,043, respectively, in interest as a result of the Term Loan (September 30, 2016 – $44,570 and $97,409). Pursuant to the Cash Sweep, during the nine month period ended September 30, 2017, the Company paid a total of $239,908 to the Lenders consisting of $152,044 in interest and $87,864 in principal repayments. At September 30, 2017, the Company owes the Lenders a payment of $14,618, consisting fully of interest which was paid to the Lenders on October 19, 2017 as per the terms of the Cash Sweep.17

18 The relative fair value of the warrants issued in relation to the Term Loan and Term Loan amendments were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Term Loan was $1,053,993 including a debt discount of $33,609 (December 31, 2017 – $1,051,334 including a debt discount of $54,815). During the three month periods ended March 31, 2018 and 2017, the Company expensed $25,435 and $14,300, respectively, in interest expense related to the amortization of the debt discount. Neither the Chief Executive Officer nor the Chief Financial Officer participated in the warrants issued or warrants extended in connection with the Term Loan Amendment.

During the three month period ended March 31, 2018, the Company expensed $42,577 in interest on the Term Loan (March 31, 2017 – $42,563). Pursuant to the Cash Sweep, during the three month period ended March 31, 2018, the Company paid a total of $44,651 to the Lenders consisting of $42,394 in interest and $2,257 in principal repayments. During the three month period ended March 31, 2017, the Company paid a total of $110,809 to the Lenders consisting of $57,514 in interest and $53,295 in principal payments.

The amount owing on the Term Loan is as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Opening balance/amount advanced	$1,~~144~~051,~~337~~334	$1,~~219~~061,~~840~~269
Exchange loss (gain) during the period/year	92,720	(28,159)
Accretion of debt discount	25,435	14,300
Principal payments made	(87,864)	(76,815)
Exchange loss (gain) during the period/year	(20,702)	86,143
Interest accrued	129,043	140,540
Principal payments made	(2,257)	(88,066)
Interest payments made	(152,044)	(111,069)
Interest accrued	42,577	173,035
Ending balance	$1,126,192	$1,144,337
Interest payments made	(42,394)	(195,347)
Ending balance	$1,053,993	$1,051,334

1413. PROMISSORY NOTES

The Company has outstanding current promissory notes as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Unsecured, bears interest at 18% per annum, matures June 19, 2019(ii)	$30,000	$-
Unsecured, bears interest at 15% per annum, matures April 12, 2018(i)	$225,330	$230,109
Unsecured, bears interest at 10% per annum, matures December 15, 2017(iii)	7,500	-
Unsecured, bears interest at 15% per annum, matures February 18, 2019(ii)	231,398	-
Unsecured, bears interest at 10% per annum, matures September 28, 2017(iv)	2,000	17,750
Unsecured, bears interest at 18% per annum, matures June 19, 2019(iii)	30,000	30,000
Secured, bears interest at RBP + 2% per annum, due on demand(v)	40,066	-
Secured, bears interest at RBP + 2% per annum, due on demand(iv)	38,778	39,855
Secured, bears interest at RBP + 3% per annum, due on demand(vi)	69,362	-
Secured, bears interest at RBP + 3% per annum, due on demand(v)	58,912	64,774
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vii)	18,173	-
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vi)	22,809	23,441
Unsecured, interest free, matures October 29, 2017(viii)	12,020
Unsecured, interest free, matured October 29, 2017(vii)	-	7,971
	$179,121	$17,750
Secured, bears interest at 24%, matured March 6, 2018 (viii)	99,610	102,372
	$706,837	$498,522

The Company has outstanding long term promissory notes as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Unsecured, bears interest at 15% per annum, matures February 18, 2019(i)	$240,390	$-
Unsecured, bears interest at 15% per annum, matures February 18, 2019(ii)	$-	$234,034
Unsecured, bears interest at 18% per annum, matures June 19, 2019(ii)	22,500	-
Unsecured, bears interest at 18% per annum, matures June 19, 2019(iii)	7,500	17,500
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vii)	104,820	-
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vi)	87,542	94,468
	$367,710	$-
	$95,042	$346,002

(i) On ~~August~~October 1812, 2017, the Company issued an unsecured promissory note in the principal amount of CAD $300,000 ~~(US $240,390)~~. The promissory note matured ~~matures~~ on ~~February~~ 18April 12, ~~2019~~2018 and bears interest at a rate of 15% per annum, ~~paid~~ ~~monthly in arrears with interest payments beginning on March 18, 2018. The interest~~ accrued ~~for~~monthly ~~the~~and ~~initial seven (7) months shall be~~ due at maturity. In connection to the promissory note, the Company issued warrants for the purchase of ~~150~~ 100,000 Common Shares of the Company exercisable at $0.20 per share until ~~February~~April 1811, 2019. The relative fair value of the warrants issued were ~~valued~~recorded atas a debt discount to be amortized over the life of the loan. During the three month periods ended March 31, 2018 and 2017, the Company expensed $111,670 and ~~booked~~$nil, ~~as prepaid~~respectively, ~~financing~~in interest expense related to bethe ~~expensed~~amortization ~~over term~~ of ~~promissory~~the ~~note~~debt discount (note 17 16(eegg)). During the three ~~and~~month ~~nine~~period ~~months~~ ended ~~September 30~~March 31, ~~2017~~2018, the Company accrued $49,~~248~~387 in interest ~~expense~~ on ~~this~~the promissory note which has been recorded in accrued liabilities (~~September~~March 3031, ~~2016~~ 2017 – $nil). At March 31, 2018, the value of the promissory note was $225,330 inclusive of a debt discount of $7,351 (December 31, 2017 – $230,109 inclusive of a debt discount of $9,021). As at the date of these financial statements, this note is currently in default.

(ii) On ~~June~~On 30August 18, 2017, the Company issued an unsecured promissory note in in the principal amount of ~~$60~~CAD 300,000. The ~~principal~~promissory ~~together~~note ~~with~~matures on February 18, 2019 and bears interest at a rate of 1815% per annum, paid ismonthly ~~payable~~ in ~~monthly instalments~~arrears ~~of $3,400~~ with ~~the~~interest ~~first~~payments ~~payment~~beginning ~~due~~ on ~~July 19~~March 18, ~~2017 and~~2018. ~~the~~The ~~final~~interest ~~payment~~accrued ~~due~~for onthe ~~June~~initial ~~19,~~seven ~~2019.~~(7) ~~In the event of~~months ~~default,~~shall bybe ~~way~~due ofat ~~any~~maturity. ~~missed~~In ~~payment~~connection ~~under~~to the promissory note, ~~and~~the ~~not~~Company ~~cured~~issued warrants for athe ~~period~~purchase of ~~15 days~~150,000 atCommon Shares of the ~~option~~Company ofexercisable ~~the~~at ~~holder,~~$0.20 ~~the~~per share until February 18, ~~entire~~2019. ~~unpaid~~The ~~principal~~relative ~~amount~~fair ~~remaining~~value ~~will~~of ~~become~~the ~~due~~warrants ~~and~~issued were recorded ~~payable~~as ~~without~~a ~~notice.~~debt Atdiscount ~~September~~to ~~30,~~be ~~3017,~~amortized ~~$30,000~~over inthe ~~principal~~life of the loan. onDuring ~~this~~the ~~promissory~~three ~~note~~month ~~has~~periods ~~been~~ended ~~classified~~March as31, a2018 ~~current~~and ~~liability~~2017, the ~~and~~Company expensed $223,~~500~~813 ~~has~~and ~~been~~$nil, ~~classified~~respectively, asin ainterest ~~long~~expense related ~~term~~to ~~liability~~the onamortization of the ~~Company’s~~ ~~consolidated~~debt ~~balance~~discount ~~sheet.~~(note 16(ee)). During the three ~~and nine~~month ~~months~~period ended ~~September~~March 3031, ~~2017~~2018, the Company accrued ~~paid~~ $29,~~700~~489 in interest on ~~this~~the promissory note which has been recorded in accrued liabilities (~~September~~March 3031, ~~2016~~2017 – $nil). At March 31, 2018, the value of the promissory note was $231,398 inclusive of a debt discount of $1,283 (December 31, 2017 – $234,034 inclusive of a debt discount of $5,096).

(iii) On June 30, 2017, the Company issued an unsecured promissory note in the principal amount of $60,000. The principal together with interest at a rate of 18% per annum is payable in monthly instalments of $3,400 with the first payment due on July 19, 2017 and the final payment due on June 19, 2019. In the event of default, by way of any missed payment under the promissory note and not cured for a period of 15 days, at the option of the holder, the entire unpaid principal amount outstanding would become due and payable. During the three month period ended March 31, 2018, the Company expensed and paid $2,700 in interest on the promissory note (March 31, 2017 – $nil). At March 31, 2018, $30,000 in principal on the promissory note has been classified as a current liability and $7,500 has been classified as a long term liability on the Company’s consolidated balance sheet.

(iv) On July 18, 2016, VBI entered into a revolving credit facility with The Royal Bank of Canada (“RBC”) for CAD $50,000. The facility is secured by the assets of VBI, due on demand and bears interest at a rate of RBC Prime (“RBP”) + 2%. Interest is payable monthly in arrears. During the three month period ended March 31, 2018, the Company expensed and paid $520 in interest on the facility (March 31, 2017 – $nil). At March 31, 2018, $38,778 (December 31, 2017 - $39,855) in principal remains owing on the facility.

(v) On July 18, 2016, VBI entered into a credit facility with RBC for CAD $106,000. The facility is secured by the assets of VBI, due on demand and bears interest at the rate of RBP + 3%, maturing on July 18, 2021. Interest is payable monthly in arrears and the Company is required to make monthly principal payments of CAD $1,416. During the three month period ended March 31, 2018, the Company paid $987 in interest and made principal repayments of $4,112 on the facility (March 31, 2017 – $nil and $nil, respectively). At March 31, 2018, $58,912 (December 31, 2017 - $64,774) in principal remains owing on the facility.

(~~iii~~vi) On ~~April~~October 2013, ~~2017~~2016, ~~the~~VBI ~~Company~~entered ~~issued~~into ana ~~unsecured~~capital ~~promissory~~lease ~~note~~agreement inwith RBC for the ~~principal~~lease of manufacturing equipment in the amount of CAD $20175,~~000~~132. ~~The~~Under ~~principal~~the ~~together~~lease ~~with interest~~agreement, atthe aCompany ~~rate~~is ofrequired ~~10%~~to make ~~over~~monthly ~~the~~payments ~~term~~ of ~~the~~interest ~~promissory~~and ~~note~~principal ~~is payable~~to RBC in ~~monthly~~the amount ~~instalments~~ of CAD $2,~~750~~451, ~~with~~ the ~~first~~lease ~~payment~~matures ~~due~~ on ~~May~~October 1513, ~~2017~~2023. ~~and~~ During the ~~final~~three ~~payment~~month ~~due~~period onended ~~December~~March 1531, ~~2017.~~2018, In the ~~event~~Company ~~of default~~paid $1,357 byin ~~way~~interest ofand ~~any~~made ~~missed~~principal ~~payment~~repayments ~~under~~of $4,371 on the ~~promissory~~facility ~~note~~(March ~~and~~31, ~~not~~2017 ~~cured~~– ~~for~~$nil aand ~~period~~$nil, ofrespectively). 15At March ~~days~~31, at2018, ~~the option~~a total of ~~the holder~~$110,351 ~~the~~(December ~~entire~~31, ~~unpaid~~2017 ~~principal~~- ~~amount remaining~~$117,909) ~~will~~in ~~become~~principal ~~due~~remains ~~and~~ payable ~~without~~under ~~notice.~~the ~~During~~lease ~~the~~with ~~three~~$22,809 ~~and~~(December ~~nine~~31, ~~months~~2017 ~~ended~~– ~~September 30~~$23,441) ~~2017,~~being ~~the~~allocated ~~Company~~to ~~paid~~current ~~$750 and~~liabilities and $187,~~000,~~542 ~~respectively~~(December 31, in2017 ~~interest~~– on$94,468) ~~this~~being ~~promissory~~allocated ~~note~~to ~~(September~~long ~~30,~~term ~~2016~~liabilities –on ~~$nil)~~the consolidated balance sheet.

(ivvii) On ~~September~~closing ~~28,~~of ~~2016,~~ the ~~Company~~VBI ~~issued~~acquisition, VBI had an ~~unsecured~~amount ~~promissory~~owing ~~note~~to a vendor of VBI in the principal amount of CAD $2120,000. ~~The~~Pursuant ~~principal~~to ~~together with~~the ~~interest~~share atpurchase aagreement, ~~rate~~the ofCompany ~~10%~~agreed ~~per~~to ~~annum~~repay isthe ~~payable~~loan ~~in monthly~~to ~~instalments~~the ofvendor ~~$2,000~~ with ~~the~~two ~~first~~(2) ~~payment~~payments ~~due~~of onCAD ~~October 28~~$5, ~~2016 and the final payment due on September 28~~000, ~~2017.~~payable Inthirty ~~the event~~(30) ofand ~~default,~~sixty by(60) ~~way~~days ofafter ~~any missed payment under~~ the ~~promissory~~closing ~~note~~ and ~~not cured for~~ a ~~period~~final payment of ~~15 days~~CAD $10,000 atdue ~~the~~ninety ~~option~~(90) ofdays ~~the~~after ~~holder,~~ the ~~entire~~closing. ~~unpaid~~The ~~principal~~loan ~~amount~~is unsecured ~~remaining will become due~~ and ~~payable~~ ~~without~~interest ~~notice~~free. ~~During~~At ~~the~~December ~~three and nine months ended September 30~~31, 2017, the ~~Company~~loan ~~paid~~was ~~$750~~in default and CAD $210,000, ~~respectively, in interest on this promissory note~~ (~~September~~USD ~~30, 2016 –~~ $~~nil~~7,971). Atin ~~September~~principal ~~30,~~remained outstanding ~~2017,~~which the Company ~~was~~repaid ~~delinquent on its September 30, 2017 payment and $250~~ in ~~interest~~January ~~was accrued and remains due at September 30, 2017~~2018.

(vviii) On ~~July~~December 187, ~~2016~~2017, ~~VBI~~ the Company entered into a revolving credit facility ~~with~~(the ~~The~~“Revolving ~~Royal~~Facility”) ~~Bank~~in ofthe ~~Canada~~aggregate ~~(“RBC”)~~principal ~~for~~amount of CAD $50200,000 ~~(US $40,066)~~. The ~~revolving facility~~Revolving Facility is secured by ~~the~~certain ~~assets~~inventory and receivables of ~~VBI~~the Company, due onMarch ~~demand~~6, 2018 with an option to extend and bears interest at a rate of ~~RBC~~24% per ~~Prime~~annum ~~(“RBP”)~~payable +monthly 2%in arrears. ~~Interest~~ The Revolving Facility is also subject to a standby fee with respect to the unused portion of the facility, calculated on a daily basis as being the difference between the CAD $200,000 revolving limit and the then outstanding advances, multiplied by 3% and divided by 365 and payable ~~monthly~~in arrears on the last day of each month. During the year ended December 31, 2017, the Company received $100,000 in ~~arrears~~advances under the Revolving Facility. During the three ~~and~~month ~~six~~period ~~months~~ ended ~~September 30~~March 31, ~~2017~~2018, the Company ~~paid~~accrued $~~342~~6,227 in interest onand ~~this~~$419 in ~~facility~~standby fees on the Revolving Facility (~~September~~March 3031, ~~2016~~2017 – $nil and $nil, respectively). At ~~September~~March 3031, ~~2017~~2018, $4099,~~065~~610 in principal remains owing on ~~this~~the ~~facility~~Revolving Facility.

~~(vi) On~~ ~~July 18, 2016, VBI entered into a credit facility with RBC for CAD $106,000 (US $84,938)~~14. ~~The~~CONVERTIBLE credit facility is secured by the assets of VBI, due on demand and bears interest at the rate of RBP + 3%. Interest is payable monthly in arrears and VBI is required to make monthly principal payments in the amount of $1,416. During the three and nine months ended September 30, 2017, the Company paid $728 in interest (September 30, 2016 – $nil) and made principal payment of $2,832 on this facility. At September 30, 2017, $69,362 in principal remains owing on this facility.DEBENTURES

(vii) On October 13, 2016, VBI entered into a capital lease agreement with RBC for the lease of manufacturing equipment in the amount of CAD $175,132 (US $140,333). As a result of the lease agreement, VBI is required to make monthly payments of interest and principal to RBC in the amount of CAD $2,451 (US $1,964). During the three and nine months ended September 30, 2017, the Company paid $2,946 in principal and $981 in interest (September 30, 2016 – $nil). At September 30, 2017, $122,993 in principal remains payable on the capital lease with $18,173 being allocated to current liabilities and $104,820 being allocated to long term liabilities on the consolidated balance sheet.

(viii) On closing of the VBI acquisition, VBI had an amount owing to a vendor of VBI in the principal amount of CAD $20,000 (US $16,026). Pursuant to the share purchase agreement to acquire VBI, the Company agreed to repay the vendor the loan with two (2) payments of CAD $5,000, payable thirty (30) and sixty (60) days after the closing and a final payment of CAD $10,000 due ninety (90) days after the closing. The loan is unsecured and interest free. During the three and nine months ended September 30, 2017, the Company paid $4,006 on this loan (September 30, 2016 – $nil). At September 30, 2017, $12,020 in principal remains outstanding on this loan.

15. CONVERTIBLE DEBENTURES

Convertible Debentures Series A

On September 3, 2013, December 23, 2013 and February 11, 2014, the Company issued $425,000, $797,000 and $178,000, respectively, of unsecured subordinated convertible debentures (“Convertible Debentures Series A”). The Convertible Debentures Series A matured on January 31, 2016 and charged interest at a rate of 12% per annum, payable quarterly in arrears. The Convertible Debentures Series A were convertible into Common Shares at a fixed conversion rate of $0.07 per share at any time prior to the maturity date. Of the $178,000 in face value of Convertible Debentures Series A issued on February 11, 2014, $3,000 were issued in settlement of loans from shareholders and $50,000 were issued in settlement of loans from related parties.

Convertible Debentures Series B

On December 31, 2015, the Company issued 650 unsecured subordinated convertible debenture units (“Convertible Debentures Series B”) for proceeds of $650,000. Each Convertible Debentures Series B consisted of an unsecured subordinated convertible debenture having a principal amount of $1,000 and warrants for the purchase of 5,000 Common Shares at a price of $0.20 per share for a period of twenty-four months from the date of issuance (note 1716(c)). The Convertible Debentures Series B ~~mature~~matured on January 31, 2018 and ~~bear~~charged interest at a rate of 8% per annum, payable ~~quarterly~~ quarterly in arrears. The face value of the Convertible Debentures Series B, together with all accrued and unpaid interest thereon, ~~are~~ are convertible into Common Shares at a fixed conversion rate of $0.10 per share at any time prior to maturity. The Company also has ~~the~~ the option to force conversion of any outstanding Convertible Debentures Series B at any time after six months from issuance and prior to maturity. Of the $650,000 in face value of Convertible Debentures Series B issued on December 31, 2015, $276,000 were issued in settlement of loans from related parties, $10,000 were issued in settlement of related party consulting fees $20,000 were issued in settlement of consulting fees owing to an unrelated party and $227,000 were issued in settlement of loans from shareholders.

Convertible Debentures Series C

On May 20, 2016, the Company issued 375 unsecured subordinated convertible debenture units (the “Convertible Debentures Series C”) for proceeds of $375,000. Each Convertible Debentures Series C consisted of an unsecured subordinated convertible debenture having a principal amount of $1,000 and warrants for the purchase of 10,000 Common Shares at a price of $0.20 per share for a period of twenty-four months from the date of issuance (note 1716(ji)). The Convertible Debentures Series C ~~mature~~matured on January 31, 2018 and ~~bear~~ charged interest at a rate of 8% per annum, accrued quarterly in arrears. The face value of the Convertible Debentures Series C, ~~together~~ together with all accrued and unpaid interest thereon, are convertible into Common Shares at a fixed conversion rate of $0.10 per share at any time prior to maturity. The Company also has the option to force conversion of any outstanding Convertible Debentures Series C at any time after six months from issuance and prior to maturity. For Canadian holders, the Company may only force conversion of any outstanding Convertible Debentures Series C at such time that the Company is a reporting issuer within the jurisdiction of Canada. Of the $375,000 in face value of Convertible Debentures Series C issued on May 20, 2016 (“Convertible Debentures Series C-1”), $55,000 were issued in settlement of amounts owing to related parties (note 20 19(c)) and $10,000 were issued in settlement of amounts owing to an employee. The Company incurred costs of $22,725 as a result of the issuance of Convertible Debentures Series C-1 on May 20, 2016.

On December 31, 2016, the Company issued an additional 275 units of Convertible Debentures Series C (“Convertible Debentures Series C-2”) for proceeds of $275,000 which were fully issued in exchange for cash.

On January 20, 2017, the Company issued an additional 75 units of Convertible Debentures Series C (“Convertible Debentures Series C-3”) in settlement of $65,000 owing to a related party (note 2019(c)) and $10,000 owing in shareholder loans (note 11(ii)).

The Company evaluated the terms and conditions of the Convertible Debentures Series A, Convertible Debentures Series B and each tranche of Convertible Debentures Series C (together, the “Convertible Debentures”) under the guidance of ASC No. 815, Derivatives and Hedging (“ASC 815”). The conversion feature met the definition of conventional convertible for purposes of applying the conventional convertible exemption. The definition of conventional contemplates a limitation on the number of shares issuable under the arrangement. The instrument was convertible into a fixed number of shares and there were no down round protection features contained in the contracts.

Since a portion of the Convertible Debentures were issued in exchange for nonconvertible instruments at the original instrument’s maturity date, the guidance of ASC 470-20-30-19 & 20 were applied. The fair value of the newly issued Convertible Debentures were equal to the redemption amounts owed at the maturity date of the original instruments. Therefore, there was no gain or loss on extinguishment of debt recorded. After the exchange occurred, the Company was required to consider whether the new hybrid contracts embodied a beneficial conversion feature (“BCF”).

For the face value $425,000 of Convertible Debentures Series A issued on September 3, 2013, the calculation of the effective conversion amount did not result in a BCF because the effective conversion price was greater than the Company’s stock price on the date of issuance, therefore no BCF was recorded. However, for the face value $797,000 of Convertible Debentures Series A that were issued on December 23, 2013 and the face value $178,000 of Convertible Debentures Series A that were issued on February 11, 2014, the calculation of the effective conversion amount resulted in a BCF because the effective conversion price was less than the Company’s stock price on the date of issuance and a BCF in the amount of $797,000 and $178,000, respectively, were recorded in additional paid-in capital.

For the face value $650,000 of Convertible Debentures Series B issued on December 31, 2015, the relative fair value of the warrants included in the issuance totaling $287,757 was calculated using the Black-Scholes option pricing model. The resulting fair value of such Convertible Debentures Series B issuance was calculated to be $362,243. The calculation of the effective conversion amount resulted in a BCF because the effective conversion price was less than the Company’s stock price on the date of issuance and a BCF in the amount of $133,657 was recorded in additional paid-in capital.

For the face value $375,000 of Convertible Debentures Series C-1 issued on May 20, 2016, the relative fair value of the warrants included in the issuance totaling $234,737 (note 1716(i)) was calculated using the Black-Scholes option pricing model. The resulting fair value of such Convertible Debentures Series C-1 was calculated to be $140,263. The calculation of the effective conversion amount resulted in a BCF because the effective conversion price was less than the Company’s stock price on the date of issuance and a BCF in the amount of $117,538, net of transaction costs, was recorded in additional paid-in capital.

For the face value $275,000 of Convertible Debentures Series C-2 issued on December 31, 2016, the relative fair value of the warrants included in the issuance totaling $143,871 (note 1716(m)) was calculated using the Black-Scholes option pricing model. The resulting fair value of such Convertible Debentures Series C-2 was calculated to be $131,129. The calculation of the effective conversion amount resulted in a BCF because the effective conversion price was less than the Company’s stock price on the date of issuance and a BCF in the amount of $131,129, was recorded in additional paid-in capital.

For the face value $75,000 of Convertible Debentures Series C-3 issued on January 20, 2017, the relative fair value of the warrants included in the issuance totaling $43,737 (note 1716(o)) was calculated using the Black-Scholes option pricing model. The resulting fair value of such Convertible Debentures Series C-3 was calculated to be $31,263. The calculation of the effective conversion amount resulted in a BCF because the effective conversion price was less than the Company’s stock price on the date of issuance and a BCF in the amount of $31,263, was recorded in additional paid-in capital.

The BCF and the fair value of the warrants, which represents debt discount, is accreted over the life of the Convertible Debentures using the effective interest rate. Amortization of debt discount was recorded as follows:

	For the Three Months Ended September 30, 2017	For the Three Months Ended September 30, 2016	For the Nine Months Ended September 30, 2017	For the Nine Months Ended September 30, 2016
	March 31, 2018	March 31, 2017
Convertible Debentures Series A	$-	$-	$-	$17,342
Convertible Debentures Series B	$38,190	$43,737
Convertible Debentures Series B	46,128	14,483	129,969	27,613
Convertible Debentures Series C-1	21,661	20,172
Conversion of Convertible Debentures Series B	-	-	342,399	-
Convertible Debentures Series C-2	-	5,209
Convertible Debentures Series C-1	37,095	5,411	81,679	11,225
Convertible Debentures Series C-3	-	2,171
Conversion of Convertible Debentures Series C-1	-	-	163,599	-
	$59,851	$71,289
Convertible Debentures Series C-2	43,637	-	63,923	-
Convertible Debentures Series C-3	11,901	-	18,184	-
	$138,761	$19,894	$799,753	$56,180

~~Convertible Debentures as of September 30, 2017 and December 31, 2016, are as follows:~~21

Balance, December 31, 2015	$87,158
Face value Convertible Debentures Series C-1	375,000
Face value Convertible Debentures Series C-2	275,000
Relative fair value of detachable warrants	(378,608)
BCF	(248,667)
Transaction costs	(22,725)
Amortization of debt discount	94,546
Conversion	(23,000)
Cash settlements	(75,000)
Balance, December 31, 2016	$83,704
Face Value Convertible Debentures Series C-3	75,000
Relative fair value of detachable warrants	(43,737)
BCF	(31,263)
Conversion of Convertible Debentures Series B	(423,000)
Conversion of Convertible Debenture Series C-1	(190,000)
Amortization of debt discount	799,753
Balance, September 30, 2017	$270,457

Convertible Debentures as of March 31, 2018 and December 31, 2017, are as follows:


Balance, December 31, 2016	$83,704
Face Value Convertible Debentures Series C-3	75,000
Relative fair value of detachable warrants	(43,737)
BCF	(31,263)
Conversion of Convertible Debentures Series B	(423,000)
Conversion of Convertible Debenture Series C-1	(265,000)
Conversion of Convertible Debenture Series C-2	(275,000)
Conversion of Convertible Debenture Series C-3	(75,000)
Amortization of debt discount	1,231,445
Balance, December 31, 2017	$277,149
Amortization of debt discount	59,851
Balance, March 31, 2018	$337,000

Conversions and Repayments of Convertible Debentures Series A

The Company received forms of election whereby holders of the Convertible Debentures Series A elected to convert the face value of the debentures into Common Shares at $0.07 per share pursuant to the terms of the Convertible Debentures Series A. As at ~~September~~March 31, 302018, ~~2017,~~ the Company received the following forms of elections ~~from~~ from holders of the Convertible Debentures:

Date Form of Election Received	Face Value of Convertible Debentures Series A Converted	Number of Common Shares Issued on Conversion
April 15, 2014	$50,000	714,286
September 30, 2014	800,000	11,428,572
November 10, 2014	275,000	3,928,571
March 9, 2015(1)	52,000	742,857
July 15, 2015	105,000	1,500,000
September 1, 2015	20,000	285,714
	$1,302,000	18,600,000

~~(1) On March 9,~~ ~~2015, the Company settled interest payable on the Convertible~~ ~~Debentures Series A in the amount of $~~(1~~,096 with the issuance of Common Shares at a price of $0.15 per share, of which, $358 of interest payable on the Convertible Debentures Series A was settled with a Director of the Company.~~)

On March 9, 2015, the Company settled interest payable on the Convertible Debentures Series A in the amount of $1,096 with the issuance of Common Shares at a price of $0.15 per share, of which, $358 of interest payable on the Convertible Debentures Series A was settled with a Director of the Company.

On January 25, 2016, the Company received a form of election to convert face value $23,000 of Convertible Debentures Series A, such 328,571 Common Shares remain unissued. On March 10, 2016, the Company settled face value $25,000 of Convertible Debentures Series A with a cash payment. On July 6, 2016, the Company settled face value $50,000 of Convertible Debentures Series A and agreed to pay to the holders such face value in monthly payments ending on November 1, 2016. As at December 31, 2016, the $50,000 was fully paid.

As at ~~September~~March 3031, ~~2017~~2018, all Convertible Debentures Series A had been ~~fully~~ fully settled and only the 328,571 Common Shares valued at $23,000 remain unissued (note 18).

Conversions and Repayments of Convertible Debentures Series B & C

On April 30, 2017 and pursuant to the terms of the Convertible Debentures Series B, the Company sent notices of its election to convert $423,000 in face value and $45,058 in accrued interest to holders of Convertible Debentures Series B at $0.10 per share for a total of 4,680,581 Common Shares of the Company. As a result of these conversions, the Company recorded a debt discount in the amount of $342,399. The above amount included the conversion of $286,000 in face value and $30,465 in accrued interest held by related parties of the Company (note 2019(c)).

On April 30, 2017 and pursuant to the terms of the Convertible Debentures Series C, the Company sent notices of its election to convert $190,000 in face value and $14,367 in accrued interest to holders of Convertible Debentures Series C-1 at $0.10 per share for a a total of 2,043,670 Common Shares of the Company. As a result of these conversions, the Company recorded a debt discount in the amount of $~~163~~168,~~599~~798. The above amount included the conversion of $5,000 in face value and $378 in accrued interest held by related parties of the Company (note 2019(c)).

~~As at September 30, 2017, face value $227,000 of Convertible Debentures Series B and face value $535,000 of Convertible Debentures Series C remain owing to their respective debenture holders.~~22

On December 29, 2017 and pursuant to the terms of the Convertible Debentures Series C, the Company converted $425,000 in face value and $37,184 in accrued interest to holders of Convertible Debentures Series C at $0.10 per share for a total of 4,621,836 Common Shares of the Company. As a result of these conversions, the Company recorded a debt discount in the amount of $119,172. The above amount included the conversion of $130,000 in face value and $13,264 in accrued interest held by related parties of the Company (note 19(c)).

As at March 31, 2018, face value $227,000 of Convertible Debentures Series B and face value $110,000 of Convertible Debentures Series C remain owing to their respective debenture holders.

Interest on Convertible Debentures

During the three ~~and nine~~ month ~~periods~~period ended ~~September~~March 3031, ~~2017~~2018, the Company recorded interest expense in the amount of $116,~~320~~648 ~~and $57,343, respectively,~~ on the Convertible Debentures (~~September~~March 3031, ~~2016~~ 2017 – $2126,~~714 and $53,494~~794). The interest owing on ~~the~~ the convertible debentures is included in accrued liabilities on ~~the~~ the Company’s consolidated balance sheet.

15. COMMON STOCK

During the three month period ended March 31, 2018, the Company:

	●	Issued 50,000 Common Shares on the exercise of warrants, at a price of $0.20 per common share, for cash proceeds of $10,000;
	●	Issued 3,486,362 Common Shares on a private placement basis, at a price of $0.11 per common share for cash proceeds of $383,500;
	●	Issued 190,909 Common Shares on a private placement basis, at a price of $0.11 per common share for payment of consulting fees in the amount of $21,000 owing to an unrelated party; and
	●	Issued 4,621,836 Common Shares at a price of $0.10 per share, for conversion of $425,000 in face value and $37,184 in accrued interest to holders of Convertible Debentures, including the conversion of $130,000 in face value and $13,264 in accrued interest held by related parties of the Company.

16. ~~COMMON STOCK~~WARRANTS

During the nine months ended September 30, 2017, the Company:

●

Issued 19,083,818 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for cash proceeds, net of issuance costs, of $1,818,672;

●

Issued 1,998,950 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for settlement of $199,895 in amounts owing to related parties (note 20(c));

●

Issued 226,920 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for settlement of $22,692 in amounts owing to a shareholder (note 11(i));

●

Issued 320,022 Common Shares, at an average price of $0.156 per share, for settlement of $50,000 in consulting fees owing to a shareholder, previously granted and recognized as Common Shares to be issued at December 31, 2016;

●

Issued 143,715 Common Shares, at an average price of $0.129 per share, for settlement of $18,550 in consulting fees owing to an unrelated party, previously granted and recognized as Common Shares to be issued as at December 31, 2016;

●

Issued 366,667 Common Shares, at a price of $0.15 per share, for settlement of $55,000 in consulting fees owing to an unrelated party, previously granted and recognized as Common Shares to be issued as at December 31, 2016;

●

Issued 300,000 Common Shares, at a price of $0.10 per share, for settlement of $30,000 in amounts owing to a director of the Company (note 20(a)). The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $33,000. The balance of $3,000 has been recorded as a loss on settlement of debt;

●

Issued 300,000 Common Shares, at a price of $0.167 per share, for settlement of $50,000 in charitable contributions owing to an unrelated party (note 22(d)). The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $36,000. The balance of $14,000 has been recorded as a gain on settlement of debt;

●

Issued 50,000 Common Shares, at a price of $0.12 per share, as $6,000 in employment income to an unrelated party;

●

Issued 871,000 Common Shares, at a price of $0.10 per share, for settlement of $87,100 in directors fees owing to former directors of the Company (note 20(a)). The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $121,940. The balance of $34,840 has been recorded as a loss on settlement of debt;

●

Issued 500,000 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, as settlement of $50,000 in financing fees in connection to the Term Loan Amendment No.2 (note 13). Of the 500,000 Common Shares issued, 93,622 Common Shares were issued to related parties (note 20(c));

●

Issued 6,130,000 Common Shares, at a price of $0.10 per share, on conversion of $613,000 of Convertible Debentures (note 15). The above amount included the conversion of $291,000 of Convertible Debentures held by related parties of the Company (note 20(c));

●

Issued 594,251 Common Shares, at price of $0.10 per share, for settlement of $59,425 in interest owing on Convertible Debentures (note 15). The above amount included the settlement of $30,843 of interest owing on Convertible Debentures held by related parties of the Company (note 20(c));

●

Issued 2,500,000 Common Shares, at a price of $0.14, for the acquisition of a subsidiary; and

●

Issued 730,280 Common Shares on a private placement basis, at a price of $0.10 per share, for cash proceeds of $50,000 and settlement of amounts owing to an unrelated party in the amount of $23,028.

During the year ended December 31, 2016, the Company:

●

Issued 480,000 Common Shares, at a price of $0.10 per share, for settlement of $48,000 in deferred fees owing to a related party (note 20(c)). The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $76,800. The balance of $28,800 has been recorded as a loss on settlement of debt;

●

Issued 562,715 Common Shares, at an average price of $0.141 per share, for settlement of $79,154 in consulting fees owing to unrelated parties. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $78,780. The balance of $374 has been recorded as a gain on settlement of debt; and

●

Issued 150,000 Common Shares, at a price of $0.14 per share, as $21,000 in related party employment income (note 20(c)).

17. WARRANTS

The following schedule summarizes the outstanding warrants for the purchase of Common Shares of the Company:

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	Warrants Outstanding	Weighted Average Exercise Price	Weighted Average Life Remaining (yrs)	Warrants Outstanding	Weighted Average Exercise Price	Weighted Average Life Remaining (yrs)
Beginning of period	1728,~~310~~237,~~000~~782	$0.23	10.2184	817,~~177~~560,~~373~~000	$0.2523	1.3921
Issued	17250,~~477,782~~000	0.2120	1.6584	1118,~~935~~927,~~000~~782	0.21	21.0561
Cancelled	~~(1,750,000)~~-	~~0.25~~-	~~1.03~~-	(1,~~125~~750,000)	0.25	~~1.13~~-
Expired	(31,~~000~~725,000)	0.3422	-	(16,~~677~~500,~~373~~000)	0.1927	-
End of period	3026,~~037~~762,782	$0.2120	0.8963	1728,~~310~~237,~~000~~782	$0.23	10.2184

2524

The Company has issued warrants for the purchase of Common Shares of the Company as follows:

Issuance Date		Number of Warrants	~~Expected Life in Years~~	~~Exercise~~Expected ~~Price~~Life ~~($)~~in Years	~~Risk Free Rate~~	~~Dividend~~Exercise ~~Yield~~Price ($)	~~Expected Volatility~~	~~Fair~~Risk ~~Value~~Free ~~($)~~Rate	Dividend Yield	Expected Volatility	Fair Value ($)
May 29, 2015	(a)	250,000	~~2.00~~	02.4000	~~0.85%~~	~~Nil~~0.40	~~298%~~	~~35,362~~0.85%	Nil	298%	35,362
May 29, 2015	(a)	250,000	~~2.00~~	02.5000	~~0.85%~~	~~Nil~~0.50	~~298%~~	~~35,134~~0.85%	Nil	298%	35,134
May 29, 2015	(a)	250,000	~~2.00~~	02.6000	~~0.85%~~	~~Nil~~0.60	~~298%~~	~~34,934~~0.85%	Nil	298%	34,934
May 29, 2015	(a)	250,000	~~2.00~~	02.7000	~~0.85%~~	~~Nil~~0.70	~~298%~~	~~34,755~~0.85%	Nil	298%	34,755
December 30, 2015	(b)	250,000	1.50	0.20	0.88%	Nil	190%	26,821
December 31, 2015	(b)	3,250,000		2.00		0.20		1.19%	Nil	265%	516,343
December 31, 2015	(c)	3,250,000	2.00	0.20	1.19%	Nil	265%	516,343
January 18, 2016	(c)	250,000		2.46		0.20		0.91%	Nil	263%	51,598
January 18, 2016	(d)	250,000	2.46	0.20	0.91%	Nil	263%	51,598
March 2, 2016	(d)	1,000,000		2.00		0.20		0.91%	Nil	271%	158,995
February 18, 2016	(e)	300,000	2.00	0.25	0.80%	Nil	275%	30,501
May 20, 2016	(e)	3,750,000		2.00		0.20		1.03%	Nil	259%	234,737
February 18, 2016	(f)	1,500,000	2.00	0.25	0.80%	Nil	275%	152,503
May 20, 2016	(f)	85,000		2.00		0.20		1.03%	Nil	259%	14,225
March 2, 2016	(g)	1,000,000	2.00	0.20	0.91%	Nil	271%	158,995
July 15, 2016	(g)	300,000		2.46		0.20		0.91%	Nil	263%	45,799
April 13, 2016	(h)	1,750,000	2.00	0.25	0.88%	Nil	264%	241,754
December 22, 2016	(h)	250,000		1.50		0.20		0.87%	Nil	180%	18,840
May 20, 2016	(i)	3,750,000	2.00	0.20	1.03%	Nil	259%	234,737
December 31, 2016	(i)	2,750,000		2.00		0.20		1.20%	Nil	259%	143,871
May 20, 2016	(j)	85,000	2.00	0.20	1.03%	Nil	259%	14,225
January 12, 2017	(j)	50,000		1.00		0.20		0.81%	Nil	191%	4,988
July 15, 2016	(k)	300,000	2.46	0.20	0.91%	Nil	263%	45,799
January 20, 2017	(k)	750,000		2.00		0.20		1.20%	Nil	267%	43,737
December 22, 2016	(l)	250,000	1.50	0.20	0.87%	Nil	180%	18,840
January 31, 2017	(l)	3,773,006		1.00		0.20		0.84%	Nil	173%	224,479
December 31, 2016	(m)	2,750,000	2.00	0.20	1.20%	Nil	259%	143,871
January 31, 2017	(m)	411,361		1.00		0.20		0.84%	Nil	173%	24,474
January 12, 2017	(n)	50,000	1.00	0.20	0.81%	Nil	191%	4,988
February 17, 2017	(n)	907,948		1.00		0.20		0.82%	Nil	167%	63,641
January 20, 2017	(o)	750,000	2.00	0.20	1.20%	Nil	267%	43,737
February 17, 2017	(o)	108,954		1.00		0.20		0.82%	Nil	167%	7,615
January 31, 2017	(p)	3,773,006	1.00	0.20	0.84%	Nil	173%	224,479
March 8, 2017	(p)	1,500,000		2.00		0.25		1.36%	Nil	266%	193,438
January 31, 2017	(q)	411,361	1.00	0.20	0.84%	Nil	173%	24,474
March 21, 2017	(q)	3,270,045		1.00		0.20		1.00%	Nil	165%	236,773
February 17, 2017	(r)	907,948	1.00	0.20	0.82%	Nil	167%	63,641
March 21, 2017	(r)	27,623		1.00		0.20		1.00%	Nil	165%	2,000
February 17, 2017	(s)	108,954	1.00	0.20	0.82%	Nil	167%	7,615
April 4, 2017	(s)	250,000		1.00		0.20		1.03%	Nil	163%	19,703
March 8, 2017	(t)	1,500,000	2.00	0.25	1.36%	Nil	266%	193,438
April 6, 2017	(t)	500,000		2.00		0.25		1.24%	Nil	167%	52,643
March 21, 2017	(u)	3,270,045	1.00	0.20	1.00%	Nil	165%	236,773
June 2, 2017	(u)	1,634,615		1.00		0.20		1,16%	Nil	171%	110,602
March 21, 2017	(v)	27,623	1.00	0.20	1.00%	Nil	165%	2,000
June 16, 2017	(v)	769,230		1.00		0.20		1.21%	Nil	171%	57,765
April 4, 2017	(w)	250,000	1.00	0.20	1.03%	Nil	163%	19,703
June 28, 2017	(w)	300,000		1.00		0.20		1.21%	Nil	159%	23,020
April 6, 2017	(x)	500,000	2.00	0.25	1.24%	Nil	167%	52,643
July 1, 2017	(x)	75,000		1.50		0.20		1.24%	Nil	158%	7,000
June 2, 2017	(y)	1,634,615	1.00	0.20	1,16%	Nil	171%	110,602
July 31, 2017	(y)	2,000,000		2.00		0.20		1.34%	Nil	245%	252,631
June 16, 2017	(z)	769,230	1.00	0.20	1.21%	Nil	171%	57,765
July 31, 2017	(z)	1,000,000		2.00		0.20		1.34%	Nil	245%	21,930
June 28, 2017	(aa)	300,000	1.00	0.20	1.21%	Nil	159%	23,020
August 18, 2017	(aa)	150,000		1.50		0.20		1.24%	Nil	159%	11,233
July 1, 2017	(bb)	75,000	1.50	0.20	1.24%	Nil	158%	7,000
October 1, 2017	(bb)	350,000		1.50		0.20		1.31%	Nil	161%	36,925
July 31, 2017	(cc)	2,000,000	2.00	0.20	1.34%	Nil	245%	252,631
October 12, 2017	(cc)	100,000		1.50		0.20		1.41%	Nil	159%	8,860
July 31, 2017	(dd)	1,000,000	2.00	0.20	1.34%	Nil	245%	21,930
November 15, 2017	(dd)	1,000,000		1.50		0.20		1.55%	Nil	137%	89,053
August 18, 2017	(ee)	150,000	1.50	0.20	1.24%	Nil	159%	11,670
February 1, 2018	(ee)	250,000		2.00		0.20		1.26%	Nil	206%	33,681
		33,912,782						3,134,281
		31,812,782									2,850,784

2625

(a)

Issued in connection to a commission agreement. The warrants vest in four tranches of 250,000 warrants each. The first tranche has an exercise price of $0.40 per share and vested upon execution of the agreement. The second tranche has an exercise price of $0.50 per share and will vest upon the sales agent delivering $500,001 in sales revenue to Gilla Worldwide. The third tranche has an exercise price of $0.60 per share and will vest upon the sales agent delivering $1,000,001 in sales revenue to Gilla Worldwide. The fourth tranche has an exercise price of $0.70 per share and will vest upon the sales agent delivering $1,500,001 in sales revenue Gilla Worldwide. During the year ended December 31, 2015, the Company booked the fair value of the vested warrants in the amount of $35,362 as a prepaid to be expensed over the two year life of the commission agreement. During the ~~nine~~three month periods ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017, the Company expensed $~~7,367~~nil and $84,~~840~~420, respectively, in stock based compensation which has been ~~recorded~~ recorded as an administrative expense. No portion of the value of ~~the~~ the unvested warrants has been expensed as the sales agent had not ~~yet~~ yet delivered any sales revenue to Gilla Worldwide.

(b)

Issued in connection to the ~~Secured~~issuance ~~Notes~~of ~~(note~~Convertible 11Debentures Series B (ivnote 14)). ~~During~~The ~~the~~relative ~~year ended December 31, 2015, the Company booked the~~ fair value of the warrants in the amount of $26516,~~821~~343, asalong awith ~~prepaid~~the toBCF, berepresents ~~expensed~~debt ~~over~~discount on the Convertible Debentures Series B and is accreted over the life of the convertible debentures using the ~~Secured~~effective ~~Notes.~~interest rate. During the ~~nine~~three month periods ended ~~September~~ 30March 31, ~~2017~~2018 and ~~2016~~2017, the Company ~~expensed~~recorded interest expense in the amount of $838,~~843~~190 and $843,~~892~~737, respectively, ofrelated ~~the~~to ~~prepaid~~debt asdiscount ~~financing fees~~ which ~~has~~includes the ~~been~~accretion ~~recorded~~of asthe anBCF ~~interest~~of ~~expense~~the Convertible Debentures Series B.

(c)

Issued in connection to the ~~issuance~~Term ofLoan ~~Convertible~~(note ~~Debentures~~12). ~~Series~~On BJuly ~~(note~~15, 2016, the ~~14). The~~Company ~~relative~~extended ~~fair~~the ~~value~~expiration date of the warrants, inpreviously issued with the ~~amount~~credit ~~of $516~~facility to December 31,~~343~~ 2018, ~~along~~ with all other terms of the ~~BCF,~~warrants ~~represents~~remaining ~~debt~~the ~~discount~~same. onDuring the year ~~Convertible~~ended ~~Debentures~~December ~~Series~~31, B2016, the Company booked the fair value of the warrants and isthe ~~accreted~~extension in the amount of $51,598 as a debt issuance cost to be expensed over the life of the ~~convertible~~Term ~~debentures~~Loan. ~~using~~On July 15, 2016 and in connection to the ~~effective~~Term ~~interest~~Loan ~~rate.~~Amendment, the ~~During~~Company also extended the ~~nine~~expiration ~~month~~date ~~periods~~of ~~ended~~the ~~September~~warrants 30for the purchase of 250,000 ~~2017~~Common ~~and~~Shares ~~2016~~that were issued on August 1, 2014 in connection to the ~~Company~~Credit ~~recorded~~Facility ~~interest~~(note ~~expense~~12) and extended on January 18, 2016 in connection to the ~~amount~~Term ofLoan ~~$129,969~~(note ~~and~~12) until ~~$27~~December 31,~~613,~~ ~~respectively~~2018, ~~related~~with toall ~~debt~~other ~~discount~~terms ~~which~~of ~~includes~~the warrants remaining the same. During the year ended December 31, 2016, the Company ~~accretion~~booked the fair value of the ~~BCF~~extensions in the amount of $42,325 as debt discount to be amortized over the ~~Convertible~~life ~~Debentures~~of ~~Series~~the Bloan.

(d)

Issued in connection to the ~~Term~~ Loan Agreement (note 1311(v)). OnThe ~~July~~warrants ~~15,~~shall vest ~~2016 and~~ in ~~connection~~ totwo ~~the~~equal ~~Term~~tranches, ~~Loan~~with ~~Amendment~~500,000 ~~the Company extended the expiration date of the~~ warrants to ~~December~~vest ~~31,~~upon ~~2018, with all~~the ~~other~~close ~~terms~~ of ~~the~~Loan ~~warrants~~Tranche ~~remaining~~A ~~the~~and ~~same. During~~ the ~~year ended~~remaining ~~December 31~~500,000 ~~2016, the Company booked the fair value of the~~ warrants ~~and~~to ~~the extension in the amount of $51,598 as a debt~~vest ~~issuance~~upon ~~cost to be expensed over~~ the ~~life~~close of ~~the~~Loan ~~Term~~Tranche ~~Loan~~B. ~~During the~~On ~~nine~~March ~~months ended September 30~~3, ~~2017~~2016 and ~~2016,~~April ~~the Company expensed $~~14,~~198 and $18,077, respectively, as financing fees which~~ ~~has been recorded as interest expense. On July 15,~~ 2016 ~~and in connection to the Term Loan Amendment~~, the Company ~~also~~closed ~~extended the~~Loan ~~expiration~~Tranche ~~date~~A ofand ~~the~~Loan ~~warrants~~Tranche ~~for the purchase of 250~~B,~~000~~ ~~Common Shares that were issued on August 1~~respectively, ~~2014~~at inwhich ~~connection~~dates to the ~~Credit~~warrants ~~Facility~~became ~~(note~~fully ~~12)~~vested and ~~extended on January 18, 2016 in~~ ~~connection to the Term Loan (note 13) until December 31, 2018, with all other terms of the warrants remaining the same~~exercisable. During the year ended December 31, 2016, the Company booked the fair value of the ~~extensions~~ warrants in the amount of $42158,~~325~~995 ~~as a prepaid to be expensed~~the ~~over~~fair ~~the~~value ~~life~~ of the ~~Term~~warrants ~~Loan.~~issued ~~During~~were ~~the~~recorded ~~nine~~as ~~month~~debt ~~periods~~discount ~~ended~~to ~~September~~be ~~30,~~amortized ~~2017~~over ~~and 2016,~~ the ~~Company~~life ~~expensed~~of ~~$12,144~~the ~~and $13,724,~~Shareholder ~~respectively, as financing fees which has been recorded as interest expense~~Loan.

(e)

Issued in ~~relation~~ connection to athe ~~consulting~~issuance ~~agreement.~~of ~~The~~Convertible ~~warrants~~Debentures ~~shall~~Series ~~vest quarterly in~~C-1 ~~eight~~(note ~~equal~~14). ~~tranches,~~The ~~with~~relative ~~the~~fair ~~first~~value ~~tranche~~of ~~vesting immediately and~~ the ~~final~~warrants ~~tranche~~in ~~vesting on November 18, 2017. If~~ the ~~consulting~~ ~~agreement~~amount ~~was terminated prior to the expiration~~ of ~~the~~ ~~warrants~~$234,737, ~~any~~along ~~unexercised~~with ~~fully~~the ~~vested~~BCF, ~~warrants~~represents ~~would~~debt ~~expire~~discount ~~thirty calendar~~on ~~days following~~ the Convertible ~~effective~~Debentures ~~termination~~Series ~~date~~C-1 and ~~any unvested~~is ~~warrants~~accreted ~~would~~over bethe ~~automatically~~life ~~canceled. On August 31,~~of ~~2016,~~ the ~~Company~~convertible ~~terminated~~debentures using the ~~consulting~~effective ~~agreement~~interest ~~and 187,500~~rate. ofDuring the ~~unvested~~three ~~warrants~~month ~~have~~periods ~~been~~ended ~~cancelled~~March ~~and the remaining 112~~31,~~500~~ ~~vested~~2018 ~~warrants remain outstanding~~ and ~~exercisable~~2017, ~~until~~the ~~February~~Company ~~17,~~recorded ~~2018~~interest asexpense ~~mutually agreed~~ in the ~~termination.~~amount ~~During~~of ~~the nine month periods ended September 30~~$21,661 ~~2017~~ and ~~2016, the Company~~ ~~expensed~~ $~~nil and $16~~20,~~511~~172, respectively, asrelated ~~stock~~to ~~based compensation~~debt discount which ~~has~~includes ~~been~~the accretion ~~recorded~~of asthe anBCF ~~administrative~~of the Convertible Debentures Series ~~expense~~C-1.

(f)

Issued inas ~~relation to~~ a ~~consulting agreement. The warrants shall vest quarterly in~~ ~~eight~~commission ~~equal~~payment ~~tranches,~~related ~~with the first tranche vesting immediately and the final tranche vesting on November 18, 2017. If the consulting agreement was terminated prior~~ to the ~~expiration~~issuance of the ~~warrants,~~ ~~any unexercised fully vested warrants would expire thirty~~Convertible ~~calendar~~Debentures ~~days~~Series ~~following the effective termination date and any unvested warrants shall be automatically canceled~~C-1. OnThe ~~October~~fair ~~25, 2016,~~value ~~the~~of ~~Company terminated~~ the ~~consulting agreement and 937,500 unvested~~ warrants ~~have~~in ~~been cancelled and~~ the ~~remaining~~amount of ~~562~~$14,~~500 vested~~225 ~~warrants~~was ~~remain~~recorded ~~outstanding and exercisable until June 30, 2018~~ as ~~mutually~~a ~~agreed~~reduction into the ~~termination.~~proceeds ~~During the nine month~~received ~~periods~~from ~~ended September 30, 2017 and 2016,~~ the ~~Company~~Convertible ~~expensed $nil~~Debentures ~~and~~Series ~~$108,656,~~C-1 ~~respectively,~~(note ~~as stock based compensation which has been recorded as an administrative expense~~14).

(g)

Issued in connection to the Term Loan ~~Agreement~~Amendment (note ~~11(v~~12)). The warrants shall vest in two equal tranches, with 500,000 warrants to vest upon the close of Loan Tranche A and the remaining 500,000 warrants to vest upon the close of Loan Tranche B. On March 3, 2016 and April 14, 2016, the Company closed Loan Tranche A and Loan Tranche B, respectively, at which dates the warrants became fully vested and exercisable. During the year ended December 31, 2016, the Company booked the fair value of the warrants in the amount of $~~158~~45,~~995~~799 were recorded as a ~~prepaid~~debt todiscount to be ~~expensed~~amortized over the life of the ~~Shareholder~~Term Loan. ~~During the nine month periods ended September 30, 2017 and 2016, the Company expensed $61,610 and $42,619, respectively, of the prepaid as financing fees which has been recorded as interest expense.~~

(h)

Issued in connection to ~~a consulting agreement. Forty percent of~~ the ~~warrants vested~~Secured ~~immediately~~Notes ~~with~~(note ~~the~~11(iii ~~remaining sixty percent vesting in equal tranches of fifteen percent on September 30, 2016, December 31 2016, September 30, 2017~~ and ~~December 31, 2017~~iv)). If the consulting agreement is terminated prior to the expiration of the warrants, any unexercised fully vested warrants shall expire ninety calendar days following the effective termination date and any unvested warrants shall be automatically canceled. During the ~~nine~~ ~~month~~year ~~period~~ ended ~~September~~December 3031, ~~2017~~2016, the Company ~~terminated~~booked the ~~consulting~~ ~~agreement~~fair ~~for~~value ~~cause~~of the ~~and all~~ warrants ~~issued~~ in ~~connection~~ to the ~~consulting~~amount ~~agreement were canceled. As a result~~ of ~~the termination~~$18,840 ~~the~~were ~~Company~~recorded ~~did~~as ~~not record any stock based~~debt ~~compensation~~discount ~~during~~to ~~the~~be ~~nine~~amortized ~~month~~over ~~period ended September 30, 2017. During~~ the ~~nine~~life ~~month~~of ~~period ended September 30, 2016,~~ the ~~Company~~Secured ~~expensed $180,242 in stock based compensation in relation to these warrants~~Notes.

(i)

Issued in connection to the issuance of Convertible Debentures Series C-12 (note 1514). The relative fair value of the warrants in the amount of $~~234~~143,~~737~~871, along with the BCF, represents debt discount on the Convertible Debentures Series C-12 and is accreted over the life of the convertible debentures using the effective interest rate. During the ~~nine~~three month periods ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017, ~~the~~ the Company recorded interest expense in the amount of $~~81,679~~nil and $115,~~225~~209, respectively, related to debt discount which includes the ~~accretion~~ accretion of the BCF of the Convertible Debentures Series C-12.

(j)

Issued ~~as a~~in ~~commission~~connection ~~payment~~to ~~related~~the toBridge Loan Agreement (note 11(vi)). During the years ~~issuance~~ended ofDuring the ~~Convertible~~three month periods ended March 31, 2018 and ~~Debentures~~2017, ~~Series~~the ~~C-1.~~Company ~~The~~expensed the fair value of the warrants in the ~~amount~~ amount of $~~14,225~~nil ~~was~~and ~~recorded~~$4,988, respectively, as afinancing ~~reduction~~fees ~~to the proceeds received~~which ~~from~~has ~~the~~been ~~Convertible~~recorded ~~Debentures~~as ~~Series~~interest ~~C-1 (note 15)~~expense.

(k)

Issued in connection to the ~~Term~~issuance ~~Loan~~of ~~Amendment~~Convertible Debentures Series C-3 (note 1314). ~~During~~The ~~the~~relative ~~year ended December 31, 2016, the Company booked the~~ fair value of the warrants in the amount of $4543,~~799~~737, asalong awith ~~prepaid~~the toBCF, berepresents ~~expensed~~debt ~~over~~discount on the Convertible Debentures Series C-3 and is accreted over the life of the convertible debentures using the ~~Term~~effective ~~Loan.~~interest rate. During the ~~nine~~three month periods ended ~~September~~ 30March 31, ~~2017~~2018 and ~~2016~~2017, the Company ~~expensed~~recorded interest expense in the amount of $~~17,439~~nil and $42,~~855~~171, respectively, ofrelated ~~the~~to ~~prepaid~~debt asdiscount ~~financing~~which ~~fees~~includes ~~which~~the ~~has~~accretion ~~been~~of ~~recorded~~the asBCF ~~interest~~of ~~expense~~the Convertible Debentures Series C-3.

(l)

Issued in connection to ~~the~~private ~~Secured~~placement ~~Notes (note 11)~~units. ~~During~~No ~~the~~stock ~~year~~based ~~ended~~compensation ~~December~~expense ~~31,~~was ~~2016,~~recorded ~~the~~since ~~Company booked~~ the ~~fair value of the~~ warrants inwere ~~the~~issued ~~amount of $18,840~~ as ~~debt~~part ~~issuance~~of ~~cost to be~~a ~~expensed~~private ~~over~~placement ~~the life~~ of ~~the~~Common ~~Secured Notes~~Shares. ~~During~~The ~~the~~fair ~~nine~~value ~~month periods ended September 30, 2017 and 2016, the Company expensed $9,267 and $nil, respectively,~~ of the ~~prepaid as financing fees~~warrants ~~which~~were ~~has~~calculated ~~been~~and recorded asin ~~interest~~additional ~~expense~~paid in capital.

(m)

Issued inas a ~~connection~~commission payment related to the issuance of ~~Convertible~~private ~~Debentures Series C-2~~placement ~~(note 15)~~units. The ~~relative~~ fair value of the warrants in the amount of $~~143~~24,~~871,~~474 ~~along with the BCF, represents debt discount on the~~was Convertible Debentures Series C-2 and is accreted over the life of the convertible debentures using the effective interest rate. During the nine month periods ended September 30, 2017 and 2016, the Company recorded ~~interest~~as ~~expense~~a inreduction ~~the amount of $63,923 and $nil, respectively, related~~ to ~~debt discount which includes~~ the ~~accretion~~ ofproceeds ~~the~~received ~~BCF~~from of the ~~Convertible Debentures Series~~private ~~C-2~~placement issuance.

(n)

Issued in connection to ~~the~~private ~~Bridge~~placement ~~Loan~~units. ~~Agreement~~No ~~(note~~stock ~~11(vi)).~~based ~~During the~~compensation ~~nine~~expense ~~month~~was ~~periods~~recorded ~~ended~~since ~~September~~the ~~30,~~warrants ~~2017~~were ~~and~~issued ~~2016,~~as ~~the~~part ~~Company~~of a ~~expensed~~private ~~the~~placement ~~fair value~~ of ~~the~~Common ~~warrants~~Shares. inThe ~~the~~fair ~~amount~~value of ~~$4,988~~the ~~and~~warrants ~~$nil,~~were ~~respectively,~~calculated asand ~~financing~~recorded ~~fees~~in ~~which~~additional ~~has~~paid ~~been recorded as~~in ~~interest expense~~capital.

(o)

Issued inas a ~~connection~~commission payment related to the issuance of ~~Convertible~~private ~~Debentures Series C-3~~placement ~~(note 15)~~units. The ~~relative~~ fair value of the warrants in the amount of $437,~~737,~~615 ~~along with the BCF, represents debt discount on the~~was Convertible Debentures Series C-3 and is accreted over the life of the convertible debentures using the effective interest rate. During the nine month periods ended September 30, 2017 and 2016, the Company recorded ~~interest~~as ~~expense~~a inreduction ~~the amount of $18,184 and $nil, respectively, related~~ to ~~debt discount which includes~~ the ~~accretion~~ ofproceeds ~~the~~received ~~BCF~~from of the ~~Convertible Debentures Series~~private ~~C-3~~placement issuance.

(p)

Issued in connection to ~~private~~an ~~placement~~employment ~~units~~agreement. NoThe ~~stock~~warrants ~~based~~will ~~compensation~~vest in ~~expense~~three ~~was~~equal ~~recorded~~tranches, ~~since~~with the ~~warrants~~first ~~were~~tranche ~~issued~~vesting asupon ~~part~~the employee generating over $25,000 in sales of anew business for two ~~private~~consecutive ~~placement~~months, ofthe ~~Common~~second ~~Shares.~~tranche ~~The~~vesting ~~fair~~upon ~~value~~the employee generating cumulative sales of over $500,000 and the ~~warrants~~third tranche ~~were~~vesting ~~calculated~~upon ~~and~~the employee generating cumulative sales of over $1,000,000 of new business. At March 31, 2018, no stock based compensation has been recorded inas ~~additional~~the ~~paid~~employee inhas not yet begun to ~~capital~~generate new business sales.

(q)

Issued as a commission payment related to the issuance of private placement units. The fair value of the warrants in the amount of $24,474 was recorded as a reduction to the proceeds received from the private placement issuance.

(r)

Issued in connection to private placement units. No stock based compensation expense was recorded since the warrants were issued as part of a private placement of Common Shares. The fair value of the warrants were calculated and recorded in additional paid in capital.

28(r)

Issued as a commission payment related to the issuance of the private placement units. The fair value of the warrants in the amount of $2,000 was recorded as a reduction to the proceeds received from the private placement issuance.

(s)

Issued ~~as a~~in ~~commission~~connection ~~payment related~~ to ~~the issuance of~~ private placement units. ~~The~~No ~~fair~~stock ~~value~~based ofcompensation expense was recorded since the warrants inwere ~~the~~issued ~~amount~~as part of ~~$7,615 was~~a ~~recorded~~private asplacement aof ~~reduction~~Common toShares. ~~the~~The ~~proceeds~~fair ~~received~~value ~~from~~of the ~~private~~warrants ~~placement~~were ~~issuance~~calculated and recorded in additional paid in capital.

(t)

Issued in connection to an employment agreement., ~~The~~the warrants ~~will~~shall vest in ~~three~~two equal tranches, with the first tranche vesting upon the ~~employee~~commercial ~~generating~~sale ~~over~~of ~~$25,000~~a innew ~~sales~~product ofto ~~new~~be ~~business~~developed ~~for~~by ~~two~~the employee ~~consecutive~~and ~~months,~~ the second tranche vesting upon the ~~employee generating~~commercial ~~cumulative~~sale ~~sales~~ of ~~over~~a ~~$500,000~~total of ~~and~~two ~~the~~new ~~third~~products ~~tranche vesting~~developed ~~upon~~by the employee. ~~generating~~Both ~~cumulative~~tranches ~~sales of over~~have $1vested,~~000,000~~ ofthe ~~new~~Company ~~business.~~has Atrecorded ~~September~~$nil ~~30,~~in ~~2017, no~~ stock based compensation during ~~has~~the ~~been~~three ~~recorded~~month asperiods ~~the~~ended ~~employee~~March ~~has~~31, ~~not~~2018 ~~yet~~and ~~begun~~2017 related to ~~generate~~ ~~new~~these ~~business sales~~warrants.

(u)

(v)

Issued ~~as a~~in ~~commission~~connection ~~payment related~~ to ~~the issuance of the~~ private placement units. ~~The~~No ~~fair~~stock ~~value~~based ofcompensation expense was recorded since the warrants inwere ~~the~~issued ~~amount~~as part of ~~$2,000 was~~a ~~recorded~~private asplacement aof ~~reduction~~Common toShares. ~~the~~The ~~proceeds~~fair ~~received~~value ~~from~~of the ~~private~~warrants ~~placement~~were ~~issuance~~calculated and recorded in additional paid in capital.

(w)

(x)

Issued in connection towith ana ~~employment~~consulting agreement,. ~~the~~During ~~warrants shall vest in two equal tranches, with~~ the ~~first~~three ~~tranche vesting upon the~~month ~~commercial~~periods ~~sale~~ended ofMarch a31, ~~new~~2018 ~~product to be developed by the employee~~ and ~~the~~2017, ~~second tranche vesting upon~~ the ~~commercial sale of a total of two new products developed by the employee. Both tranches have vested and the~~ Company ~~has~~expensed ~~recorded~~ $52nil,~~643~~ as in stock -based compensation ~~for~~which ~~the~~was ~~nine~~recorded ~~month~~as ~~period~~an ~~ended September 30, 2017~~administrative ~~(September 30, 2016 - $nil)~~expense.

(y)

Issued in connection towith ~~private placement units. No stock based compensation expense was recorded since~~ the ~~warrants~~acquisition ~~were issued as part~~ of a ~~private~~ ~~placement~~subsidiary ~~of Common Shares. The fair value of the warrants~~(note ~~were calculated and recorded in additional paid in capital~~4(c)).

(z)

Issued in connection to ~~private~~an ~~placement~~employment ~~units.~~agreement, Nothe ~~stock~~warrants ~~based~~shall ~~compensation~~vest in ~~expense~~four ~~was~~equal ~~recorded~~tranches ~~since~~every ~~the~~six ~~warrants~~months ~~were~~following ~~issued~~the asdate ~~part~~ of a ~~private~~issuance. ~~placement~~During ofthe ~~Common~~three ~~Shares.~~month ~~The~~periods ~~fair~~ended ~~value~~March of31, ~~the~~2018 ~~warrants~~and ~~were~~2017, ~~calculated~~the Company expensed $22,367 and ~~recorded~~$nil, inrespectively, ~~additional~~as stock-based ~~paid~~compensation inwhich was recorded as an administrative ~~capital~~expense.

(aa)

Issued in connection towith ~~private~~a ~~placement~~promissory ~~units.~~note No(note ~~stock~~(13)). ~~based~~During ~~compensation~~the year ~~expense~~ended ~~was~~December ~~recorded~~31, ~~since~~2017, the ~~warrants~~Company ~~were~~booked ~~issued~~the asrelative ~~part~~fair value of ~~a private~~the ~~placement~~warrants ofin ~~Common~~the ~~Shares.~~amount ~~The~~of ~~fair~~$11,233 ~~value~~were ofrecorded ~~the~~as ~~warrants~~debt ~~were~~discount ~~calculated~~to ~~and~~be ~~recorded~~amortized inover ~~additional~~the ~~paid~~life inof the promissory ~~capital~~note.

(bb)

Issued in connection ~~with~~to a consulting agreement., ~~During~~ the ~~nine~~warrants ~~month periods~~shall ~~ended~~vest ~~September~~in two 30equal tranches, ~~2017~~with ~~and~~the ~~2016,~~first tranche vesting upon the Company entering ~~$7,000~~into ~~and~~a definitive agreement for the licensing of any of ~~$nil,~~the ~~respectively,~~Company’s ascannabis ~~stock~~products or intellectual property to a Canadian based ~~compensation~~license ~~which~~producer ~~was~~that ~~recorded~~is introduced by the asconsultant. anCompany ~~administrative~~has not yet recorded any expense related to the issuance of these warrants.

(cc)

Issued in connection with a promissory note (note 13). During the ~~acquisition~~year ended December 31, 2017, the Company booked the relative fair value of the awarrants ~~subsidiary~~in ~~(note~~the amount of $8,860 were recorded as debt discount ~~4(c))~~to be amortized over the life of the promissory note.

(dd)

Issued in connection towith anthe ~~employment~~extension ~~agreement,~~of the ~~warrants~~Shareholder ~~shall~~Loans ~~vest in~~(note ~~four~~11(iii, ~~equal~~iv, ~~tranches~~vii, ~~every~~and ~~six~~vii)). ~~months~~During ~~following~~ the ~~date~~year ~~of issuance.~~ended ~~During~~December 31, 2017, the ~~nine~~Company ~~month~~booked ~~periods~~the ~~ended~~relative ~~September~~fair ~~30,~~value ~~2017 and~~of ~~2016,~~ the ~~Company~~warrants ~~$21,930~~in the ~~and~~amount of $~~nil~~89,053 ~~respectively,~~were recorded as ~~stock~~debt discount to be ~~based~~amortized ~~compensation~~over ~~which~~the ~~was~~life ~~recorded~~of asthe anShareholder ~~administrative expense~~Loans.

(ee)

Issued in connection ~~with~~to a ~~promissory~~consulting ~~note (note (x))~~agreement. ~~During~~The ~~the~~warrants ~~nine~~vest ~~month~~in eight ~~period~~tranches ~~ended~~of ~~September 30~~31,250 ~~2017,~~warrants ~~the~~each. ~~Company~~The ~~booked~~first ~~the~~tranche ~~fair~~vested ~~value~~upon execution of the ~~warrants~~agreement inand the ~~amount~~remaining oftranches ~~$11,670~~vest ~~as a prepaid to be~~every ~~expensed~~three ~~over~~months ~~the life of the promissory note~~thereafter. During the ~~nine~~ three month periods ended ~~September 30~~March 31, ~~2017~~2018 and ~~2016~~2017, the Company expensed $~~914~~11,488 and $nil, respectively, ofin ~~the~~stock ~~prepaid~~based ascompensation ~~financing fees~~ which has been recorded as an ~~interest~~administrative expense.

29 17. STOCK BASED COMPENSATION

18. STOCK BASED COMPENSATION

The Company recorded stock based compensation as follows:

	Three Months Ended September 30, 2017	Three Months Ended September 30, 2016	Nine Months Ended September 30, 2017	Nine Months Ended September 30, 2016
	March 31, 2018	March 31, 2017
Warrants Issued as Stock Based Compensation
Warrants issued in connection to the Bridge Loan Agreement	$-	$-	$4,988	$-
Warrants issued in connection to the Bridge Loan Agreement (note 11(vi))	$-	$4,988
Warrants issued in connection to the issuance of Promissory Note	11,670	-	11,670	-
Warrants issued as commission related to private placements units	-	34,089
Warrants issued as commission related to private placements units	-	-	34,089	-
Warrants issued in relation to consulting agreements	33,855	-
Warrants issued in relation to consulting agreements	24,549	-	59,643	222,939
Total Warrants Issued as Stock Based Compensation	$33,855	$39,077
Warrants issued in relation to employment agreements	28,930		21,930
Shares issued for consulting fees	21,000	-
Total Warrants Issued as Stock Based Compensation	65,149	-	132,320	222,939
Total Stock Based Compensation	$54,855	$39,077
Issuance of stock options (note 21)	-	-	1,213,605	-
Common shares issued for consulting fees	-	-	6,000	100,154
Common shares to be issued for consulting fees	-	-	-	32,710
Total Stock Based Compensation	$-	$-	$1,351,925	$355,803

1918. SHARES TO BE ISSUED

As at ~~September~~March 3031, ~~2017~~2018, the Company has $23,000 in Common Shares to be issued, consisting of the following:

●

328,571 Common Shares, valued at $0.07 per share, to be issued due to the conversion of $23,000 of Convertible Debentures Series A (note 1514).

As at December 31, ~~2016~~2017, the Company ~~had~~has $~~146~~485,~~550~~184 in Common Shares to be issued, consisting of the following:

●

328,571 Common Shares, valued at $0.07 per share, to be issued due to the conversion of $23,000 of Convertible Debentures Series A (note 1514);

●

~~320~~1,~~022~~300,000 Common Shares, valued at ~~an average price of~~ $0.~~156~~10 per share, to be issued due to the conversion ~~settlement~~ of $50130,000 inof ~~consulting~~Convertible ~~fees~~Debenture ~~owing~~Series toC by related aparties ~~shareholder~~(note 14). Such Common Shares were issued on ~~April~~March 529, ~~2017~~2018;

●

~~143~~132,~~715~~637 Common Shares, valued at ~~an average price of~~ $0.~~129~~10 per share, to be issued due to the settlement of $1813,~~550~~264 inof ~~consulting~~interest ~~fees~~ owing to related parties on anConvertible ~~unrelated~~Debenture ~~party~~Series C (note 14). Such Common Shares were issued on ~~April~~March 529, ~~2017;~~ ~~and~~2018;

●

~~366~~2,~~667~~950,000 Common Shares, valued at $0.1510 per share, to be issued due to the ~~settlement~~conversion of $55295,000 inof ~~consulting~~Convertible ~~fees~~Debenture ~~owing~~Series toC ~~an unrelated~~by ~~party~~unrelated parties (note 14). Such Common Shares were issued on March ~~April 5~~29, ~~2017.~~ 2018; and

30 ●

239,199 Common Shares, valued at $0.10 per share, to be issued due to the 20settlement of $23,920 of interest owing to unrelated parties on Convertible Debenture Series C (note 14). ~~RELATED~~Such ~~PARTY~~Common ~~TRANSACTIONS~~Shares were issued on March 29, 2018.

19. RELATED PARTY TRANSACTIONS

Transactions with related parties are incurred in the normal course of business and are as follows:

(a)

The Company’s current and former officers and shareholders have advanced funds on an unsecured, non-interest bearing basis to the Company, unless stated otherwise below, for travel related and working capital purposes. The Company has not entered into any agreement on the repayment terms for these advances.

Advances from related parties ~~were~~due asover the next 12 months are as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Advances by and amounts payable to Officers of the Company, two of which are also Directors	$~~258~~150,~~599~~471	$95169,~~759~~666
Advances by and consulting fees payable to a corporation owned by two Officers of the Company, one of which is also a Director	~~140~~13,~~455~~800	~~313,745~~-
Consulting fees owing to persons related to Officers who are also Directors of the Company	7122,~~642~~838	~~77,463~~485
Advances by Officers of the Company, one of which is also a Director, bears interest at 1.5% per month	554,409	901,784
Amounts payable to a corporation related by virtue of a common Officer of the Company	99,973	-
Amounts payable to a corporation related by virtue of a common Officer and Director of the Company	-	76,407
Directors fees payable to Directors of the Company	13,500	-
Consulting fees and directors fees payable to Directors of the Company	39,225	13,725
Incentive fee bonus	104,023	82,690
Deferred related party payables	1,101,891	-
	$404,605	$252,841
	$2,166,221	$1,478,883

AtDuring ~~September 30, 2017,~~ the ~~Company~~year ~~had~~ended ~~deferred amounts of $1,101,891 (~~December 31, ~~2016 – $1~~2017,~~085,906)~~ ~~owing~~the tofollowing related parties. ~~The~~agreed ~~deferred amounts consist of $574,201 (December 31, 2016 – $572,506) owing~~ to ~~Officers~~defer ~~of the Company, two of which are also Directors, for consulting fees payable,~~ amounts ~~of $61,000 owing to Directors of the Company for directors fees~~ payable ~~and amounts of $400,650 (CAD $500,000) (December 31, 2016 – $372,400; CAD $500,000) owing~~ to athem ~~corporation~~until owned by two Officers of the Company, one of which is also a Director, for management service fees payable and $66,940 of amounts accrued towards the incentive bonus to be paid at maturity. The amounts are non-interest bearing and payable on April 1, 2018, in exchange for agreeing to defer the fees, the Directors and Officers will receive an incentive bonus equal to 10% of the amount deferred and payable on April 1, 2018. The bonus will be expensed over the term of the deferrals. During the nine month periods ended September 30, ~~2017 and 2016, the~~ ~~Company expensed $66,940 and $nil, respectively, in interest expense related to the incentive bonus.~~2019:

During the nine month period ended September 30, 2017, the Company settled $87,100 of fees payable, deferred and otherwise, to two former Directors of the Company with the issuance of 871,000 Common Shares at a price of $0.10 per share. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $121,940. The balance of $34,840 has been recorded as a loss on settlement of debt (note 16).

	March 31, 2018	December 31, 2017
Advances by and amounts payable to Officers of the Company, two of which are also Directors	$856,369	$856,975
Advances by and consulting fees payable to a corporation owned by two Officers of the Company, one of which is also a Director	670,225	682,360
Consulting fees owing to persons related to Officers who are also Directors of the Company	76,348	76,348
Advances by Officers of the Company, one of which is also a Director, bears interest at 1.5% per month	530,662	552,590
Consulting fees and directors fees payable to Directors of the Company	113,500	113,500
	$2,247,104	$2,281,773

During the ~~nine~~year ~~month period~~ ended ~~September~~December 3031, 2017, the Company settled $3087,~~000~~100 of fees ~~amounts~~ payable, deferred and otherwise, to atwo ~~Director~~former ofDirectors of the Company with the issuance of ~~300~~871,000 Common Shares at a price of $0.10 per share. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $33121,~~000~~940. The balance of $334,~~000~~840 has been recorded as a loss on settlement of debt (note 1615).

~~During the year ended December 31, 2016, the Company settled $48,000 of the deferred amounts owing to an Officer and Director of the Company with 480,000 Common Shares.~~29

During the year ended December 31, 2017, the Company settled $30,000 of amounts payable to a Director of the Company with the issuance of 300,000 Common Shares at a price of $0.10 per share. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $33,000. The balance of $3,000 has been recorded as a loss on settlement of debt (note 15).

During the year ended December 31, 2016, the Company deferred amounts payable to a number of related parties. The amounts were non-interest bearing and payable on April 1, 2018, in exchange for agreeing to defer the fees, the Directors and Officers would receive an incentive bonus equal to 10% of the amount deferred and payable on April 1, 2018. The incentive bonus would be expensed over the term of the deferrals. During the three month period ended March 31, 2018 and 2017, the Company expensed $21,333 and $21,793, respectively, in interest expense related to the incentive bonus.

(b)	Interest accrued to related parties were as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Interest accrued on advances by Officers of the Company, one of which is also a Director	$~~375~~445,~~131~~613	$~~234~~413,~~121~~477
Advances by and consulting fees payable to a corporation owned by two Officers of the Company, one of which is also a Director	5066,~~054~~063	2955,~~669~~348
	$425,185	$263,790
	$511,676	$468,825

During the year ended December 31, 2017, the Company deferred the interest owing to related parties until April 30, 2019.

(c)	Transactions with related parties were as follows:

During the three month period ended March 31, 2018, the Company expensed $14,095 (March 31, 2017 – $4,985) in costs related to vehicles for the benefit of three Officers, two of which are also Directors of the Company, and for the benefit of a person related to an Officer and Director of the Company. The Company also expensed $7,592 (March 31, 2017 – $26,411) in travel and entertainment expenses incurred by Officers and Directors of the Company. During the three month period ended March 31, 2018, the Company received $144,537 from a related corporation for accounting and administrative services provided, $99,973 of this amount is an advance on services to be provided.

~~During~~On ~~the~~March ~~nine~~29, ~~month~~2018, ~~period~~the ~~ended~~Company ~~September~~issued 301,432,637 ~~2017~~Common Shares, ~~the~~at ~~Company~~a ~~expensed~~price of $~~nil~~0.10 ~~(September~~per 30share, ~~2016~~to –related ~~$72~~parties,~~659)~~ inon ~~rent~~the ~~expense~~conversion of ~~payable~~$130,000 toin aface ~~corporation~~value ~~related~~of bythe ~~virtue~~Convertible ofDebentures aSeries ~~common~~C ~~Officer~~ and athe ~~common~~settlement ~~Director~~ of $13,264 in interest accrued on the ~~Company~~Convertible Debentures Series C (note 14).

~~During the~~On ~~nine month period ended September~~ June 30, 2017, the Company ~~expensed~~ ~~$34~~issued 3,~~784~~042,931 ~~(September~~Common 30Shares, ~~2016~~at –a price of $~~21,252)~~0.10 inper ~~costs related~~share, to ~~vehicles~~an ~~for~~Officer ~~the~~who ~~benefit~~is ofalso ~~three~~a ~~Officers,~~Director ~~two~~ of ~~which are also Directors of~~ the Company, ~~and~~on ~~for~~ the ~~benefit~~conversion of a$275,000 ~~person related~~in toface anvalue ~~Officer and Director~~ of the Convertible ~~Company.~~Debentures ~~The~~Series ~~Company~~B ~~also expensed~~and ~~$51,672~~the ~~September~~settlement ~~30,~~of ~~2016 –~~ $~~178~~29,~~749)~~293 in ~~travel and~~ ~~entertainment~~interest ~~expenses~~accrued ~~incurred~~on bythe ~~Officers~~Convertible ~~and~~Debentures ~~Directors~~Series ofB ~~the~~(note ~~Company~~14).

On ~~January~~ 20June 30, 2017, the Company issued 65121,717 ~~units~~Common Shares, at a price of $0.10 ~~Convertible~~per share, to a person related to an Officer who is also a Director of the Company, on the conversion of $11,000 in face value of the Convertible Debentures Series ~~C-3~~B inand the settlement of $651,~~000~~171 in ~~owing~~interest toaccrued aon ~~related party~~the Convertible Debentures Series B (note 15 14).

On ~~February~~ 2June 30, ~~2016~~2017, the Company ~~settled~~issued ~~$48~~53,~~000~~781 inCommon ~~consulting~~Shares, ~~fees~~at a price of ~~payable~~$0.10 per share, to a ~~related~~Director ~~party~~of ~~and~~the ~~agreed~~Company, toon ~~issue~~the ~~480~~conversion of $5,000 ~~Common Shares~~in atface avalue ~~price~~of the Convertible Debentures Series C-1 and the settlement of $~~0.10~~378 ~~per~~in ~~share.~~interest ~~Such~~accrued ~~Common~~on ~~Shares were~~Convertible ~~issued~~Debentures onSeries ~~May~~C-1 ~~19,~~(note ~~2016~~14).

On June 30, 2017, the Company issued 3,042,931 Common Shares, at a price of $0.10 per share, to an Officer who is also a Director of the Company, on the conversion of $275,000 in face value of the Convertible Debentures Series B and the settlement of $29,293 in interest accrued on the Convertible Debentures Series B (note 15).

On June 30, 2017, the Company issued 121,717 Common Shares, at a price of $0.10 per share, to a person related to an Officer who is also a Director of the Company, on the conversion of $11,000 in face value of the Convertible Debentures Series B and the settlement of $1,171 in interest accrued on the Convertible Debentures Series B (note 15).

On June 30, 2017, the Company issued 53,781 Common Shares, at a price of $0.10 per share, to a Director of the Company, on the conversion of $5,000 in face value of the Convertible Debentures Series C-1 and the settlement of $378 in interest accrued on Convertible Debentures Series C-1 (note 15).

On March 21, 2017, the Company issued 1,998,950 Common Shares as part of private placement units, at a price of $0.10 per private placement unit, for settlement of $199,895 in amounts owing to related parties.

~~During~~On ~~the~~January ~~year ended December 31~~20, ~~2016~~2017, ~~amounts~~the ~~owing~~Company toissued a65 ~~former~~units ~~related~~of Convertible ~~party~~Debentures inSeries ~~the~~C-3 ~~amount~~in settlement of $965,~~263~~000 ~~were~~owing ~~forgiven,~~to as a ~~result, the~~related ~~Company~~party ~~recorded~~(note ~~a gain on settlement in the amount of $9,263~~14).

~~On June 17, 2016, the Company issued 150,000 Common Shares, at a price of $0.14 per share, to a person related to an Officer and Director of the Company, on the signing of a new employment agreement.~~30

On May 20, 2016, the Company issued face value $55,000 of Convertible Debentures Series C-1 to related parties consisting of $10,000 to a person related to an Officer and Director for settlement of fees payable, $10,000 to a Director of the Company for settlement of directors fees payable and $35,000 to a corporation owned by two Officers of the Company, one of which is also a Director, for settlement of loans payable (note 15).

On May 20, 2016, the Company issued face value $15,000 of Convertible Debentures Series C-1 to two Directors of the Company for cash (note 15).

The Company expensed consulting fees payable to related parties as follows:

	September 30, 2017	September 30, 2016
	March 31, 2018	March 31, 2017
Officers	$~~263~~92,~~043~~931	$~~248~~82,~~040~~680
Persons related to a Director	~~111~~38,~~447~~044	~~105~~36,~~650~~779
	$374,490	$353,690
	$130,975	$119,459

The Company’s Chief Executive Officer and Chief Financial Officer are both participants of the consortium of Lenders of the Credit Facility and the Term Loan, each committed to provide a total of CAD $150,000 of the Term Loan (notes 12 and 13).

On February 27, 2017 and in connection to the Term Loan Amendment No.2, the Company agreed to issue 500,000 private placement units, at a price of $0.10 per unit, for settlement of $50,000 in financing fees. The Company’s Chief Executive Officer and its Chief Financial Officer received a total of 93,622 units which included 93,622 Common Shares and warrants for the purchase of 46,811 Common Shares.

32 20. STOCK OPTION PLAN

21. STOCK OPTION PLAN

On June 16, 2017, the Company adopted a stock option plan (the “Option Plan”), under which the Board of Directors may from time to time, in its discretion, grant to directors, officers, employees and consultants of the Company non-transferable options to purchase Common Shares.

Pursuant to the Option Plan, the Company may issue options for such period and exercise price as may be determined by the Board of Directors, and in any case not exceeding ten years from the date of grant and equal to not more than 10% of the then issued and outstanding Common Shares. The minimum exercise price of an option granted under the Option Plan must not be less than 100% of the market value of the Common Shares on the date such option is granted, and if the option is issued to a 10% shareholder of the Company, the exercise price will not be less than 110% of the market value of the Common Shares on the date such option is granted.

Outstanding options at ~~September~~March 3031, ~~2017~~2018 are as follows:

	Options Outstanding	Exercise Price	~~Expiry Date~~
Executive Officers	4,500,000	$0.20	~~June 15, 2020~~
Directors	1,250,000	$0.20	~~June 15, 2020~~
Employees	3,~~000~~422,~~000~~500	$0.20	~~June 15, 2020~~
	8,750,000
	9,172,500

Grant Date		Expiry Date	Options Outstanding	Options Exercisable	Exercise Price	Fair Value Expense
June 16, 2017		June 15, 2020	8,750,000	8,750,000	$0.20	$1,213,605

The options were granted to Officers, Directors and employees of the Company which were fully vested on issuance. ~~and~~The ~~the~~ fair value of $1,213,605 was determined using the Black Scholes option-pricing model with the following weighted average assumptions:

Stock price		$0.14
Risk-free interest rate		1.49%
Expected life		3 years
Estimated volatility in the market price of the Common Shares		306%

~~During the three and nine months ended September 30, 2017, the Company expensed $nil and $1,213,605, respectively, as a stock option expense (September 30, 2016 – $nil).~~31

22. COMMITMENTS AND CONTINGENCIES

Grant Date		Expiry Date	Options Outstanding	Options Exercisable	Exercise Price	Fair Value Expense
December 12, 2017		December 11, 2020	422,500	422,500	$0.20	$54,262

a)The ~~Premises~~options ~~Lease~~were –granted ~~Florida~~to employees of the Company which were fully vested on issuance. The fair value of $54,262 ~~USA~~was determined using the Black Scholes option-pricing model with the following weighted average assumptions:

Effective January 1, 2015, a subsidiary of the Company entered into an operating lease agreement for a rental premises in Daytona Beach, Florida, USA. The terms of this agreement are to be for a period of 36 months and ending on December 31, 2017 with payments made monthly. Minimum annual lease payments are as follows:

Stock price	$0.13
Risk-free interest rate	1.95%
Expected life	3 years
Estimated volatility in the market price of the Common Shares	297%

During the three month periods ended March 31, 2018 and 2017 the Company expensed $14nil,~~028~~ as a stock option expense.

b) ~~Premises~~21. ~~Leases~~COMMITMENTS –AND ~~Mississauga, Ontario~~CONTINGENCIES

~~Effective April 1, 2016,~~ a ~~subsidiary of the Company entered into a lease~~) ~~agreement~~Premises ~~for~~Leases a– ~~rental premises in~~ Mississauga, Ontario~~, Canada. The terms of the agreement are to be for a period of 3 years ending on June 30, 2019 with payments made monthly. Minimum annual lease payments are as follows and denominated in CAD:~~

2017	$19,531
2018	78,125
2019	39,063
	$136,719

Effective April 1, 2016, a subsidiary of the Company entered into a lease agreement for a rental premises in Mississauga, Ontario, Canada. The terms of the lease agreement are to be for a period of 3 years and ending on June 30, 2019 with payments made monthly. Minimum annual lease payments are as follows and denominated in CAD:

2018	$58,594
2019	39,063
	$97,657

cb) ~~Charitable~~Royalty ~~Sales Promotion~~Agreement

On ~~January~~ 21June 14, 2016, the Company entered into ana royalty agreement ~~with~~related to ~~Wounded~~an ~~Warriors~~E-liquid ~~Family~~recipe ~~Support~~purchased ~~Inc.~~from an unrelated party in which the Company agreed to ~~make~~ pay to the recipe developer, a ~~donation~~royalty of $10.0025 per ~~for~~60 ~~each~~ml ~~sale~~ of ~~its “Vape Warriors”~~ E-liquid ~~product~~sold ~~during~~that contains the ~~period~~recipe, ~~from~~up ~~January~~to 1,a ~~2016~~maximum toof ~~December 31~~$100,000. ~~2016,~~Although ~~with~~the aCompany ~~minimum~~has ~~donation~~the ofability ~~$50,000.~~to sell ~~During~~the E-liquid globally, the ~~year~~royalty ~~ended~~was ~~December~~only ~~31,~~paid ~~2016,~~on E-liquid sold within the United States. The Company ~~accrued~~is no longer selling the ~~full~~original ~~$50~~recipe and,~~000~~ inas ~~charitable~~of ~~contributions~~December ~~regarding~~31, 2017, had stopped accruing royalty payments under this agreement. During the ~~nine~~three ~~months~~month periods ended ~~September~~March 3031, 2018 and 2017, the Company ~~settled~~ ~~the~~paid ~~full~~$nil ~~amount~~and $649, ~~owing~~respectively, in ~~exchange~~relation ~~for~~to ~~300,000~~the ~~Common~~royalty ~~Shares~~agreement.

d) ~~Royalty~~22. ~~Agreement~~FINANCIAL INSTRUMENT

On June 14, 2016, the Company entered into a royalty agreement related to an E-liquid recipe purchased from an unrelated party in which the Company agreed to pay to the recipe developer, a royalty of $0.25 per 60 ml of E-liquid sold that contains the recipe, up to a maximum of $100,000. Although the Company has the ability to sell the E-liquid globally, the royalty is paid only on the E-liquid sold within the United States. The Company is no longer selling the original recipe and as of September 30, 2017, has stopped accruing royalty payments on this agreement. During the three and nine months ended September 30, 2017, the Company paid $nil and $649, respectively, in relation to the royalty agreement (September 30, 2016 – $8,389).

e) Litigation

On September 20, 2017, Qews Distribution, LLC filed a complaint against the Company in the Superior Court of California, County of Los Angeles alleging breach of written contract and is seeking damages in the amount of approximately $341,374 as a direct result of the Company’s breach of contract. There can be no assurance that the outcome of this complaint would not have a material adverse effect on the business, results of operations and financial condition. The legal proceeding has been brought in the Superior Court for the State of California, County of Los Angeles under the following caption: Qews Distribution, LLC v. Gilla Operations, LLC, Gilla, Inc., Case No. BC676675, filed September 20, 2017.

23. FINANCIAL INSTRUMENT

(i) Credit Risk

~~Credit~~ Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet ~~its~~ its contractual obligations. The Company’s credit risk is primarily attributable to fluctuations in the realizable values of its cash and trade receivables. Cash accounts are maintained with major international financial institutions of reputable credit and therefore bear minimal credit risk. In the normal course of business, the Company is exposed to credit risk from its customers and the related trade receivables which are subject to normal ~~commercial~~ commercial credit risks. A substantial portion of the Company’s trade receivables are concentrated with a limited number of large customers, all of which the Company believes are subject to normal industry credit risks. At ~~September~~March 3031, ~~2017~~2018, the Company recorded an allowance of $~~161~~283,~~340~~011 (December 31, ~~2016~~ 2017 – $~~nil~~190,543) in regards to customers with past due amounts. AsAt March at31, ~~September 30~~2018, ~~2017,~~ 3922% (December 31, ~~2016~~2017 – 1534%) of the Company’s trade receivables are due from one customer and 5268% (December 31, 2017 – 68%) of the trade receivables are due from ~~two~~six customers. During the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~ 2018, 268% (~~September~~March 3031, ~~2016~~2017 – 31 13%) of the Company’s sales were to one customer.

(ii) Liquidity Risk

~~Liquidity~~ Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure, as far as possible, that it will have sufficient liquidity to meet ~~its~~ its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation. The Company manages liquidity risk by closely monitoring changing conditions in its investees, participating in the day to day management and by forecasting cash flows from operations and anticipated investing and financing activities. At ~~September~~March 3031, ~~2017~~2018, the Company had liabilities due to to unrelated parties through its financial obligations over the ~~next~~ next six years in the aggregate principal amount of $78,~~463~~578,~~688~~064. Of ~~such~~ such amount, the Company has obligations to repay $56,~~278~~440,~~142~~823 over ~~the~~ the next twelve months with the remaining $2,~~185~~137,~~546~~241 becoming due within the following five years.

(iii) Foreign Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The risks and fluctuations are related to cash, accounts payable and trade receivables that are denominated in CAD, HUF and EUR.

Analysis by currency in CAD, HUF and EUR equivalents is as follows:

September 30, 2017	Accounts Payable	Trade Receivables	Cash
March 31, 2018	Accounts Payable	Trade Receivables	Cash
CAD	$~~543~~1,~~540~~078,036	$4389,~~034~~801	$4(9,~~919~~996)
HUF	$~~208~~135,~~213~~968	$~~38,423~~-	$~~4,428~~992
EUR	$54249,~~392~~293	$3347,~~468~~529	$3011,~~694~~871

The effect of a 10% strengthening of the United States Dollar against the Canadian Dollar, the Hungarian Forint and the Euro at the reporting date on the CAD, HUF and EUR-denominated trade receivables and payables carried at that date would, had all other variables held constant, have resulted in an increase in profit for the year and increase of net assets of $1699,~~536~~823, $2513,~~106~~498 and $~~977~~20, 042, respectively. A 10% weakening in the exchange rate would, on the same basis, have decreased profit and decreased net assets by by $1699,~~536~~823, $2513,~~106~~498 and $~~977~~20,042, respectively.

~~The~~ The Company purchases some of its inventory in a foreign currency, at ~~September~~March 3031, ~~2017~~ 2018, the Company included $74105,~~126~~823 (December 31, ~~2016 –~~2017 – $~~238~~99,~~888~~518) in inventory that was purchased in a foreign currency on its condensed consolidated ~~balance~~interim balance sheet. The Company does not use derivative financial instruments to reduce its exposure to this risk.

(iv) Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its fixed interest rate financial instruments. These fixed-rate instruments subject the Company to a fair value risk. The interest rates on ~~all~~the majority of the Company’s existing interest bearing debt are fixed. Sensitivity to a plus or minus 25 basis points change in rates would not significantly affect the fair value of this debt.

2423. SEGMENTED INFORMATION

The Company currently operates in only one business segment, namely, manufacturing, marketing and distributing of vaping products in North America and Europe. Total long lived assets by geographic location are as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Canada	$~~271~~1,~~005~~804,202	$~~826~~1,830,696
United States	31,~~297~~474,~~414~~286	1,~~125~~522,~~704~~641
Europe	64,976	235,~~418~~977
	$3,575,395	$1,149,948
	$3,283,464	$3,359,314

Total sales by geographic location are as follows:

	September 30, 2017	September 30, 2016
	March 31, 2018	March 31, 2017
Canada	$~~241~~755,~~075~~392	$-19,463
United States	~~800~~276,~~015~~338	2175,~~394,711~~095
Europe	2234,~~544,450~~509	~~922~~1,~~291~~048,981
	$3,585,540	$3,317,002
	$1,266,239	$1,243,539

2524. SUBSEQUENT EVENTS

On ~~October~~On 1April 3, ~~2017~~2018, ~~and~~the Company issued an unsecured promissory note in ~~connection~~the toprincipal aamount ~~consulting~~of ~~agreement~~CAD $65,000. ~~the~~The promissory note matured ~~Company~~on ~~issued~~April ~~warrants~~20, ~~for~~2018 ~~the~~and ~~purchase~~bears interest at a rate of ~~350,000~~15% ~~Common~~per ~~Shares~~annum, ~~exercisable~~accrued ~~over~~monthly ~~eighteen~~but ~~months~~subject atto ana ~~exercise~~minimum ~~price~~interest payment of CAD $0750.20 ~~per Common~~The ~~Share~~Company is currently in default on this promissory note.

35 On April 2, 2018, the Company entered into an equipment financing facility (the “Equipment Facility”) in the aggregate principal amount of CAD $340,850. The Equipment Facility is secured by certain equipment of the Company, due April 1, 2020 and bears interest at a rate of 15% per annum. The Company shall be required to make principal and interest payments of CAD $16,527, monthly in arrears. On April 2, 2018 and in connection with the Equipment Facility, the Revolving Facility entered into on December 7, 2017 was terminated and retired and all amounts due under the Revolving Facility were rolled into the Equipment Facility. On April 11, 2018, the Company received the balance of the aggregate principal amount made available to the Company under the Equipment Facility.

~~ITEM 2~~ On May 7, 2018, the Company entered into a consulting agreement and agreed to issue 600,000 Common Shares of the Company. Such Common Shares were issued on June 21, 2018.

~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATION~~34

The following discussion of the financial condition and results of operations of the Company should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q (this “Report”)ITEM 2. ~~This Report contains certain forward-looking~~ ~~statements~~MANAGEMENT’S ~~and~~DISCUSSION ~~the~~AND ~~Company's~~ANALYSIS ~~future~~OF ~~operating~~FINANCIAL ~~results could differ~~CONDITION ~~materially~~AND ~~from~~RESULTSOF those discussed herein. Our disclosure and analysis included in this Report concerning our operations, cash flows and financial position include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “may”, “project”, “will likely result”, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include (i) the ability to raise additional capital; and (ii) expectations regarding anticipated growth. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and are more fully described under “Part I, Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. In any event, these and other important factors, including those set forth in Item 1A – “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016 may cause actual results to differ materially from those indicated by our forward-looking statements. We assume no obligation to update or revise any forward-looking statements we make in this Report, except as required by applicable securities laws.OPERATION

The following discussion of the financial condition and results of operations of the Company should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). This Report contains certain forward-looking statements and the Company's future operating results could differ materially from those discussed herein. Our disclosure and analysis included in this Report concerning our operations, cash flows and financial position include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “may”, “project”, “will likely result”, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include (i) the ability to raise additional capital; and (ii) expectations regarding anticipated growth. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and are more fully described under “Part I, Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. In any event, these and other important factors, including those set forth in Item 1A – “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017 may cause actual results to differ materially from those indicated by our forward-looking statements. The Company assumes no obligation to update or revise any forward-looking statements made in this Report, except as required by applicable securities laws.

Except as otherwise stated or required by the context, references in this document to “Gilla” the “Registrant”, the “Company,” “we,” and “our” refer to Gilla Inc.

Overview

Gilla Inc. (the “Company”, the “Registrant” or “Gilla”) was incorporated under the laws of the State of Nevada on March 28, 1995 under the name of Truco, Inc. The Company later changed its name to Web Tech, Inc., and then to Cynergy, Inc., Mercantile Factoring Credit Online Corp., Incitations, Inc., Osprey Gold Corp. and to its present name. The Company adopted the present name, Gilla Inc., on February 27, 2007. The Company’s registered address is 475 Fentress Blvd., Unit L, Daytona Beach, Florida 32114.

Recent Developments

On May 10, 2016, the U.S. Federal Food & Drug Administration (“FDA”) finalized a new rule, captioned, the “Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act”, which extends the FDA’s authority to include the regulation of electronic nicotine delivery systems (such as e-cigarettes and vape pens), all cigars, hookah (waterpipe) tobacco, pipe tobacco and nicotine gels, among others. Going forward, the FDA will be able to review new nicotine products not yet on the market; regulate claims by nicotine product manufacturers and distributers; require evaluation and reporting of the ingredients of nicotine products and how they are made; and require disclosures regarding risks of nicotine products. The final rule went into effect on August 8, 2016. The Company is assessing the impact of the new FDA rule. Prospective investors are directed to the “Risk Factors” contained in the Company’s Annual Report filed with the U.S. Securities and Exchange Commission (the “SEC”) for the fiscal year ended December 31, ~~2016~~2017.

On ~~July~~ 1January 26, ~~2017~~2018 and in ~~connection~~accordance towith athe ~~consulting~~terms of a warrant agreement, the Company ~~issued~~ ~~warrants~~received ~~for~~a ~~the~~form ~~purchase~~ of 75election to purchase 50,000 Common Shares ~~exercisable~~ ~~over~~of ~~eighteen~~the ~~months~~Company at ana ~~exercise~~ price of $0.20 per share for total gross proceeds of $10,000. Such Common ~~Share~~Shares were issued on March 15, 2018.

36 On February 1, 2018 and in connection to a consulting agreement, the Company issued warrants for the purchase of 250,000 Common Shares exercisable until January 31, 2020 at an exercise price of $0.20 per Common Share. The warrants shall vest in eight equal tranches, with the first tranche vested upon issuance and the remaining seven tranches to vest equally every three months thereafter.

On ~~July~~ 31March 23, ~~2017~~2018, the Company ~~acquired all of the~~ issued and ~~outstanding shares~~sold ofon ~~Vape Brands International Inc. (“VBI”),~~ a ~~Canada-based~~ ~~E-liquid~~private ~~manufacturer and distributor, through its~~placement ~~wholly owned subsidiary Gilla Enterprises Inc.~~basis, ~~pursuant to the terms of a share purchase agreement~~3, ~~dated July 31~~677,271 ~~2017. Pursuant to the share purchase agreement, the Company paid to the vendors of VBI the following consideration: (i) 2,500,000~~ Common Shares of the Company ~~valued~~ at ~~$0.14 per Common Share for~~ a ~~total value of $350,000; (ii) warrants for the purchase of 2,000,000 Common Shares of the Company exercisable over twenty-four months at an exercise~~ price of $0.~~20 per Common Share from the closing date, such~~11 warrants vesting in five equal tranches every four months following the closing date; (iii) a total of $550,000 Canadian Dollars (“CAD”) in non-interest bearing, unsecured vendor-take-back loans due over twenty-four months, with principal repayments beginning five months from the closing date until maturity of up to CAD $25,000 per ~~month;~~share ~~and~~for ~~(iv) an earn-out capped at (a) the~~ total ~~cumulative amount of CAD $2,000,000; or (b) five years from the closing date (the “Earn-Out”). The Earn-Out shall be calculated as: (x) 15% of the~~ gross ~~profit generated~~proceeds ~~in Canada by VBI’s co-pack and distribution business; (y) 10%~~ of the revenue generated in Canada by Gilla’s existing E-liquid brands; and (z) 15% of the revenue generated globally on VBI’s existing E-liquid brands. Furthermore, the Earn-Out shall be calculated and paid to the vendors of VBI quarterly in arrears and only as 50% of the aforementioned amounts on incremental revenue between CAD $~~300~~404,000 and CAD $600,000 per quarter and 100% of the aforementioned amounts on incremental revenue above CAD $600,000 per quarter with the Earn-Out payable to the vendors in the fifth year repeated and paid to the vendors in four quarterly payments after the end of the Earn-Out period, subject to the cumulative limit of the Earn-Out500. No Earn-Out shall be payable to the vendors of VBI if total revenue for the Earn-Out calculation period is less than CAD $300,000 per quarter. On July 31, 2017, the Company also entered into an employment agreement with one of the vendors at a base salary of CAD $155,000 per annum and issued warrants for the purchase of 1,000,000 Common Shares of the Company exercisable over twenty-four months at an exercise price of $0.20 per Common Share, such warrants vesting in four equal tranches every six months from the issuance date.

~~On August 4, 2017, the Company issued and sold, on a private placement basis, 500,000 Common Shares of the Company at a price of $0.10 per share for total gross proceeds of $50,000.~~35

On September 21, 2017, the Company issued and sold, on a private placement basis, 230,280 Common Shares of the Company at a price of $0.10 per share for total gross proceeds of $23,028.

Subsequent Events

On ~~October~~April 13, ~~2017~~2018, ~~and~~the Company issued an unsecured promissory note in the ~~connection~~principal toamount aof ~~consulting~~CAD ~~agreement~~$65,000. ~~the~~The promissory note matures on ~~Company~~April ~~issued~~20, ~~warrants~~2018 ~~for~~and ~~the~~bears ~~purchase~~interest at a rate of ~~350,000~~15% ~~Common~~per ~~Shares~~annum, ~~exercisable~~accrued ~~over~~monthly ~~eighteen~~but ~~months~~subject atto ana ~~exercise~~minimum ~~price~~interest payment of CAD $0750.~~20 per Common Share.~~

On ~~October~~April 122, ~~2017~~2018, the Company ~~issued~~entered into an ~~unsecured~~equipment ~~promissory note~~financing facility (the “Equipment Facility”) in the aggregate principal amount of CAD ~~300~~$340,~~000~~850. The ~~promissory~~Equipment ~~note~~Facility ~~matures~~is secured onby certain equipment of the Company, due April 121, ~~2018~~2020 and bears interest at a rate of 15% per annum,. The Company shall be required ~~accrued~~to ~~monthly~~make principal and ~~due~~interest atpayments ~~maturity~~of CAD $16,527, monthly in arrears. InOn April 2, 2018 and in connection towith the ~~promissory~~ ~~note~~Equipment Facility, the ~~Company~~Revolving ~~issued~~Facility ~~warrants~~entered ~~for~~into ~~the~~on ~~purchase~~December ~~of 100~~7,~~000~~ ~~Common~~2017 was ~~Shares~~terminated ~~exercisable~~and atretired aand ~~price~~all ofamounts ~~$0.20~~due ~~per~~under ~~Common~~the Revolving ~~Share~~Facility ~~until~~were rolled into the Equipment Facility. On April 11, 2018, ~~2019~~the Company received the balance of the aggregate principal amount made available to the Company under the Equipment Facility.

On May ~~RESULTS~~7, OF2018, ~~OPERATIONS~~the ~~FOR~~Company ~~THE~~entered ~~THREE~~into ~~AND~~a ~~NINE~~consulting ~~MONTHS~~agreement ~~ENDED~~and ~~SEPTEMBER~~agreed 30to issue 600,000 ~~2017~~Common ~~AND~~Shares ~~2016~~of the Company. Such Common Shares were issued on June 21, 2018.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND 2017

Revenue

For the three month period ended ~~September~~March 3031, ~~2017~~2018, the Company generated $1,~~075~~266,~~975~~239 in sales from E-liquids, vaporizers, E-cigarettes and accessories as compared to $1,~~048~~243,~~474~~539 in sales for the three month period ended ~~September~~March 3031, ~~2016~~2017. Of the $1,~~075~~266,~~975~~239 in revenue ~~generated~~ generated for the three month period ended ~~September~~March 3031, ~~2017~~2018, $~~560~~755,~~408~~392 (5260% of total sales) was generated in ~~Europe~~Canada, $~~329~~276,~~655~~ 338 (3122% of total sales) was generated in the United States and $~~185~~234,~~912~~509 (1719% of total sales) was generated in ~~Canada~~Europe. Of the $1,~~048~~243,~~474~~539 in revenue generated for the three month period ended ~~September~~ ~~30,~~March ~~2016~~31, 2017, $~~556~~1,~~520~~048,981 (5384% of total sales) was generated in ~~the~~ ~~United~~Europe, ~~States and~~ $~~491~~175,~~954~~ 095 (4714% of total sales) was generated in ~~Europe. The increase~~ in ~~international sales is~~ the ~~result~~United ofStates ~~the Company’s~~and ~~focus on building its global business as well as~~$19,463 ~~growing~~(2% ~~demand~~of ~~for~~total ~~its~~sales) ~~E-liquid~~was ~~products~~generated ~~contained~~in ~~within the Company’s E-liquid brand portfolio~~Canada.

~~For~~The Company’s cost of goods sold for the ~~nine~~ three month period ended March ~~September 30~~31, ~~2017,~~2018 ~~the~~was ~~Company generated~~ $3528,~~585,540~~900 inwhich ~~sales~~represents ~~from~~ E-~~liquids~~liquid, ~~vaporizers~~bottles, hardware ~~E-cigarettes~~ and ~~accessories~~ related packaging as compared to $3546,~~317,002~~733 ~~in sales~~ for the ~~nine~~three month period ended March ~~September 30~~31, ~~2016~~2017. OfGross ~~the~~profit ~~$3,585,540 in revenue generated~~ for the ~~nine~~three month period ended ~~September 30, 2017,~~March $231,~~544,450~~ ~~(71%~~2018 ~~of total sales)~~ was ~~generated in Europe,~~ $~~800~~737,~~015 (22%~~339 ofwith ~~total~~margins ~~sales)~~of ~~was~~58% ~~generated~~as incompared ~~the~~to ~~United States and~~ $~~241~~696,~~075~~806 with ~~(7%~~margins of ~~total~~56% ~~sales) was generated in Canada. Of the $3,317,002 in revenue generated~~ for the ~~nine~~comparative ~~month~~ period ~~ended September 30, 2016, $2,394,711 (72% of total sales) was generated~~ in ~~the United States and $922,291 (28% of total sales) was~~ ~~generated in Europe~~2017. The increase in international sales is the result of the Company’s focus on building its global business as well as growing demand for its E-liquid products contained within the Company’s E-liquid brand portfolio.

The Company’s cost of goods sold for the three month period ended September 30, 2017 was $451,828 which represents E-liquid, bottles, hardware and related packaging as compared to $321,729 for the three month period ended September 30, 2016. Gross profit for the three month period ended September 30, 2017 was $624,147 with margins of 58% as compared to $726,745 with margins of 69% for the comparative period in 2016.

The Company’s cost of goods sold for the nine month period ended September 30, 2017 was $1,492,548 which represents E-liquid, bottles, hardware and related packaging as compared to $1,527,711 for the nine month period ended September 30, 2016. Gross profit for the nine month period ended September 30, 2017 was $2,092,992 with margins of 58% as compared to $1,789,291 with margins of 54% for the comparative period in 2016.

Operating Expenses

For the three month period ended ~~September~~March 3031, ~~2017~~2018, the Company incurred an an administrative expense of $1,~~046~~453,~~253~~336, consulting fees due to related parties of $130,~~786~~975, depreciation expense of $2130,~~106~~761, amortization expense of $1139,~~650,~~892 ~~bad debt expense of $4,343, impairment of inventory expense of $191,143~~ and ana ~~impairment~~bad ~~of fixed~~debt ~~asset~~ expense of $1293,~~020~~030. For the three month period ended ~~September~~ 30March 31, ~~2016~~2017, the Company incurred an administrative expense of $1997,~~331~~350,~~755,~~ consulting fees due to related parties of $~~134~~119,~~046~~459, depreciation expense of $169,~~472~~656, amortization expense of $1911,~~500, impairment~~650 ~~of inventory expense of $24,453~~ and ana ~~impairment~~bad ~~of fixed~~debt ~~asset~~ expense of $70161,~~142~~340. Total operating expenses for the three month period ended ~~September~~March 3031, 2018 ~~2017~~ were $1,~~417~~747,~~301~~994 as compared to $1,~~596~~299,~~368~~455 for the three month period ended ~~September 30~~March 31, ~~2016~~2017.

Administrative costs were primarily comprised of rent, legal and audit fees, marketing fees, travel expenses, consulting fees and employee wages. The ~~decrease~~increase in administrative expenses of $~~285~~455,~~502~~986 between the three month period ended ~~September~~March 3031, ~~2017~~2018 asand ~~compared to~~ the three month period ended ~~September~~March 3031, ~~2016~~2017 is attributable to ~~cost~~the Company’s ~~cutting~~increased ~~measures~~operations byin ~~management~~Canada. The ~~decrease~~increase in consulting fees due to related parties of $311,~~260~~516 between the three month period ended ~~September~~March 3031, ~~2017~~2018 as compared to the three month period ended September 30, 2016 is attributable to the effects of foreign exchange translation. The impairment of inventory expense of $191,143 for the three month period ended September 30, 2017 and ~~$24,453~~ ~~for~~ the three month period ended ~~September~~March 3031, 2017 ~~are~~is attributable to ~~the~~new ~~Company~~consulting ~~writing~~agreements ~~off~~entered ~~obsolete~~into ~~inventory.~~with ~~The~~related impairment of fixed asset expense of $12,020 for the three month period ended September 30, 2017 is attributable to the Company writing off the value of fixed assets located at an office premises that was closed during the periodparties. The ~~impairment~~bad ofdebt ~~fixed asset~~ expense ~~of $70,142~~ for the three month ~~period~~periods ended March ~~September 30~~31, ~~2016~~ is2018 ~~attributable to the Company writing off manufacturing equipment that was not in working order~~ and ~~that the Company was unable to sell. The gain on settlement of $352,284 for the three month period ended September 30,~~ 2017 is attributable to ~~the settlement~~an ofallowance ~~promissory~~for doubtful ~~notes~~accounts ~~issued in connection to an acquisition~~receivable.

For the nine month period ended September 30, 2017, the Company incurred an administrative expense of $3,190,313, consulting fees due to related parties of $374,490, depreciation expense of $40,807, amortization expense of $34,950, bad debt expense of $165,683, stock option expense of $1,213,605, impairment of inventory expense of $191,143, impairment of fixed asset expense of $12,020 and a loss on settlement of 23,840. For the nine month period ended September 30, 2016, the Company incurred an administrative expense of $4,130,393, consulting fees due to related parties of $353,690, depreciation expense of $44,982, amortization expense of $74,500, recovery of bad debt of $1,198, impairment of inventory expense of $24,453, impairment of fixed asset expense of $70,142, impairment of goodwill expense of $208,376 and a gain on settlement of $245,625. Total operating expenses for the nine month period ended September 30, 2017 were $5,246,851 as compared to $4,659,713 for the nine month period ended September 30, 2016.

Administrative costs were primarily comprised of rent, legal and audit fees, marketing fees, travel expenses, consulting fees and employee wages. The decrease in administrative expenses of $940,080 between the nine month period ended September 30, 2017 as compared to the nine month period ended September 30, 2016 is attributable to cost cutting measures by management. The increase in consulting fees due to related parties of $20,800 between the nine month period ended September 30, 2017 as compared to the nine month period ended September 30, 2016 is attributable to the effects of foreign exchange translation. The bad debt expense of $165,683 for the nine month period ended September 30, 2017 is mainly attributable to a $161,340 allowance booked for doubtful accounts. The stock option expense incurred in the nine month period ended September 30, 2017 of $1,213,605 is attributable to the adoption of a stock option plan and issuance thereunder to the Company’s directors, officers and employees. The impairment of inventory expense of $191,143 for the nine month period ended September 30, 2017 and $24,453 for the nine month period ended September 30, 2016 are attributable to the Company writing off obsolete inventory. The impairment of fixed asset expense of $12,020 for the nine month period ended September 30, 2017 is attributable to the Company writing off the value of fixed assets located at an office premises that was closed during the period. The impairment of fixed asset expense of $70,142 for the nine month period ended September 30, 2016 is attributable to the Company writing off manufacturing equipment that was not in working order and that the Company was unable to sell. The loss on settlement of $23,840 for the nine month period ended September 30, 2017 is attributable to losses associated with the settlement of debt. The gain on settlement of $245,625 for the nine month period ended September 30, 2016 is attributable to the settlement of consideration and compensation payable to a vendor of an acquisition. As a result of the settlement, the Company also tested and impaired $208,376 in goodwill for the nine months ended September 30, 2016, related to the value of workforce and business acumen required from such acquisition.

Loss from Operations

For the three month period ended ~~September~~March 3031, ~~2017~~2018, the Company incurred a loss from operations of $~~793~~1,~~154~~010,655 as compared to a loss from operations of $~~869~~602,~~623~~649 for the three month period ended ~~September 30~~March 31, 2017 ~~2016~~ due to the reasons discussed above.

For the nine month period ended September 30, 2017, the Company incurred a loss from operations of $3,153,859 as compared to a loss from operations of $2,870,422 for the nine month period ended September 30, 2016 due to the reasons discussed above.36

Other Expenses

For the three month period ended ~~September~~March 3031, ~~2017~~2018, the Company incurred a ~~gain on settlement of $352,284, a~~ foreign exchange loss of $~~153~~81,~~764~~247, amortization of debt discount expense of $~~138~~59,~~761~~851 and interest expense of $~~247~~309,~~222~~549. For the three month period ended ~~September~~ 30March 31, ~~2016~~2017, the Company incurred a foreign exchange gain of $184,~~893~~947, amortization of debt discount expense of $1971,~~894~~289 and interest expense of $~~172~~229,~~610~~277. For the three month period ended ~~September~~ 30March 31, ~~2017~~2018, the Company incurred total other expenses of $~~187~~450,~~463~~647 as compared to $~~173~~295,~~611~~619 for the three month ~~period ended~~ ~~September 30, 2016. The gain on settlement of $352,284 for the three month~~ period ended ~~September~~March 3031, 2017 ~~is attributable to the settlement of promissory notes issued in connection to an acquisition~~. The increase in ~~amortization~~interest ~~of debt discount~~ expense of of $~~118~~80,~~867~~272 between the three month period ended ~~September~~March 3031, ~~2017 as~~2018 ~~compared to the three month period ended September 30, 2016 is attributable to an increase in accretion of the beneficial conversion feature~~ and ~~fair value of~~ the ~~warrants associated with~~ the Company’s convertible debentures resulting from the cumulative effects of the issuance of new convertible debentures in fiscal 2016 and 2017 and the conversion of convertible debentures in 2017. The increase in interest expense of $74,612 between the three month period ended ~~September~~March 3031, 2017 ~~as compared to the three month period ended September 30, 2016~~ is attributable to increased interest expenses associated with the Company’s debt instruments.

For the nine month period ended September 30, 2017, the Company incurred a gain on settlement of $352,284, a foreign exchange loss of $213,658, amortization of debt discount expense of $799,753 and interest expense of $696,870. For the nine month period ended September 30, 2016, the Company incurred a foreign exchange loss of $70,199, amortization of debt discount expense of $56,180 and interest expense of $444,526. For the nine month period ended September 30, 2017, the Company incurred total other expenses of $1,357,997 as compared to $570,905 for the nine month period ended September 30, 2016. The gain on settlement of $352,284 for the nine month period ended September 30, 2017 is attributable to the settlement of promissory notes issued in connection to an acquisition. The increase in amortization of debt discount expense of $743,573 between the nine month period ended September 30, 2017 as compared to the nine month period ended September 30, 2016 is attributable to an increase in accretion of the beneficial conversion feature and fair value of the warrants associated with the Company’s convertible debentures resulting from the cumulative effects of the issuance of new convertible debentures in fiscal 2016 and 2017 and the conversion of convertible debentures in 2017. The increase in interest expense of $252,344 between the nine month period ended September 30, 2017 as compared to the nine month period ended September 30, 2016 is attributable to increased interest expenses associated with the Company’s debt instruments.

Net Loss and Comprehensive Loss

Net loss amounted to $~~980~~1,~~617~~461,302 for the three month period ended ~~September~~ 30March 31, ~~2017~~2018 as compared to a net loss of $1898,~~043,234~~268 for the three month period ended ~~September~~March 3031, ~~2016~~2017 due to the reasons ~~discussed~~ discussed above.

~~Net~~Comprehensive loss amounted to $41,~~511~~256,~~856~~109 for the ~~nine~~three month period ended ~~September~~ 30March 31, ~~2017~~2018 as compared to a ~~net~~comprehensive loss of $3965,~~441,327~~550 for the ~~nine~~three month period ended ~~September~~March 3031, ~~2016~~2017. The change in comprehensive loss as compared to net loss was due to foreign currency translation adjustments resulting from the ~~reasons~~Company’s ~~discussed~~translation ~~above~~of financial statements from Canadian Dollars, Euros and Hungarian Forints to U.S. Dollars.

Comprehensive loss amounted to $1,142,838 for the three month period ended September 30, 2017 as compared to a comprehensive loss of $1,017,672 for the three month period ended September 30, 2016. The change in comprehensive loss as compared to net loss was due to foreign currency translation adjustments resulting from the Company’s translation of financial statements from Canadian Dollars, Euros and Hungarian Forints to U.S. Dollars.

Comprehensive loss amounted to $4,841,344 for the nine month period ended September 30, 2017 as compared to a comprehensive loss of $3,539,351 for the nine month period ended September 30, 2016. The change in comprehensive loss as compared to net loss was due to foreign currency translation adjustments resulting from the Company’s translation of financial statements from Canadian Dollars, Euros and Hungarian Forints to U.S. Dollars.

Liquidity and Capital Resources

As at ~~September~~March 3031, ~~2017~~2018, the Company had total assets of $4,~~699~~378,~~960 (as~~508 (compared to total assets of $24,~~422~~428,~~954~~858 at December 31, ~~2016~~2017) consisting of cash and cash equivalents of $753,~~683~~647, trade receivables of $~~280~~210,~~551~~553, inventory of $~~403~~527,~~583~~415, other current assets of $~~364~~353,~~748~~429, property and equipment of $~~336~~249,~~504~~860, website development of $54,583, intangibles of $~~126~~652,~~850~~416 and goodwill of $32,~~106~~376,~~458~~605. The ~~increase~~assets inof ~~assets~~the asCompany atare ~~September~~primarily ~~30,~~the ~~2017~~result asof ~~compared~~the toCompany’s ~~December~~business ~~31,~~operations ~~2016~~and isits ~~primarily~~acquisitions including ~~the~~Vape ~~result~~Brands ofInternational, ~~the acquisition~~Inc. ~~of VBI~~ (see “~~VBI~~ Acquisition”) ~~and an increase~~ of ~~trade receivables~~ VBI”).

As at ~~September~~March 3031, ~~2017~~2018, the Company had total liabilities of $1011,~~175~~741,~~006~~ 465 (as compared to total liabilities of $810,~~113~~984,~~864~~061 at December 31, ~~2016~~2017) consisting of accounts payable of $12,~~956~~633,~~323~~269, ~~accrued~~ ~~liabilities of $422,998,~~ accrued ~~interest due to related~~liabilities ~~parties~~ of $~~425~~720,~~185~~658, customer deposits of $3450,~~399~~456, loans from ~~shareholders~~ shareholders of $1284,~~210~~999,~~966,~~ ~~amounts~~ due to related parties of $2404,~~166~~605,~~221,~~ promissory notes of $~~179~~706,~~121~~837, amounts owing on acquisition of $~~468~~653,~~055~~627, ~~convertible~~Convertible Debentures ~~debentures~~of $337,000, Term Loan of $~~270~~1,~~457~~053,993, long term ~~loan~~promissory notes of $95,042, long term amounts owing on acquisitions of $1,~~126~~254,~~192~~003, long term ~~promissory~~loans ~~notes~~from shareholders of $788,196, long term due to related parties of $~~367~~2,~~710~~247,104 and long term ~~amounts~~accrued ~~owing~~interest ondue ~~acquisitions~~to related parties of $1511,~~547~~676. For more information regarding the liabilities of the Company,~~379~~ see “Shareholder Loans”, “Term Loan”, “Promissory Notes” and “Convertible Debentures”.

At ~~September~~March 3031, ~~2017~~2018, the Company had negative working capital of $75,~~135~~750,~~352~~400 and an accumulated deficit of $1721,~~762~~360,~~750~~143.

As at December 31, ~~2016~~2017, the Company had total assets of $24,~~422~~428,~~954~~858 consisting of cash and cash equivalents of $~~184~~62,~~754~~292, trade receivables of $80232,~~409~~386, inventory of $~~545~~451,~~135~~318, other current ~~assets~~ assets of $~~462~~323,~~708~~548, property and equipment of $93285,~~068~~817, website ~~development~~ development of $75,083, intangibles of $~~160~~691,~~300~~809 and goodwill of $~~889~~2,~~497~~376,605.

As at December 31, ~~2016~~2017, the Company had total liabilities of $810,~~113~~984,~~864~~061 consisting of accounts payable of $12,~~740~~335,~~071~~615, accrued liabilities of $~~404~~419,~~633~~436, ~~accrued~~customer ~~interest~~deposits of $97,400, loans from shareholders of $257,303, due to related parties of $~~263~~252,~~790~~841, ~~customer~~ ~~deposits~~promissory notes of $56498,~~834~~522, ~~loans~~amounts ~~from~~owing ~~shareholders~~on acquisition of $~~502~~538,~~288~~952, Convertible ~~amounts~~Debentures ~~due~~of to$277,149, ~~related~~Term ~~parties~~Loan of $1,~~478~~051,~~883~~334, long term promissory notes of $17346,~~750~~002, long term amounts owing on acquisitions ~~acquisition~~ of $~~838,317, term loan of $~~1,~~144~~364,~~337~~274, long term loans from shareholders of $~~497~~794,~~351~~635, long term ~~amounts~~ due to related parties of $12,~~085~~281,~~906~~773 and long ~~term~~ ~~convertible~~term ~~debentures~~accrued ofinterest due to related parties of $83468,~~704~~825.

At December 31, ~~2016~~2017, the Company had negative working capital of $54,~~173~~659,~~897~~008 and an accumulated deficit of $1319,~~250~~898,~~894~~841.

Net cash used in operating activities

For the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018, the Company used net ~~cash~~ cash of $1441,~~533,731~~844 (as compared to $1917,~~804,933~~269 during the ~~nine~~three month ~~period~~ period ended ~~September~~March 3031, ~~2016~~2017) in operating activities to fund administrative, marketing and sales. The decrease is attributable to the results of operations and changes in the operating assets and liabilities as discussed above.

Net cash used in investing activities

For the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018, the Company used net ~~cash~~ cash of $~~73,472~~590 (as compared to $8911,~~612~~673 during the ~~nine~~three month period ended March ~~September 30~~31, ~~2016~~2017) in investing activities relating to the addition of capital assets.

Net cash flow from financing activities

For the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018, net cash provided by financing activities was $1317,~~631,940~~449 (see “~~Term~~Shareholder ~~Loan~~Loans”, “~~Bridge~~Term Loan”, “Promissory Notes”, “Convertible Debentures” and “Common Shares”) as compared to net cash provided by ~~financing~~ financing activities of $1,~~932~~109,~~622~~201 for the ~~nine~~three month period ended ~~September~~ ~~30,~~March ~~2016~~31, 2017.

VBI Acquisition

On July 31, 2017, the Company’s wholly owned subsidiary, Gilla Enterprises, acquired all of the issued and outstanding shares of VBI, a Canada-based E-liquid manufacturer and distributor~~, through its wholly owned subsidiary Gilla Enterprises Inc~~.

The following summarizes the ~~preliminary~~ fair value of the assets acquired, liabilities assumed and the consideration transferred at ~~the~~ the acquisition date:

Assets acquired:	Preliminary Allocation
	Allocation
Receivables	$9,619
Assets acquired:
Other current assets	36,435
Cash	$1,377
Inventory	79,971
Receivables	5,576
Fixed assets	218,687
Other current assets	74,598
Goodwill	2,216,961
Inventory	83,820
Total assets acquired	$2,561,673
Fixed assets	214,765
Intangible assets	704,846
Goodwill	1,596,553
Total assets acquired	$2,681,535
Liabilities assumed:
Bank indebtedness	$115,~~722~~597
Accounts payable	~~185~~218,~~645~~028
Loans payable	254,131
Customer deposits	33,008
Total liabilities assumed	$451,498
Loans payable	112,218
Capital lease	125,893
Due to related parties	15,707
Deferred tax liability	186,793
Total liabilities assumed	$697,244
Consideration:
Issuance of Common Shares	$350,000
Issuance of warrants	252,631
Vendor Take Back	356,443
Earn out	1,~~151~~025,~~101~~217
Total consideration	$21,~~110~~984,~~175~~291

In consideration for the acquisition, the Company paid to the vendors of VBI the following consideration: (i) 2,500,000 Common Shares of the Company valued at $0.14 per share for a total value of $350,000; (ii) warrants for the purchase of 2,000,000 Common Shares of the Company exercisable over twenty-four (24) months at an exercise price of $0.20 per share from the closing date, such warrants vesting in five (5) equal tranches every four (4) months following the closing date; (iii) a total of CAD $550,000 in non-interest bearing, unsecured vendor-take-back loans (the “VTB”) due over twenty-four (24) months, with principal repayments beginning five (5) months from the closing date until maturity of up to CAD $25,000 per month; and (iv) an earn-out (the “Earn-~~out~~Out”) capped at: (a) the total cumulative amount of CAD $2,000,000; or (b) five (5) years from the closing date. The Earn-Out shall be calculated as: ~~(x)~~ 15% of the gross profit ~~generated~~ generated in Canada by VBI’s co-pack and distribution business; ~~(y)~~ 10% of the revenue generated in Canada by Gilla’s existing E-liquid brands; and ~~(z)~~ 15% of the revenue generated globally on VBI’s existing E-liquid brands. Furthermore, the Earn-Out shall be calculated and paid to the vendors of VBI quarterly in arrears and only as 50% of the aforementioned amounts on incremental revenue between CAD $300,000 and CAD $600,000 per quarter and 100% of the aforementioned amounts on incremental revenue above CAD $600,000 per quarter with the Earn-Out payable to the vendors in the fifth year repeated and paid to the vendors in four (4) quarterly payments after the end of the Earn-Out period, subject to the cumulative limit of the Earn-Out. No Earn-Out shall be payable to the vendors of VBI if total revenue for the Earn-Out calculation period is less than CAD $300,000 per quarter. A 15% discount rate has been used to calculate the present value of the Earn -Out on the Company’s estimate of cost of financing for comparable instruments ~~notes~~ with similar term and risk profiles. Over the term of the respective Earn -Out, interest will be accrued at 15% per annum to accrete the Earn-Out to maximum payable amount.

	Total
Present value of Earn Out at the acquisition date	$1,151,101
Interest expense related to accretion	26,619
Exchange rate differences	1,650
Less: Current amount owing	(178,597)
Present value at September 30, 2017	$1,000,773

	Total
Present value of Earn-Out at the acquisition date	$1,025,217
Interest expense related to accretion	59,110
Exchange rate differences	(3,015)
Present value at December 31, 2017	$1,081,312
Interest expense related to accretion	37,733
Exchange rate differences	(29,958)
Less: Current amount owing	(296,374)
Long term portion at March 31, 2018	$792,713

	Total
Present value of the VTB at the acquisition date	$356,443
Interest expense related to accretion	8,034
Exchange rate differences	473
Less: Current amount owing	(104,458)
Present value at September 30, 2017	$260,492

	Total
Present value of the VTB at the acquisition date	$356,443
Interest expense related to accretion	26,681
Exchange rate differences	(7,177)
Present value at December 31, 2017	$375,947
Interest expense related to accretion	12,566
Exchange rate differences	(10,406)
Less: Current amount owing	(182,253)
Long term portion at March 31, 2018	$195,854

	September 30, 2017	December 31, 2016
Pro forma revenue	$4,833,097	$5,984,345
Pro forma loss from operations	$(2,956,012)	$(3,846,459)
Pro forma net loss	$(4,650,457)	$(4,618,919)

The results of operations of VBI have been included in the consolidated statements of operations from the acquisition date. The following table presents pro forma results of operations of the Company and VBI as if the companies had been combined as of January1, 2016. The unaudited condensed combined pro forma information is presented for informational purposes only. The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.

	March 31, 2018	March 31, 2017
Pro forma revenue	$1,266,239	$1,691,581
Pro forma loss from operations	$1,010,655	$649,633
Pro forma net loss	$1,461,302	$943,349

Shareholder Loans

The Company has outstanding current loans from shareholders as follows:

	March 31, 2018	December 31, 2017
Bears interest of 1.5% per month on a cumulative basis, unsecured, no specific terms of repayment(i)	$12,763	$13,116
Bears interest of 6% per annum on a cumulative basis, secured by the assets of the Company, matured on March 2, 2018(iv)	248,192	244,187
Bears interest of 1.5% per month on a cumulative basis, unsecured, no specific terms of repayment(vii)	24,044	-
	$284,999	$257,303

The Company has outstanding long term loans from shareholders as follows:

	March 31, 2018	December 31, 2017
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(ii)	$348,424	$351,679
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(iii)	92,296	90,828
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(v)	142,701	144,611
Bears interest of 10% per annum on a cumulative basis, secured by the assets of the Company, matures on April 30, 2019(vi)	204,775	207,517
	$788,196	$794,635

(i) During the three month period ended March 31, 2018, the Company accrued interest of $1,471 on this shareholder loan (March 31, 2017 – $1,399). Total accrued interest owing on such shareholder loan at March 31, 2018 was $20,262 (December 31, 2017 – $19,341) which is included in accrued liabilities.

(ii) On February 13, 2014, the Company entered into a secured promissory note (the “Secured Note”) with a shareholder, whereby the Company agreed to pay the party the aggregate unpaid principal amount of CAD $500,000 on or before August 13, 2014, bearing interest at a rate of 10% per annum, such interest to accrue monthly and added to the principal. The Secured Note is secured by a general security agreement granting a general security interest over all the assets of the Company. During the years ended December 31, 2014 and 2015, the Company and the shareholder extended the maturity date of the Secured Note to January 1, 2016 and July 1, 2017, respectively. During the years ended December 31, 2016 and 2017, the Company and the shareholder extended the maturity date of the Secured Note to July 1, 2018 and April 30, 2019, respectively. In connection to the maturity date extensions, the Company issued warrants for the purchase of Common Shares (note 16(l and hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Secured Note was $348,424 (December 31, 2017 – $351,679) including a debt discount of $39,376 (December 31, 2017 - $46,871). During the three month periods ended March 31, 2018 and 2017, the Company expensed $7,495 and $2,386, respectively, in interest expense related to the amortization of the debt discount. The amendments to the Secured Note were accounted for as a modification of debt and no gain or loss was recognized on the amendments.

(iii) On July 15, 2014, the Company entered into a secured promissory note (the “Secured Note No.2”) with a shareholder, whereby the Company agreed to pay the party the aggregate unpaid principal amount of $100,000 on or before July 18, 2014, bearing interest at a rate of 10% per annum, such interest to accrue monthly and added to the principal. The Secured Note No.2 is secured by the general security agreement issued with the Secured Note. During the years ended December 31, 2014 and 2015, the Company and the shareholder extended the maturity date of the Secured Note No.2 to January 1, 2016 andJuly 1, 2017, respectively. During the years ended December 31, 2016 and 2017, the Company and the shareholder extended the maturity date of the Secured Note No.2 to July 1, 2018 and April 30, 2019, respectively. In connection to the maturity date extensions, the Company issued warrants for the purchase of Common Shares (note 15(l and hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Secured Note No.2 was $92,296 (December 31, 2017 - $90,828) including a debt discount of $7,704 (December 31, 2017 – $9,172). During the three month periods ended March 31, 2018 and 2017, the Company expensed $1,468 and $629, respectively, in interest expense related to the amortization of the debt discount. The amendments to the Secured Note were accounted for as a modification of debt and no gain or loss was recognized on the amendments.

(iv) On March 2, 2016, the Company entered into a loan agreement (the “Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $670,000 (the “Shareholder Loan”) for capital expenditures, marketing expenditures and working capital. Under the terms of the Loan Agreement, the Shareholder Loan was made available to the Company in two equal tranches of CAD $335,000, for a total loan amount of CAD $670,000, with the first tranche (“Loan Tranche A”) received on March 3, 2016 and the second tranche (“Loan Tranche B”) received on April 14, 2016. The Shareholder Loan bears interest at a rate of 6% per annum, on the outstanding principal, and matured on March 2, 2018, whereby the outstanding principal together with all accrued and unpaid interest thereon became due and payable. The Company was also to repay 5% of the initial principal amount of Loan Tranche A and 5% of Loan Tranche B, monthly in arrears, with the first principal repayment beginning on June 30, 2016. TheCompany could elect to repay the outstanding principal of the Shareholder Loan together with all accrued and unpaid interest thereon prior to maturity without premium or penalty. The Company also agreed to service the Shareholder Loan during the term prior to making any payments to the Company’s Chief Executive Officer, Chief Financial Officer and Board of Directors. The Shareholder Loan is secured by a general security agreement granting a general security interest over all the assets of the Company. On March 2, 2016 and in connection to the Loan Agreement, the Company issued warrants for the purchase of 1,000,000 Common Shares exercisable until March 2, 2018 at an exercise price of $0.20 per share. The warrants shall vest in two equal tranches, with 500,000 warrants to vest upon the close of Loan Tranche A and the remaining 500,000 warrants to vest upon the close of Loan Tranche B. On March 3, 2016 and April 14, 2016, the Company closed Loan Tranche A and Loan Tranche B, respectively, at which dates the warrants became fully vested and exercisable (note 16(g)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Shareholder Loan was $248,192 (December 31, 2017 – $244,187), at March 31, 2018 the debt discount on this loan had fully accreted. During the three month periods ended March 31, 2018 and 2017, the Company expensed $10,885 and $11,234, respectively, in interest expense related to the amortization of the debt discount. During the year ended December 31, 2017, CAD $350,000 of the Shareholder Loan was assumed by a separate shareholder (see (vii) below).

(v) On January 12, 2017, the Company entered into a bridge loan agreement (the “Bridge Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $200,000 (the “Bridge Loan”) in two equal tranches of CAD $100,000. The Company received the first tranche on January 12, 2017 (“Bridge Loan Note A”) and the second tranche on January 18, 2017 (“Bridge Loan Note B”). The Bridge Loan is non-interest bearing and was to mature on March 12, 2017. Pursuant to the terms of the Bridge Loan Agreement, the shareholder received a 5% upfront fee upon the closing of Bridge Loan Note A and a 5% upfront fee upon the closing of Bridge Loan Note B. The Bridge Loan is secured by the general security agreement issued in connection to the Secured Note. On January 12, 2017 and in connection to the Bridge Loan Agreement, the Company issued warrants for the purchase of 50,000 Common Shares exercisable until January 11, 2018 at an exercise priceof $0.20 per share, with 25,000 warrants to vest upon the closing of Bridge Loan Note A and the remaining 25,000 warrants vest upon the closing of Bridge Loan Note B. On January 12, 2017 and January 18, 2017, the Company closed Bridge Loan Note A and Bridge Loan Note B, respectively, at which dates the warrants became fully vested and exercisable (note 16(n)). During the year ended December 31, 2017, the Company and the shareholder extended the maturity date of Bridge Loan to April 30, 2019 and, commencingon November 15, 2017, the Company began accruing interest at a rate of 10% per annum. In connection to the amendment, the Company issued warrants for the purchase of Common Shares (note 16(hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Bridge Loan was $142,701 (December 31, 2017 - $144,611) including a debt discount of $12,419 (December 31, 2017 – $14,809). During the three month periods ended March 31, 2018 and 2017, the Company expensed $2,390 and $nil, respectively, in interest expense related to the amortization of the debt discount. The amendment to the Bridge Loan was accounted for as a modification of debt and no gain or loss was recognized on the amendments.

During the three month period ended March 31, 2018, the Company accrued interest of $4,037 on the Bridge Loan (March 31, 2017 – $nil). Total accrued interest owing on the Bridge Loan at March 31, 2018 was $5,904 (December 31, 2017 – $1,998) which is included in accrued liabilities.

(vi) On November 15, 2017, CAD $350,000 of the Shareholder Loan was assumed by a separate shareholder (the “Shareholder Loan No.2”). Upon assumption of the Shareholder Loan No.2, CAD $52,000 (USD $41,449) was offset by the amount held in trust by the shareholder under the Shareholder Loan (see (v) above) and CAD $11,000 (USD $8,769) was forgiven by the shareholder. During the year ended December 31, 2017 and as a result of the loan forgiveness, the Company recorded a gain on loan settlement in the amount of $8,221 and the principal amount due under the Shareholder Loan No.2 was CAD $287,000. The Company agreed to repay the unpaid principal amount of the Shareholder LoanNo.2 on or before April 30, 2019, bearing interest at a rate of 10% per annum, such interest to accrue monthly and due at maturity. In connection to the amendment, the Company issued warrants for the purchase of Common Shares (note 16(hh)). The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan. At March 31, 2018, the value of the Shareholder Loan No.2 was $204,775 (December 31, 2017 - $207,517) including a debt discount of $17,822 (December 31, 2017 – $16,939). During the three month periods ended March 31, 2018 and 2017, the Company expensed $3,429 and $nil, respectively, in interest expense related to the amortization of the debt discount.

During the three month period ended March 31, 2018, the Company accrued interest of $5,865 on the Shareholder Loan No.2 (March 31, 2017 – $nil). Total accrued interest owing on the Shareholder Loan No.2 at March 31, 2018 was $11,299 (December 31, 2017 – $5,701) which is included in accrued liabilities.

(vii) On March 21, 2018, the Company received CAD $31,000 (USD $24,044) from a Shareholder of the Company. The loan bears interest of 1.5% per month on a cumulative basis is unsecured and has no specific terms of repayment. During the three month period ended March 31, 2018, the Company accrued interest of $105 on this shareholder loan (March 31, 2017 – $nil). Total accrued interest owing on such shareholder loan at March 31, 2018 was $105 (December 31, 2017 – $nil) which is included in accrued liabilities.

Term Loan

On January 18, 2016, the Company entered into a term loan (the “Term Loan”) with an unrelated party acting as an agent to a consortium of participants (the “Lenders”), whereby the Lenders would loan the Company the aggregate principal amount of CAD $1,000,000 for capital expenditures, marketing expenditures and working capital. The agent who arranged the Term Loan was not a related party of the Company. The Term Loan bears interest at a rate of 16% per annum, on the outstanding principal, and was to mature on July 3, 2017, whereby any outstanding principal together with all accrued and unpaid interest thereon shall be due and payable. The Term Loan is secured ~~the~~by a intercreditor and subordination agreement as well as ~~the~~a security ~~agreement issued in~~ ~~connection to the Credit Facility~~agreement. The Term Loan is subject to a monthly ~~cashsweep,~~cash sweep, calculated as the total of (i) CAD $0.50 for every E-liquid bottle, smaller than 15 ml, sold by the Company within a monthly period; and (ii) CAD $1.00 for every E-liquid bottle, greater than 15 ml, sold by the Company within a monthly period (the “Cash Sweep”). The Cash Sweep will be disbursed to the Lenders in the following priority: first, to pay the monthly interest due on the Term Loan; and second, to repay any remaining principal outstanding on the Term Loan. The Company may elect to repay the outstanding principal of the Term Loan together with all accrued and unpaid interest thereon prior to the maturity, subject to an early repayment penalty of the maximum of (i) 3 months interest on the outstanding principal; or (ii) 50% of the interest payable on the outstanding principal until maturity (the “Early Repayment Penalty”). The Term Loan shall be immediately due and payable at the option of the Lenders if there is a change in key personnel meaning the Company’s current Chief Executive Officer and Chief Financial Officer. On January 18, 2016 and in connection to the Term Loan, the Company issued warrants for the purchase of 250,000 Common Shares (note 16(d)) exercisable ~~until~~ until December 31, 2017 at an exercise price of $0.20 per share. In addition, the Company also extended the expiration date of the 250,000 warrants (note 16(d)) issued on August 1, 2014 in connection with the Credit Facility until December 31, 2017, with all other terms of the warrants remaining the same. The relative fair value of the warrants issued were recorded as debt discount to be amortized over the life of the loan.

The Company’s Chief Executive Officer and Chief Financial Officer are both participants of the consortium of Lenders of the Term Loan, each having committed to provide ten percent of the principal amount of the Term Loan. Neither the Chief Executive Officer nor the Chief Financial Officer participated in the warrants issued or warrants extended in connection with the Term Loan and both parties have ~~been~~ appropriately abstained from voting on the Board of ~~Directors~~ Directors to approve the Term Loan, where applicable.

On July 15, 2016 and in connection to the Term Loan Amendment, the Company issued warrants for the purchase of 300,000 Common Shares exercisable until December 31, 2018 at an exercise price of $0.20 per share. The Company also extended the expiration dates of: (i) the warrants for the purchase of 250,000 Common Shares issued on January 18, 2016 in connection to the Term Loan; and (ii) the warrants for the purchase of 250,000 Common Shares issued on August 1, 2014 and extended on January 18, 2016 in connection to the Term Loan, both until December 31, 2018, with all other terms of the warrants remaining the same. Neither the Chief Executive Officer nor the Chief Financial Officer participated in the warrants issued or warrants extended in connection with the Term Loan Amendment.42

~~During~~On July 15, 2016 and in connection to the ~~year~~Term ~~ended~~Loan Amendment, the Company issued warrants for the purchase of 300,000 Common Shares (note 16(k)) exercisable until December 31, ~~2016,~~2018 ~~the~~at ~~Company~~an ~~was~~exercise ~~advanced~~price of $~~1,219,840~~0.20 per share. The Company also extended the expiration dates of: (~~CAD~~i) $1the warrants for the purchase of 250,~~600,~~000 Common Shares (note 16(d)) ~~from~~issued on January 18, 2016 in connection to the Term Loan; and ~~including~~(ii) the ~~CAD $294~~warrants for the purchase of 250,000 ~~and~~Common ~~CAD~~Shares (note $316(d)) issued on August 1,~~093~~ ~~rolled~~2014 and extended on January 18, 2016 in ~~from~~connection to the ~~Credit~~Term ~~Facility~~Loan, asboth ~~well as~~until ~~CAD~~December ~~$240~~31,~~581~~ 2018, with all other terms of ~~advances~~the ~~from~~warrants remaining the ~~Company’s~~same. ~~Chief~~The ~~Executive~~relative ~~Officer~~fair ~~and~~value ~~Chief~~of ~~Financial~~the ~~Officer~~warrants issued were recorded as debt discount to be amortized over the life of the loan.

OnDuring ~~February 27, 2017,~~ the ~~Company~~year ~~and~~ended ~~the~~December ~~Lenders~~31, ~~of the Term Loan entered into a term loan amendment (the “Term Loan Amendment No.2”) to amend certain terms and conditions of the Term Loan. Pursuant to the Term Loan Amendment No.2~~2016, the ~~parties~~Company ~~agreed to~~was ~~modify~~advanced ~~the Cash Sweep to be calculated as the total of~~ CAD $~~0.01667 per ml of E-liquid sold by the Company within a monthly period, such modification to be retroactively applied as of January~~ 1, ~~2017. The Lenders also agreed to cancel the Early Repayment Penalty and waive any interest payment penalties due under the Term Loan. On February 27~~600,000 ~~2017~~from ~~and in connection to~~ the Term Loan ~~Amendment~~ ~~No.2,~~including the ~~Company~~CAD ~~agreed to issue 500~~$294,000 ~~private placement~~and ~~units at a price of $0.10 per unit as a settlement of~~CAD $503,~~000~~093 rolled in ~~financing~~from ~~fees. Each unit consisted of one Common Share and~~ a ~~half~~revolving ~~Common~~credit ~~Share~~facility ~~purchase~~the ~~warrant exercisable over twelve~~Company ~~months~~previously atentered aninto ~~exercise~~with ~~price~~the ofLenders ~~$0.20~~as ~~per~~well ~~share.~~as OnCAD ~~April 4~~$240,581 ~~2017,~~of ~~the~~advances ~~Company~~from ~~issued~~ the ~~500,000 units. The~~ Company’s Chief Executive Officer and ~~its~~ Chief Financial Officer ~~received a total of 93,622 units which included 93,622 Common Shares and warrants for the purchase of 46,811 Common Shares~~. ~~The Term Loan Amendment No.2 was accounted for as a modification of debt and no gain or loss was recognized on the amendment.~~

41 On February 27, 2017, the Company and the Lenders of the Term Loan entered into a term loan amendment (the “Term Loan Amendment No.2”) to amend certain terms and conditions of the Term Loan. Pursuant to the Term Loan Amendment No.2, the parties agreed to modify the Cash Sweep to be calculated as the total of CAD $0.01667 per ml of E-liquid sold by the Company within a monthly period, such modification to be retroactively applied as of January 1, 2017. The Lenders also agreed to cancel the Early Repayment Penalty and waive any interest payment penalties due under the Term Loan. On February 27, 2017 and in connection to the Term Loan Amendment No.2, the Company agreed to issue 500,000 private placement units at a price of $0.10 per unit as a settlement of financing fees with a relative fair value of $48,485. Each unit consisted of one Common Share and a half Common Share purchase warrant exercisable over twelve months at an exercise price of $0.20 per share. On April 4, 2017, the Company issued the 500,000 units. The Company’s Chief Executive Officer and its Chief Financial Officer received a total of 93,622 units which included 93,622 Common Shares and warrants for the purchase of 46,811 Common Shares. The Term Loan Amendment No.2 was accounted for as a modification of debt and no gain or loss was recognized on the amendment.

~~During~~The ~~the~~relative ~~three~~fair ~~and~~value ~~nine~~of ~~month~~the ~~periods~~warrants ~~ended~~issued ~~September~~in ~~30,~~relation ~~2017,~~to the Term ~~Company~~Loan ~~expensed $42,370~~ and ~~$129,043,~~Term ~~respectively,~~Loan inamendments ~~interest~~were recorded as a ~~result~~debt ofdiscount to be amortized over the ~~Term~~life ~~Loan~~of ~~(September~~the ~~30,~~loan. ~~2016~~At –March ~~$44~~31,~~570~~ ~~and $97~~2018,~~409).~~ ~~Pursuant~~the tovalue of the ~~Cash~~Term ~~Sweep~~Loan was $1,053,993 ~~during~~including ~~the~~a ~~nine~~debt ~~month~~discount ~~period~~of ~~ended~~$33,609 ~~September~~(December 3031, 2017, ~~the~~– ~~Company~~$1,051,334 ~~paid~~including a ~~total~~debt discount of $~~239~~54,~~908~~815). to During the ~~Lenders~~three ~~consisting~~month ofperiods ~~$152~~ended March 31,~~044~~ in2018 ~~interest~~ and ~~$87~~2017,~~864~~ ~~in principal~~the ~~repayments.~~Company Atexpensed ~~September 30~~$25,435 ~~2017~~and $14,300, respectively, ~~the~~in ~~Company~~interest ~~owes~~expense related to the amortization of ~~Lenders~~the adebt ~~payment~~discount. ofNeither ~~$14,618,~~the ~~consisting~~Chief ~~fully~~Executive ofOfficer ~~interest~~nor ~~which~~the ~~was~~Chief ~~paid~~Financial toOfficer participated in the ~~Lenders~~warrants onissued ~~October~~or warrants ~~19,~~extended ~~2017~~in asconnection ~~per~~with the ~~terms~~Term ~~of the~~Loan ~~Cash Sweep~~Amendment.

The amount owing on the Term Loan is as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Opening balance/amount advanced	$1,~~144~~051,~~337~~334	$1,~~219~~061,~~840~~269
Exchange loss (gain) during the period/year	92,720	(28,159)
Accretion of debt discount	25,435	14,300
Principal payments made	(87,864)	(76,815)
Exchange loss (gain) during the period/year	(20,702)	86,143
Interest accrued	129,043	140,540
Principal payments made	(2,257)	(88,066)
Interest payments made	(152,044)	(111,069)
Interest accrued	42,577	173,035
Ending balance	$1,126,192	$1,144,337
Interest payments made	(42,394)	(195,347)
Ending balance	$1,053,993	$1,051,334

~~Bridge Loan~~43

On January 12, 2017, the Company entered into a bridge loan agreement (the “Bridge Loan Agreement”) with a shareholder, whereby the shareholder would make available to the Company the aggregate principal amount of CAD $200,000 (USD $160,260) (the “Bridge Loan”) in two equal tranches of CAD $100,000. The Company received the first tranche on January 12, 2017 (“Bridge Loan Note A”) and the second tranche on January 18, 2017 (“Bridge Loan Note B”). The Bridge Loan is non-interest bearing and matures on March 12, 2017. Pursuant to the terms of the Bridge Loan Agreement, the shareholder received a 5% upfront fee upon the closing of Bridge Loan Note A and a 5% upfront fee upon the closing of Bridge Loan Note B. The Bridge Loan is secured by the general security agreement issued in connection to the Secured Note. On January 12, 2017 and in connection to the Bridge Loan Agreement, the Company issued warrants for the purchase of 50,000 Common Shares exercisable until January 11, 2018 at an exercise price of $0.20 per share, with 25,000 warrants to vest upon the closing of Bridge Loan Note A and the remaining 25,000 warrants vest upon the closing of Bridge Loan Note B. On January 12, 2017 and January 18, 2017, the Company closed Bridge Loan Note A and Bridge Loan Note B, respectively, at which dates the warrants became fully vested and exercisable. The Bridge Loan matured on March 12, 2017 and is currently in default.

Promissory Notes

The Company has outstanding current promissory notes as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Unsecured, bears interest at 18% per annum, matures June 19, 2019(ii)	$30,000	$-
Unsecured, bears interest at 15% per annum, matures April 12, 2018(i)	$225,330	$230,109
Unsecured, bears interest at 10% per annum, matures December 15, 2017(iii)	7,500	-
Unsecured, bears interest at 15% per annum, matures February 18, 2019(ii)	231,398	-
Unsecured, bears interest at 10% per annum, matures September 28, 2017(iv)	2,000	17,750
Unsecured, bears interest at 18% per annum, matures June 19, 2019(iii)	30,000	30,000
Secured, bears interest at RBP + 2% per annum, due on demand(v)	40,066	-
Secured, bears interest at RBP + 2% per annum, due on demand(iv)	38,778	39,855
Secured, bears interest at RBP + 3% per annum, due on demand(vi)	69,362	-
Secured, bears interest at RBP + 3% per annum, due on demand(v)	58,912	64,774
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vii)	18,173	-
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vi)	22,809	23,441
Unsecured, interest free, matures October 29, 2017(viii)	12,020
Unsecured, interest free, matured October 29, 2017(vii)	-	7,971
	$179,121	$17,750
Secured, bears interest at 24%, matured March 6, 2018 (viii)	99,610	102,372
	$706,837	$498,522

The Company has outstanding long term promissory notes as follows:

	September 30, 2017	December 31, 2016
	March 31, 2018	December 31, 2017
Unsecured, bears interest at 15% per annum, matures February 18, 2019(i)	$240,390	$-
Unsecured, bears interest at 15% per annum, matures February 18, 2019(ii)	$-	$234,034
Unsecured, bears interest at 18% per annum, matures June 19, 2019(ii)	22,500	-
Unsecured, bears interest at 18% per annum, matures June 19, 2019(iii)	7,500	17,500
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vii)	104,820	-
Lease agreement, bears interest at 4.7% per annum, matures October 13, 2023(vi)	87,542	94,468
	$367,710	-
	$95,042	$346,002

(i) On October 12, 2017, the Company issued an unsecured promissory note in the principal amount of CAD $300,000. The promissory note matured on April 12, 2018 and bears interest at a rate of 15% per annum, accrued monthly and due at maturity. In connection to the promissory note, the Company issued warrants for the purchase of 100,000 Common Shares of the Company exercisable at $0.20 per share until April 11, 2019. The relative fair value of the warrants issued were recorded as a debt discount to be amortizedover the life of the loan. During the three month periods ended March 31, 2018 and 2017, the Company expensed $1,670 and $nil, respectively, in interest expense related to the amortization of the debt discount (note 16(gg)). During the three month period ended March 31, 2018, the Company accrued $9,387 in interest on the promissory note which has been recorded in accrued liabilities (March 31, 2017 – $nil). At March 31, 2018, the value of the promissory note was $225,330 inclusive of a debt discount of $7,351 (December 31, 2017 – $230,109 inclusive of a debt discount of $9,021). As at the date of these financial statements, this note is currently in default.

(ii) On August 18, 2017, the Company issued an unsecured promissory note in the principal amount of CAD 300,000 ~~(US $240,390)~~. The promissory note matures on February 18, 2019 and bears interest at a rate of 15% per annum, paid monthly in arrears with interest payments beginning on March 18, 2018. The interest accrued for the initial seven (7) months shall be ~~due~~dueat at maturity. In connection to the promissory note, the Company issued warrants for the purchase of 150,000 Common Shares of the Company exercisable at $0.20 per share until February 18, 2019. The relative fair value of the warrants issued were ~~valued~~recorded atasa ~~$11~~debt discount to be amortized over the life of the loan. During the three month periods ended March 31,~~670~~ 2018 and ~~booked~~2017, asthe ~~prepaid~~Company expensed $3,813 and $nil, ~~financing~~respectively, ~~expense~~in tointerest beexpense ~~expensed~~related ~~over~~to ~~term~~the amortization of the ~~promissory~~debt discount (note 16(ee)). During the three ~~and~~month ~~nine months~~ period ended ~~September~~March 3031, ~~2017~~2018, the Company accrued $49,~~248~~489 in interest ~~expense~~ on ~~this~~ the promissory note which has been recorded in accrued liabilities (~~September~~March 3031, ~~2016~~ 2017 – $nil). At March 31, 2018, the value of the promissory note was $231,398 inclusive of a debt discount of $1,283 (December 31, 2017 – $234,034 inclusive of a debt discount of $5,096).

(iiiii) On June 30, 2017, the Company issued an unsecured promissory note in the principal amount of $60,000. The principal together with interest at a rate of 18% per annum is payable in monthly instalments of $3,400 with the first payment due on July 19, 2017 and the final payment due on June 19, 2019. In the event of default, by way of any missed payment under the promissory note and not cured fora period of 15 days, at the option of the holder, the entire unpaid principal amount outstanding would become due and payable. During the three month period ended March 31, 2018, the Company expensed and paid $2,700 in interest on the promissory note (March 31, 2017 – $nil). At March 31, 2018, $30,000 in principal on the promissory note has been classified as a current liability and $7,500 has been classified as a long term liability on the Company’s consolidated balance sheet.

On June 30, 2017, the Company issued an unsecured promissory note in the principal amount of $60,000. The principal together with interest at a rate of 18% per annum is payable in monthly instalments of $3,400 with the first payment due on July 19, 2017 and the final payment due on June 19, 2019. In the event of default, by way of any missed payment under the promissory note and not cured for a period of 15 days, at the option of the holder, the entire unpaid principal amount remaining will become due and payable without notice. At September 30, 3017, $30,000 in principal on this promissory note has been classified as a current liability and $22,500 has been classified as a long term liability on the Company’s consolidated balance sheet. During the three and nine months ended September 30, 2017, the Company paid $2,700 in interest on this promissory note (September 30, 2016 – $nil).

(iii)

On April 20, 2017, the Company issued an unsecured promissory note in the principal amount of $20,000. The principal together with interest at a rate of 10% over the term of the promissory note is payable in monthly instalments of $2,750 with the first payment due on May 15, 2017 and the final payment due on December 15, 2017. In the event of default, by way of any missed payment under the promissory note and not cured for a period of 15 days, at the option of the holder, the entire unpaid principal amount remaining will become due and payable without notice. During the three and nine months ended September 30, 2017, the Company paid $750 and $1,000, respectively, in interest on this promissory note (September 30, 2016 – $nil).

(iv)

On September 28, 2016, the Company issued an unsecured promissory note in the principal amount of $21,000. The principal together with interest at a rate of 10% per annum is payable in monthly instalments of $2,000 with the first payment due on October 28, 2016 and the final payment due on September 28, 2017. In the event of default, by way of any missed payment under the promissory note and not cured for a period of 15 days, at the option of the holder, the entire unpaid principal amount remaining will become due and payable without notice. During the three and nine months ended September 30, 2017, the Company paid $750 and $2,000, respectively, in interest on this promissory note (September 30, 2016 – $nil). At September 30, 2017, the Company was delinquent on its September 30, 2017 payment and $250 in interest was accrued and remains due at September 30, 2017.

(v)

On July 18, 2016, VBI entered into a revolving facility with The Royal Bank of Canada (“RBC”) for CAD $50,000 (US $40,066). The revolving facility is secured by the assets of VBI, due on demand and bears interest at a rate of RBC Prime (“RBP”) + 2%. Interest is payable monthly in arrears. During the three and six months ended September 30, 2017, the Company paid $342 in interest on this facility (September 30, 2016 – $nil). At September 30, 2017, $40,065 in principal remains owing on this facility.

(vi)

On July 18, 2016, VBI entered into a credit facility with RBC for CAD $106,000 (US $84,938). The credit facility is secured by the assets of VBI, due on demand and bears interest at the rate of RBP + 3%. Interest is payable monthly in arrears and VBI is required to make monthly principal payments in the amount of $1,416. During the three and nine months ended September 30, 2017, the Company paid $728 in interest (September 30, 2016 – $nil) and made principal payment of $2,832 on this facility. At September 30, 2017, $69,362 in principal remains owing on this facility.

(vii)

On October 13, 2016, VBI entered into a capital lease agreement with RBC for the lease of manufacturing equipment in the amount of CAD $175,132 (US $140,333). As a result of the lease agreement, VBI is required to make monthly payments of interest and principal to RBC in the amount of CAD $2,451 (US $1,964). During the three and nine months ended September 30, 2017, the Company paid $2,946 in principal and $981 in interest (September 30, 2016 – $nil). At September 30, 2017, $122,993 in principal remains payable on the capital lease with $18,173 being allocated to current liabilities and $104,820 being allocated to long term liabilities on the consolidated balance sheet.

(viii)

On closing of the VBI acquisition, VBI had an amount owing to a vendor of VBI in the principal amount of CAD $20,000 (US $16,026). Pursuant to the share purchase agreement to acquire VBI, the Company agreed to repay the vendor the loan with two (2) payments of CAD $5,000, payable thirty (30) and sixty (60) days after the closing and a final payment of CAD $10,000 due ninety (90) days after the closing. The loan is unsecured and interest free. During the three and nine months ended September 30, 2017, the Company paid $4,006 on this loan (September 30, 2016 – $nil). At September 30, 2017, $12,020 in principal remains outstanding on this loan.

Common Shares

During the nine months ended September 30, 2017, the Company:

● Issued 19,083,818 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for cash proceeds, net of issuance costs, of $1,818,672; ● Issued 1,998,950 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for settlement of $199,895 in amounts owing to related parties; ● Issued 226,920 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, for settlement of $22,692 in amounts owing to a shareholder; ● Issued 320,022 Common Shares, at an average price of $0.156 per share, for settlement of $50,000 in consulting fees owing to a shareholder, previously granted and recognized as Common Shares to be issued at December 31, 2016; ● Issued 143,715 Common Shares, at an average price of $0.129 per share, for settlement of $18,550 in consulting fees owing to an unrelated party, previously granted and recognized as Common Shares to be issued as at December 31, 2016; ● Issued 366,667 Common Shares, at a price of $0.15 per share, for settlement of $55,000 in consulting fees owing to an unrelated party, previously granted and recognized as Common Shares to be issued as at December 31, 2016; ● Issued 300,000 Common Shares, at a price of $0.10 per share, for settlement of $30,000 in amounts owing to a director of the Company. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $33,000. The balance of $3,000 has been recorded as a loss on settlement of debt; ● Issued 300,000 Common Shares, at a price of $0.167 per share, for settlement of $50,000 in charitable contributions owing to an unrelated party. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $36,000. The balance of $14,000 has been recorded as a gain on settlement of debt; ● Issued 50,000 Common Shares, at a price of $0.12 per share, as $6,000 in employment income to an unrelated party; ● Issued 871,000 Common Shares, at a price of $0.10 per share, for settlement of $87,100 in directors fees owing to former directors of the Company. The amount allocated to Shareholders’ Deficiency, based on their fair value, amounted to $121,940. The balance of $34,840 has been recorded as a loss on settlement of debt; ● Issued 500,000 Common Shares on a private placement basis, at a price of $0.10 per private placement unit, as settlement of $50,000 in financing fees in connection to the Term Loan Amendment No.2. Of the 500,000 Common Shares issued, 93,622 Common Shares were issued to related parties; ● Issued 6,130,000 Common Shares, at a price of $0.10 per share, on conversion of $613,000 of Convertible Debentures. The above amount included the conversion of $291,000 of Convertible Debentures held by related parties of the Company; ● Issued 594,251 Common Shares, at price of $0.10 per share, for settlement of $59,425 in interest owing on Convertible Debentures. The above amount included the settlement of $30,843 of interest owing on Convertible Debentures held by related parties of the Company; ● Issued 2,500,000 Common Shares, at a price of $0.14, for the acquisition of a subsidiary; and ● Issued 730,280 Common Shares on a private placement basis, at a price of $0.10 per share, for cash proceeds of $50,000 and settlement of amounts owing to an unrelated party in the amount of $23,028.

(vi) On October 13, 2016, VBI entered into a capital lease agreement with RBC for the lease of manufacturing equipment in the amount of CAD $175,132. Under the lease agreement, the Company is required to make monthly payments of interest and principal to RBC in the amount of CAD $2,451, the lease matures on October 13, 2023. During the three month period ended March 31, 2018, the Company paid $1,357 in interest and made principal repayments of $4,371 on the facility (March 31, 2017 – $nil and $nil, respectively). At March 31, 2018, a total of $110,351 (December 31, 2017 - $117,909) in principal remains payable under the lease with $22,809 (December 31, 2017 – $23,441) being allocated to current liabilities and $87,542 (December 31, 2017 – $94,468) being allocated to long term liabilities on the consolidated balance sheet.

(vii) On closing of the VBI acquisition, VBI had an amount owing to a vendor of VBI in the principal amount of CAD $20,000. Pursuant to the share purchase agreement, the Company agreed to repay the loan to the vendor with two (2) payments of CAD $5,000, payable thirty (30) and sixty (60) days after the closing and a final payment of CAD $10,000 due ninety (90) days after the closing. The loan is unsecured and interest free. At December 31, 2017, the loan was in default and CAD $10,000 (USD $7,971) in principal remained outstanding which the Company repaid in January 2018.

(viii) On December 7, 2017, the Company entered into a revolving credit facility (the “Revolving Facility”) in the aggregate principal amount of CAD $200,000. The Revolving Facility is secured by certain inventory and receivables of the Company, due March 6, 2018 with an option to extend and bears interest at a rate of 24% per annum payable monthly in arrears. The Revolving Facility is also subject to a standby fee with respect to the unused portion of the facility, calculated on a daily basis as being the difference between the CAD $200,000 revolving limit and the then outstanding advances, multiplied by 3% and divided by 365 and payable in arrears on the last day of each month. During the year ended December 31, 2017, the Company received $100,000 in advances under the Revolving Facility. During the three month period ended March 31, 2018, the Company accrued $6,227 in interest and $419 in standby fees on the Revolving Facility (March 31, 2017 – $nil and $nil, respectively). At March 31, 2018, $99,610 in principal remains owing on the Revolving Facility.

Convertible Debentures

On April 30, 2017 and pursuant to the terms of the Convertible Debentures Series B, the Company sent notices of its election to convert $423,000 in face value and $45,058 in accrued interest to holders of Convertible Debentures Series B at $0.10 per sharefor a total of 4,680,581 Common Shares of the Company. As a result of these conversions, the Company recorded a debt discount in the amount of $342,399. The above amount included the conversion of $286,000 in face value and $30,465 in accrued interest held by related parties of the Company (note 19(c)).

On April 30, 2017 and pursuant to the terms of the Convertible Debentures Series C, the Company sent notices of its election to convert $190,000 in face value and $14,367 in accrued interest to holders of Convertible Debentures Series C at $0.10 per share for a total of 2,043,670 Common Shares of the Company. As a result of these conversions, the Company recorded a debt discount in the amount of $168,798. The above amount included the conversion of $5,000 in face value and $378 in accrued interest held by related parties of the Company (note 19(c)).

As at March 31, 2018, face value $227,000 of Convertible Debentures Series B and face value $110,000 of Convertible Debentures Series C remain owing to their respective debenture holders.

During the three month period ended March 31, 2018, the Company recorded interest expense in the amount of $6,648 on the Convertible Debentures (March 31, 2017 – $26,794). The interest owing on the convertible debentures is included in accrued liabilities on the Company’s consolidated balance sheet.

Common Shares

During the three months ended March 31, 2018, the Company:

	●	Issued 50,000 Common Shares on the exercise of warrants, at a price of $0.20 per common share, for cash proceeds of $10,000;
	●	Issued 3,486,362 Common Shares on a private placement basis, at a price of $0.11 per common share for cash proceeds of $383,500;
	●	Issued 190,909 Common Shares on a private placement basis, at a price of $0.11 per common share for payment of consulting fees in the amount of $21,000 owing to an unrelated party; and
	●	Issued 4,621,836 Common Shares at a price of $0.10 per share, for conversion of $425,000 in face value and $37,184 in accrued interest to holders of Convertible Debentures, including the conversion of $130,000 in face value and $13,264 in accrued interest held by related parties of the Company.

Satisfaction of Our Cash Obligations for the Next 12 Months

These unaudited condensed consolidated interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in these unaudited condensed consolidated interim financial statements, at ~~September~~March 3031, ~~2017~~2018, ~~the~~ the Company has an accumulated deficit of $1721,~~762~~360,~~750~~143 (December 31, 2017 – $19,898,841) and a working capital deficiency of $5,750,400 (December 31, 2017 – $74,~~135~~659,~~352~~008) as well as negative cash flows from operating activities of $1441,~~533~~844 (March 31,~~731~~ 2017 – $917,269) for the ~~nine~~three ~~month~~months ~~period~~ ended ~~September~~March 3031, ~~2017~~ 2018. These conditions represent material uncertainty that cast significant ~~doubt~~doubts about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon achieving a profitable level ~~ofoperations~~of operations or on the ability of the Company to obtain necessary financing to fund ongoing operations. Management believes that the Company will not be able to continue as a going concern for the next twelve months without additional financing or ~~increased~~ increased revenues.

These unaudited condensed consolidated interim financial statements do not include any adjustments to the recorded assets or liabilities, that might be ~~necessary~~material, should the Company have to curtail operations or be unable to continue in existence.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Recently Adopted Accounting Pronouncements

In ~~November~~ ~~2015~~May 2014, the ~~Financial Accounting Standards Board (“~~FASB”) issued ~~Accounting Standards Update (“~~ASU”) No. ~~2015~~ 2014-1709, ~~Income~~Revenue ~~Taxes~~from ~~(Topic~~Contracts ~~740):~~with ~~Balance~~Customers ~~Sheet~~(Topic ~~Classification~~606) ~~of Deferred Taxes~~ (“ASU ~~2015~~ 2014-1709”)., ~~ASU~~requiring ~~2015-17~~an ~~simplifies~~entity ~~the presentation of~~to ~~deferred~~recognize ~~income~~revenue ~~taxes~~when byit ~~eliminating~~transfers ~~the~~promised ~~separate~~goods ~~classification~~or ofservices to ~~deferred~~customers ~~income~~in ~~tax~~an ~~liabilities~~amount ~~and~~that ~~assets~~reflects ~~into~~the ~~current~~consideration ~~and~~to which the ~~noncurrent~~entity ~~amounts~~expects into ~~the~~be ~~consolidated~~entitled ~~balance~~to ~~sheet~~in ~~statement~~exchange ~~of financial~~for ~~position.~~those ~~The~~goods ~~amendments~~or services. inASU ~~the~~2014-09 ~~update~~will ~~require~~supersede ~~that~~nearly all existing revenue ~~deferred~~recognition ~~tax~~guidance ~~liabilities~~under ~~and~~U.S. ~~assets~~GAAP bewhen ~~classified~~it becomes effective. ASU 2014-09 as ~~noncurrent~~amended inby ASU No. 2015-14, ASU No. ~~the~~2016-08, ~~consolidated~~ASU ~~balance~~No. ~~sheet~~2016-10, ASU No. ~~The~~2016-12 ~~amendments~~and inASU ~~this~~No. ~~update~~2016-20, ~~are~~is effective for interim and annual periods beginning after December 15, ~~2016,~~2017 and ~~interim~~ ~~periods~~is ~~therein and may be~~ applied on either ~~prospectively~~a ormodified ~~retrospectively~~retrospective toor ~~all~~full ~~periods~~retrospective ~~presented~~basis. Adoption of ASU ~~2015-17~~No. 2014-09 did not have an impact on the Company’s ~~condensed~~ consolidated ~~interim~~ financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). This update requires that all excess tax benefits and tax deficiencies arising from share-based payment awards should be recognized as income tax expense or benefit on the income statement. The amendment also states that excess tax benefits should be classified along with other income tax cash flows as an operating activity. In addition, an entity can make an entity-wide accounting policy election to either estimate the number of awards expected to vest or account for forfeitures as they occur. The provisions of this update are effective for annual and interim periods beginning after December 15, 2016. Adoption of ASU 2016-09 did not have an impact on the Company’s condensed consolidated interim financial statements.46

In ~~October~~April 2016, the FASB issued ASU No. 2016-1710, ~~Consolidation~~Revenue from Contracts with Customers (Topic ~~810~~606): ~~Interests~~Identifying ~~Held through~~Performance ~~Related~~Obligations ~~Parties That Are under Common Control~~and Licensing (“ASU 2016-1710”). ~~The~~ASU ~~new~~2016-10 ~~guidance changed how a~~clarifies ~~reporting~~the ~~entity~~following ~~that~~two isaspects aof ~~single~~Topic ~~decision~~606: ~~maker~~identifying ~~for a variable~~performance ~~interest~~obligations ~~entity~~and ~~(“VIE”)~~the ~~will~~licensing ~~consider~~implementation ~~its~~guidance, ~~indirect~~while ~~interests~~retaining ~~in that VIE when determining whether~~ the ~~reporting~~related ~~entity is~~principles ~~the~~for ~~primary~~those ~~beneficiary and should consolidate the VIE~~areas. ~~Under previous~~The ~~U.S.~~provisions ~~GAAP, a single decision maker in a VIE is required to~~of ~~consider~~this anupdate ~~indirect~~are ~~interest~~effective ~~held~~for byannual aand ~~related~~interim ~~party~~periods ~~under common~~beginning ~~control~~after December in15, ~~its entirety. Under ASU 2016-17~~2017, ~~the~~with ~~single~~early ~~decision maker~~application ~~will consider the indirect interest on a proportionate basis~~permitted. Adoption of ASU No. 2016-1710 did not have an impact on the Company’s ~~condensed~~ consolidated ~~interim~~ financial statements.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). The core principal of ASU 2016-12 is the recognition of revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The provisions of this update are effective for annual and interim periods beginning after December 15, 2017, with early application permitted. Adoption of ASU No. 2016-12 did not have an impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) (“ASU 2016-15”), which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. Among other clarifications, the guidance requires that cash proceeds received from the settlement of corporate-owned life insurance (COLI) policies be classified as cash inflows from investing activities and that cash payments for premiums on COLI policies may be classified as cash outflows for investing activities, operating activities or a combination of both. The guidance is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. Retrospective application is required. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). ASU 2016-16 prohibits the recognition of current and deferred income taxes for an intra-entity transfer until the asset has been sold to an outside party. The amendment in ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

In ~~July~~ ~~2017~~February 2018, the FASB issued ASU No. ~~2017~~2018-1102, ~~Earnings~~Income ~~Per~~Statement ~~Share~~- ~~(Topic~~Reporting ~~260) Distinguishing~~Comprehensive ~~Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)~~Income: I.Reclassification ~~Accounting for Certain Financial Instruments with Down Round Features; II. Replacement~~ of ~~the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of~~ Certain ~~Nonpublic Entities~~Tax ~~and~~effects ~~Certain~~from ~~Mandatorily Redeemable Noncontrolling~~Accumulated ~~Interests~~Other ~~with~~Comprehensive aIncome ~~Scope Exception~~ (“ASU ~~2017~~ 2018-1102”). ~~ASU 2017-11~~ which allows afor ~~financial~~the ~~instrument~~reclassification ~~with~~from aaccumulated other ~~down-round~~comprehensive ~~feature~~income to noretained ~~longer~~earnings ~~automatically~~for bethe ~~classified~~stranded ~~as a~~tax ~~liability~~effects ~~solely~~arising ~~based~~from onthe change in the ~~existence~~reduction of the ~~down-round provision~~U.S. federal ~~The~~statutory ~~update~~income ~~also~~tax ~~means~~rate ~~the~~to ~~instrument~~21% ~~would~~from ~~not~~35%. ~~have~~The totax effects beof ~~accounted~~items ~~for~~included asin aaccumulated ~~derivative~~comprehensive ~~and~~income beat ~~subject~~December 31, to2017 ando ~~updated~~not ~~fair value~~reflect ~~measurement~~the ~~each~~appropriate ~~reporting~~tax ~~period~~rate. ~~The~~ASU ~~standard~~2018-02 is ~~effective~~ effective for interim and annual ~~reporting~~ periods beginning after December 15, 2018~~, with early adoption permitted~~. The Company is evaluating the guidance and has not yet determined the impact on its consolidated financial statements.

CRITICAL ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for a full year. These condensed consolidated interim financial statements ~~should~~shouldbe be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016~~2017, as filed with the U.S. Securities and Exchange Commission. Certain comparative figures have been reclassified to conform with the current year’s presentation.

Basis of Consolidation

These unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly owned subsidiaries: Gilla Operations, LLC; E Vapor Labs Inc. (“E Vapor Labs”); Gilla Enterprises Inc. (“Gilla Enterprises”) and its wholly owned subsidiaries Gilla Europe Kft., Gilla Operations Europe s.r.o. and Vape Brands International Inc. (“VBI”); HyStyle Brands Inc.; E-Liq World, LLC; Charlie’s Club, Inc.; Gilla Operations Worldwide Limited (“Gilla Worldwide”); Gilla Franchises, LLC and its ~~wholly~~ wholly owned subsidiary Legion of Vape, LLC; and Snoke Distribution ~~Canada~~ Canada Ltd. and its wholly owned subsidiary Snoke Distribution USA, LLC. All inter-company accounts and transactions have been eliminated in preparing these unaudited condensed consolidated interim financial statements.

Advertising Costs

47ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This item is not applicable to smaller reporting companies.

ITEM 4. DISCLOSURE CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its filings with the SEC is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based on the definition of “disclosure controls and procedures” as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

As of the end of the period covered by this Report, and under the supervision and with the participation of management, including the Company’s Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), the Company has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on this evaluation, the Company believes that disclosure controls and procedures were not effective as of ~~September~~ 30March 31, ~~2017~~2018, due to the Company’s limited resources ~~and~~ and staff.

Limitations on Effectiveness of Controls and Procedures

The Company’s management, including its Chief Executive Officer and Chief Financial Officer, does not expect that disclosure controls and procedures or its internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Furthermore, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Controls

During the quarter ended ~~September~~March 3031, ~~2017~~2018, there have been no changes in ~~the~~ the Company’s internal control over financial reporting that ~~have~~ have materially affected or are reasonably likely to materially ~~affect~~ affect its internal controls over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

~~LEGAL~~ ~~PROCEEDINGS~~The Company is not currently a party in any material legal proceeding or governmental regulatory proceeding nor is the Company aware of any pending or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against the Company.

48ITEM 1A. RISK FACTORS

~~ITEM~~ There have been no material changes in the Company’s risk factors from those disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

~~RISK~~ITEM ~~FACTORS~~2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~There~~During ~~have~~the ~~been~~period nocovered ~~material~~by ~~changes~~this inReport, the Company’s ~~risk~~did ~~factors~~not have any ~~from~~sales ~~those~~of ~~disclosed~~securities in ~~Part~~transactions I,that ~~Item~~were 1Anot ofregistered ~~our~~under the ~~Annual~~Securities ~~Report~~Act onthat have not been previously reported in a Form 8-K, Form 10-KQ ~~for~~or ~~the~~Form ~~fiscal~~10-K, ~~year~~except ~~ended~~for ~~December~~the ~~31, 2016.~~following:

~~ITEM~~ 2On March 15, 2018, the Company issued and sold 50,000 Common Shares of the Company at a price of $0. 20 per Common Share as a result of the exercise of warrants, pursuant to exemptions from the registration requirements of the Securities Act available under Rule 903 of Regulations S promulgated thereunder.

~~UNREGISTERED~~ ~~SALES~~On March OF23, ~~EQUITY~~2018, ~~SECURITIES~~the ~~AND~~Company ~~USE~~issued OFand ~~PROCEEDS~~sold, on a private placement basis, 3,677,271 Common Shares of the Company at a price of $0.11 per Common Share, pursuant to exemptions from the registration requirements of the Securities Act available under Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.

~~During~~On ~~the~~March ~~period~~29, ~~covered~~2018, bythe ~~this~~Company ~~Report~~issued 4,621,836 weCommon ~~did~~Shares ~~not~~of ~~have~~the Company ~~any~~at ~~sales~~a price of ~~securities~~ in$0.10 ~~transactions~~per ~~that~~Common ~~were~~Share ~~not~~as ~~registered~~a ~~under~~result of the ~~Securities~~conversion ~~Act~~of ~~that~~debentures, ~~have~~pursuant ~~not~~to ~~been~~exemptions ~~previously~~from ~~reported~~the registration inrequirements aof ~~Form~~the Securities Act available under ~~8-K,~~Section ~~Form~~4(a)(2) ~~10-Q~~and orRule ~~Form~~506 ~~10-K,~~of ~~except~~Regulation ~~for~~D ~~the~~and ~~following:~~Rule 903 of Regulations S promulgated thereunder.

ITEM ~~On July 31, 2017, the Company issued 2,500,000 Common Shares at a price of $0~~3.14 ~~per~~DEFAULTS ~~Common~~UPON ~~Share~~SENIOR ~~as a result of the acquisition of VBI, pursuant to exemptions from the registration requirements of the Securities Act available under Rule 903 of Regulations S promulgated thereunder.~~SECURITIES

On August 4, 2017, the Company issued and sold, on a private placement basis, 500,000 Common Shares of the Company at a price of $0.10 per share, pursuant to exemptions from the registration requirements of the Securities Act available under Rule 903 of Regulations S promulgated thereunder.

On September 21, 2017, the Company issued and sold, on a private placement basis, 230,280 Common Shares of the Company at a price of $0.10 per share, pursuant to exemptions from the registration requirements of the Securities Act available under Rule 903 of Regulations S promulgated thereunder.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

OTHER INFORMATION

None.

4950

ITEM 6.

EXHIBITS

			Incorporated by Reference
Exhibit Number	Exhibit Description	Filed Herewith	Form	Exhibit	Filing Date

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X

32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*	X

32.2	Certifications of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X

101.DEF	XBRL Taxonomy Definition Linkbase	X

101.LAB	XBRL Taxonomy Extension label Linkbase	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X

* This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

5051

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GILLA INC.
	GILLA INC. (Registrant)
	(Registrant)
June 29, 2018	By:	/s/ Graham Simmonds
November 14, 2017	By:	/s/ Graham Simmonds
		Graham Simmonds
		Name: Graham Simmonds
		Chief Executive Officer and Principal Executive Officer
		Title: Chief Executive Officer and Principal Executive Officer

By: /s/ Ashish Kapoor Name: Ashish Kapoor Title: Chief Financial Officer and Principal Accounting Officer



June 29, 2018	By:	/s/ Ashish Kapoor
		Ashish Kapoor
		Chief Financial Officer and Principal Accounting Officer

5152

Filing Compare · GILLA INC.